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Sarcopenia is the age-related loss of skeletal muscle mass and function; inflammation is 
thought to be one aetiological factor in its development. Adipose tissue accumulates with 
advancing age and adipose-derived cytokines (adipokines) contribute to inflammaging. 
Skeletal muscle myogenesis is one adaptaive mechanism by which skeletal muscle mass 
is sustained throughout the human lifespan. The effect of the adipose inflammatory milieu 
on such myogenesis is unknown, as is the relative importance of its constituent adipokines 
to myogenesis. This work demonstrates that conditioned medium generated from obese 
subcutaneuous adipose tissue has a detrimental effect on in vitro primary human 
myogenesis. Resistin is shown to be – in part – responsible for this phenomenon and is 
demonstrated to inhibit myogenesis by activating the classical NFκB pathway. Resistin is 
further shown to be a metabolic stressor of primary human myotubes, promoting 
increased oxygen consumption, fatty acid oxidation and lipid accumulation. It is important 
to identify more avenues for the development of pharmacological interventions in 
sarcopenia. To that end, this thesis also demonstrates for the first time that the myokine 
IL-15:  1) is pro-myogenic in primary human cultures; 2) can mitigate the detrimental 
effects of an inflammatory environment on myogenesis; and 3) supports myogenesis at 
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1. Introduction and Background 
1.1 General Introduction 
Skeletal muscle mass begins to decline continuously in middle age, at a rate of 3-8 % per 
decade (1). This phenomenon is known as sarcopenia; a term derived from the Greek 
sarx, meaning flesh and penia, meaning loss (2–5). In addition to this loss of muscle mass, 
definitions of sarcopenia also describe a decline in muscle strength and power as well as 
impaired physical performance (6). Indeed, the European Working Group on Sarcopenia 
in Older People (EWGSOP) guidelines require the presence of low muscle mass and 
either low muscle strength or poor physical performance for the diagnosis of sarcopenia 
(6). Globally, 5-10 % of those over 65 yr meet such criteria and the prevalence of 
sarcopenia is increased in advanced age. (7). In many individuals, sarcopenia is 
accompanied by an increase in adipose tissue mass, a condition that is termed sarcopenic 
obesity (8). Adipose tissue mass typically accumulates throughout middle age at a rate of 
0.21 kg/yr in men and 0.14 kg/yr in women, peaking in old age (4). Sarcopenia and 
sarcopenic obesity are associated with an increased risk of cardiovascular, metabolic and 
musculoskeletal diseases as well as poorer quality of life scores and an increased 
incidence of falls and fractures (9–12). These clinical conditions have profound personal 
and societal costs; sarcopenia increases all-cause mortality 4-fold (13). Indeed, the UK is 
expected to spend an additional 2.3 % of gross domestic product (GDP) on age-related 
healthcare services by 2062 (14). In 2004, it was estimated that sarcopenic individuals in 
the United States required excess healthcare spending of ~ USD 900 per annum 
compared to their non-sarcopenic counterparts (15). There are few effective therapeutic 
interventions available for the prevention or reversal of sarcopenia. Avoidance of 
3 
 
sedentary behaviour (16) and resistance exercise training, supported by adequate 
nutrition are partially effective in reversing sarcopenia (17–19). However, even lifelong 
resistance training does not facilitate the retention of skeletal muscle mass and strength 
at the levels that are observed in the young (20). No pharmacological interventions are 
currently approved for the prevention or reversal of sarcopenia, although some selective 
androgen receptor modulators (SARMs) and the myostatin antagonist bimagrumab have 
produced promising results (21). To develop effective interventions for sarcopenia, it is 
essential that we continue to characterise the mechanisms underlying its development.  
The aetiology of sarcopenia is complex and incompletely understood. A decrease in 
skeletal muscle fibre size and fibre number, as well as impaired myofibre contractile 
performance, are well characterised in ageing and underlie the deficiencies in skeletal 
muscle strength and physical performance seen in the elderly. However, the cellular and 
molecular changes that are known to promote such deficiencies in myofibre performance 
are manifold, and many questions remain to be answered as to their origins and relative 
importance in sarcopenia. The factors that are most often considered include altered 
satellite cell (SC) function, neuromuscular junction (NMJ) signalling deficits, a decline in 
neural and myofibre mitochondrial health, insulin resistance, inadequate nutrition, and a 
decline in physical activity. Often the interdependence of these events is understated, and 
it is not fully known which of these factors represent a primary pathophysiological insult in 
ageing and which occur secondarily as sarcopenia advances. The issue of SC function in 
ageing is of particular importance to the in vitro primary human myogenesis (the formation 
of skeletal myofibres) model that we employ in the experiments detailed in this thesis. 
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Adult SC physiology is considered further in Section 1.6.3.1, while our experimental model 
is appraised in Chapter 7.   
Inflammation is increasingly considered to be part of the molecular aetiology of 
sarcopenia. Indeed, a profound inflammatory burden is well established as a major 
contributor to the cachexia of chronic illness (22). Ageing is often accompanied by chronic 
low-grade inflammation, referred to as “inflammaging” (23). Plasma c-reactive protein 
(CRP) levels, a biomarker of generalised systemic inflammation, increase with age (24). 
Cross-sectional and prospective studies of elderly populations have positively associated 
high systemic levels of pro-inflammatory cytokines (e.g. Tumour necrosis factor alpha 
[TNFα] and interleukin 6 [IL-6]) with reduced skeletal muscle mass (25–27). Furthermore, 
total adipose tissue mass and visceral adipose tissue (VAT) mass are negatively 
correlated with skeletal muscle mass (28,29).  
Importantly, given the frequent co-existence of sarcopenia with adipose tissue 
accumulation, obesity is independently associated with inflammation (30–33). Adipose 
tissue is an endocrine organ that secretes pro-inflammatory cytokines, known as 
adipokines (34). Adipokines have distal effects on many tissues, including skeletal muscle 
(35) and are implicated in the pathology of diabetes, cardiovascular disease and cognitive 
decline (36–38). Intra-abdominal visceral adipose tissue (VAT) is in particular associated 
with an increased risk of the adverse cardiovascular and metabolic outcomes that are 
often attributed to adipokines (39,40). Indeed VAT is a prolific secretor of pro-inflammatory 
cytokines (41), and ageing is associated with increased VAT mass (2,5,42). Subcutaneous 
adipose tissue (SAT) mass does not appear to increase with age in men for a given body 
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mass index (BMI) (43), nor did it increase in a 2 yr prospective study of elderly African 
American women despite significant VAT gain (2). However, when younger and older 
cohorts are not BMI matched, an absolute gain of SAT in conjunction with increased body 
weight and BMI is evident with advancing age (44). Despite the prominent attention that 
VAT receives as a secretor of adipokines, SAT also secretes pro-inflammatory adipokines 
to a lesser extent (45–47). Furthermore, VAT represents a small proportion of total adipose 
tissue mass (12.7 % in endurance runners aged 27 to 69 yr (48)). Thus, SAT may be 
underappreciated as a contributor to the systemic inflammatory burden. Intramuscular 
adipose tissue (IMAT) mass also increases with age (42). However, little is known about 
adipokine secretion by IMAT due to the technical difficulties associated with its biopsy in 
adequate quantities for study.  
Recent work demonstrated an atrophic effect of adipokines secreted by adipocytes on 
human fetal myotubes (47). Myotube atrophy was most pronounced in adipocytes derived 
from VAT. However, the stromal vascular fraction (SVF) of adipose tissue, which includes 
preadipocytes and macrophages, is a more prolific secretor of pro-inflammatory cytokines 
than mature adipocytes (46). Consequently, adipokine secretion by human adipose tissue 
– not just that by adipocytes – must be characterised and its effect on aged human 
myofibre size and function determined. It must also be ascertained whether obesity alters 
the adipose tissue inflammatory milieu and the effects of these milieux on skeletal muscle 
detailed. Furthermore, there exists a need to identify which adipokine constituents of such 
milieux are most important with regard to skeletal myofibre size and function in ageing. 
TNFα and IL-6 are well studied in this respect (Section 1.7.2, 1.7.3). However, the effects 
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of other adipokines (e.g. resistin, leptin and visfatin) on myofibre size, development and 
function are not well characterised. 
Additionally, it is important to identify more avenues for the development of 
pharmacological therapeutic interventions in sarcopenia. To that end, interleukin 15 (IL-
15) is a myokine that is known to promote the formation of C2C12 myotubes in culture 
and can prevent the loss of skeletal muscle mass in mice exposed to systemic 
inflammation (49,50). It has been proposed that IL-15 is expressed by skeletal muscle in 
response to such pro-atrophic environments, to mitigate the loss of skeletal muscle mass 
(51).   However, the effect of IL-15 on human myofibre development, maintenance and 
hypertrophy remains unexplored. Furthermore, given the high concentrations of 
recombinant IL-15 (rIL-15) used in such studies, it is unclear whether autocrine skeletal 
muscle IL-15 secretion is necessary for adult myofibre maintenance and hypertrophy 
(50,52). If the pro-myogenic and hypertrophic actions of IL-15 are preserved in the skeletal 
muscle of elderly human participants, then IL-15 signalling may represent a promising 
therapeutic target in sarcopenia and cachexia. 
 
1.2      Skeletal Muscle Development, Structure and Function 
Skeletal muscle is a contractile tissue that facilitates voluntary movement and protects 
the viscera. Such movement encompasses gross and fine motor actions as well as the 
voluntary control of the urinary and gastrointestinal systems. Skeletal muscle has other 
important functions, e.g. as the body’s principal site for insulin-stimulated glucose 
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disposal and as an endocrine tissue (53). While myofibres – which are discussed in 
detail below – make up the preponderance of cells within skeletal muscle, other cells 
exist within the tissue. These include perineural cells and neurons as well as cells that 
make up the skeletal muscle vasculature, including pericytes, adventitial cells, 
endothelial cells and smooth muscle cells (54). Under normal physiological conditions 
few resident immune cells are present and are limited to a sparse population of 
macrophages (55). Importantly, fibroblasts also exist between myofibres. Fibroblasts 
are the principal producers of skeletal muscle extracellular matrix which provides 
skeletal muscle with stability and facilitates force transmission (56).  
The principal cellular units of skeletal muscle are the multinucleate muscle fibres termed 
myofibres. Embryonically, skeletal muscle originates from the mesoderm, with most 
muscles being derived from somite budding of the paraxial trunk mesoderm (57). The 
embryonic myogenic program is similar to that of adult myogenesis (Section 1.6.3.1). 
The molecular markers that define embryonic muscle precursor cells are broadly the 
same as those in adult SC, namely paired box protein 3 (PAX3) and paired box protein 
7 (PAX7), although the differentiation of some non-somite derived head and neck 
muscles is initially defined by alternative transcription factors, e.g. Paired-like 
homeodomain transcription factor 2 (PITX2) and  T-box transcription factor 1 (TBX1) 
(57). The myogenic regulatory transcription factors (MRFs) – Myogenic factor 5 (MYF5), 
MyoD, myogenin and myogenic regulatory factor 4 (MRF4) – are the master regulators 
of both adult and embryonic myogenesis, regardless of skeletal muscle mesodermic 
origin. MYF5 expression generally precedes that of MyoD and MRF4 as embryonic or 
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adult precursor cells commit to their myogenic lineage as myoblasts. However, the 
sequence of their expression varies with anatomical location (57). Myogenin expression 
occurs last, coinciding with the fusion of myoblasts to form terminally differentiated 
multinucleated myofibres. There exists a certain amount of functional redundancy in the 
embryonic expression of the MRFs, with severe defects in muscle formation occurring 
only in myogenin deficient mice (58) or those with combined MYF5, MyoD and MRF4 
gene knockouts (59,60). 
Mature adult myofibres are long, cylindrical, multinucleate structures of a diameter ~ 10 
– 100 µm and they extend from millimetres to centimetres in length (61). Individual 
muscle fibres, groups of fibres and each muscle are ensheathed by connective tissue 
layers termed the endomysium, perimysium and epimysium respectively (Fig. 1.1).  The 
myofibre membrane is referred to as the sarcolemma, and the cytoplasm is termed the 
sarcoplasm. Myonuclei exist in the sarcoplasm, between the sarcolemma and the 
contractile apparatus of the myofibre – the myofibrils. Myofibrils comprise repeated 
arrangements of contractile units called sarcomeres that are visible by electron 
microscopy. This arrangement is responsible for the striated appearance of skeletal 
muscle (Fig. 1.1).  The A and I bands correspond to the contractile thick (myosin) and 
thin filaments respectively (Fig.1.1).  An electro-dense line, the Z disc is evident in the I 
band, representing the area of the sarcomere where α-actinin anchors actin filaments 
and desmin envelops the myofibrils, binding them together. Titin forms intermediate 
filaments that span the sarcomere and connects the myosin thick filaments to the Z disc 
(61). Such filaments are untethered in the I band region of the sarcomere, conferring a 
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passive resistance to stretching and elastic recoil properties on the muscle (62).  
The thick myosin filaments comprise multiple (~ 200) myosin molecules. Each myosin 
molecule is formed by two heavy polypeptide chains and four light chains. The heavy 
chains are wrapped around one another, and their heads at one end are folded to form 
the myosin heads. Two light chains are associated with each myosin head to form the 
complete myosin molecule. Myosin molecules are bundled together to form myosin 
filaments, with myosin heads and a portion of the molecule called the arm protruding 
from the side of the filament to facilitate myosin interaction with the thin filaments (Fig. 
1.1). Thin filaments comprise a double-stranded F-actin molecule. The strands are 
composed of polymerised G-actin molecules, each of which binds one molecule of ADP, 
forming the so-called active sites for muscle contraction. Tropomyosin molecules are 
wrapped around each F-actin helix and troponin molecules (complexes of troponin I, T 
and C subunits) are attached to the side of thin filament (62). 
Human muscle fibres are commonly subdivided into ‘slow’ type I fibres and ‘fast’ type 
IIa and IIb fibres. Different isoforms of myosin exist and such fibres may be molecularly 
defined by their predominant isoform of myosin and the speed of that isoform’s ATPase 
activity.  Type I fibres display slower contraction and relaxation speeds as well as power 
outputs than type II fibres but display greater endurance and reliance on oxidative rather 
than glycolytic metabolism. Type IIa fibres are considered to be an intermediate between 




1.3    The Neuromuscular Junction and Myofibre Depolarisation 
The NMJ consists of the terminal end of a lower motor neuron (LMN), a synaptic cleft 
and the skeletal muscle fibre that it innervates. The motor neurons contain the 
neurotransmitter acetylcholine within synaptic vesicles (Fig. 1.2).  Depolarisation of the 
neuron induces the release of synaptic vesicles into the synaptic cleft where they bind 
to sarcolemmal acetylcholine-gated ion channels (receptors). The acetylcholine 
channels allow the flux of positive ions, principally the influx of sodium (Na+) ions, thus 
depolarising the sarcolemma. Sarcolemmal invaginations – the transverse tubules – 
extend throughout the muscle fibre to facilitate the spread of an action potential 
throughout the large cell. A specialised endoplasmic reticulum, termed the sarcoplasmic 
reticulum (SR) extends in a network between the myofibrils, and comes into contact with 
the transverse tubules to form triads of tubules sandwiched between SR cisternae (Fig. 
1.2).  The SR contains calcium-ATPase pumps that transport calcium into their 
cisternae, where they are sequestered by the protein calsequestrin. Transverse tubule 
depolarization causes SR calcium channels to open, releasing calcium into the 
sarcoplasm where it facilitates skeletal muscle contraction (62). 
 
1.4    Skeletal Muscle Contraction  
The sliding filament mechanism describes the interaction between myosin heads and 
the active sites of thin filaments to form myosin-actin cross bridges that initiate 
sarcomeric contraction. Myosin heads cleave adenosine triphosphate (ATP), and retain 
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the adenosine diphosphate (ADP) and phosphate ion products while storing the energy 
produced by extension of its head. Calcium ions bind to the troponin-tropomyosin 
complex, uncovering the active sites, thus facilitating the binding of the myosin head. 
The head tilts on binding, initiating a power stroke facilitated by the earlier cleavage of 
ATP. ADP and phosphate then detach from the head, allowing its detachment from the 







Figure 1.1. Skeletal Muscle Gross and Cellular Structure. Adapted from: OpenStax, Anatomy & 






Figure 1.2. Lower Motor Neuron and Skeletal Muscle Fibre Structure and Function. Adapted from: 
OpenStax, Anatomy & Physiology. OpenStax CNX. Feb 26, 2016, under a Creative Commons Attribution 
License 4.0.   
 
1.5    Primary Myogenic Cultures  
The isolation of SC, their culture as myoblasts and differentiation of such myoblasts to 
form surrogate in vitro myofibres – termed myotubes – has been extensively used in the 
exploration of skeletal muscle biology (64–70). The immortalised murine myoblast 
C2C12 cell line was developed by Blau et al. (71), building on the work of Yaffe and 
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Saxel (72) and it is widely used (64–68). Its suitability for the study of skeletal myofibre 
physiology is often justified by observations that C2C12 form multinucleated contractile 
cells that contain sarcomeres and express myosin and actin (64,71,73). The C2C12 cell 
line is convenient as it is immortal. However, its relevance to human myofibre physiology 
remains underexplored. Indeed, the expression of genes involved in myogenesis varies 
in both timing and magnitude between primary human and primary mouse myogenic 
cultures (74). C2C12 cells could suffer from the additional problem of accumulating 
chromosomal alterations and epigenetic changes with extended passaging, thus 
altering their phenotype further from that of both murine and human primary myoblasts 
(75).  
Some evidence exists to suggest that primary human myogenic cultures retain at least 
some of the characteristics of their donors. Such myotubes retain the insulin resistance 
of their donors (76), display increased palmitate oxidation rates (77) and fail to 
upregulate adiponectin receptor gene expression in response to globular adiponectin or 
leptin (78). Myotubes from obese participants accumulate lipid (79) and do not increase 
their expression of  cytochrome c Oxidase Subunit IV (COXIV) in response to leptin 
stimulation, unlike myotubes from their lean counterparts (78). However, primary human 
myotubes are not a perfect surrogate for in vivo myofibres. They express immature, fetal 
forms of myosin heavy chain (MHC) (80), generate smaller contractile forces than intact 
skeletal muscles (81–83) and handle intracellular calcium differently from mature 
skeletal muscle (84).   
Methods of SC isolation and myogenic culture conditions vary. No evidence exists to 
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suggest which protocol produces the most physiologically relevant myotubes. One 
priority in SC isolation is obtaining cultures that are free from the most likely 
contaminating cell type – fibroblasts (69,70). Fluorescence-activated cell sorting 
(FACS), or magnetic activated cell sorting (MACS) can be used to select cells based on 
a SC marker, e.g. α7 integrin (70) or CD56 (69). Alternatively, skeletal muscle digests 
can be pre-plated in an uncoated culture vessel to which fibroblasts preferentially 
adhere, before moving the cell suspension to a coated (e.g. 0.2 % gelatin) flask (73,85). 
This approach, combined with differential trypsinisation at passages one and two has 
consistently produced cultures in our lab that are negative for the fibroblast marker TE7 
(86) (see Section 2.4.1).  
Myoblast growth and differentiation conditions vary in terms of the media used. Firstly, 
the media can be divided into high and low glucose base media. Base media that 
promote the rapid expansion and differentiation of cultures are often high in glucose, 
e.g. Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12, 3.1 g/L 
glucose) (87) or high glucose DMEM (4.5 g/L glucose) (83). These glucose 
concentrations far exceed the fasting blood glucose of a non-diabetic individual (88). 
Indeed, in rodent L6 myotubes, 4.5 g/L glucose in combination with insulin (an additive 
often included in primary human myogenic culture media (69,87)), induces myotube 
insulin resistance (89). Some media that are used for the culture of human myogenic 
cells are supplemented with additional growth factors e.g. epidermal growth factor 
(EGF) and basic fibroblast growth factor (bFGF) to facilitate their rapid expansion (87). 
The concentrations of EGF and bFGF used (10 ng/mL and 1 ng/mL respectively in a 
16 
 
1.6    Sarcopenia 
The decline in skeletal muscle mass and quality in sarcopenia has been attributed to 
several important changes in skeletal muscle fibre size, type and distribution. Here, the 
performance of sarcopenic skeletal muscle is first described. The myofibre changes that 
underlie such alterations in skeletal muscle performance are then considered in detail. 
Finally, the cellular and molecular events underpinning such changes in fibre performance 
are elaborated upon. The major known aetiological factors underpinning sarcopenia are 
summarized in Fig. 1.3.  
commercially available formulation from PromoCell, Heidelberg, Germany (69)) exceed 
normal serum concentrations approximately 10-fold (90,91). We are unaware of any 
comparison of primary human myoblast culture and differentiation media to determine 
which conditions produce the most physiologically relevant myotubes. In the absence 
of such evidence, we employ a low glucose (1.1 g/L) base medium (Ham’s F10) 
supplemented with 20 % fetal bovine serum (FBS) for myoblast growth or 6 % horse 









1.6.1 Level 1: Skeletal Muscle Performance in Sarcopenia 
The presence of low muscle mass in addition to reduced muscle strength or impaired 
physical performance is required for the diagnosis of sarcopenia (6). The methods 
commonly used to measure such outcomes are summarised in Table 1.1. The EWGSOP 
guidelines summarise the diagnostic cut off points that have been used for these 
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outcomes in large studies of sarcopenia. However, no firm cut-off points were proposed 
by the working group, and the guidelines cite the need to establish firm reference values 
across ethnic groups (6). Poor skeletal muscle performance has important effects on 
activity in ageing. Low muscle mass (92,93) and poor muscle strength (92,94) predict a 
loss of physical independence. Prospective studies of sarcopenic individuals have 
reported a significant increase in the incidence of falls (12,95) and fractures (95,96), 
although co-existent low bone mineral density might be necessary to increase fracture 
risk (96).  
Sarcopenia is also independently associated with pathology at sites distinct from skeletal 
muscle itself, e.g. diabetes (97), cardiovascular disease (10), osteoarthritis (98) and 
cognitive impairment (99). A detailed discussion of the pathophysiological link between 
sarcopenia and these conditions is outside the scope of this thesis. The burden of such 
medical complications likely explains the link between sarcopenia and increased cancer 












1.6.2 Level 2: Skeletal Muscle Fibres in Sarcopenia 
1.6.2.1 Skeletal Muscle Fibre Size in Sarcopenia  
It is now well established that ageing is typified by a reduction in the size of individual 
skeletal muscle fibres, with the type II, so-called fast twitch fibres being most severely 
affected (104). Indeed, Lexell and Taylor showed that the mean vastus lateralis (VL) cross-
sectional area of type I fibres did differ significantly in men aged 69-85 compared to young 
controls aged 19-35; type II fibres were ~ 35 % smaller in an elderly cohort (105). Many 
studies have reported similar findings (Table 1.2). The VL is by far the most studied muscle 
in this regard, perhaps due to its functional importance in ageing as a major knee extensor 
Table 1.1.  Assessment of Muscle Mass, Muscle Strength and Physical Performance 
for the Diagnosis of Sarcopenia. 
Variable Measurement 




Total/partial body potassium per fat-free soft tissue 
Anthropometry 
  
Muscle strength Handgrip strength 
Knee extension/flexion 
Peak expiratory flow 
 
Physical performance SPPB 
Gait speed 
Timed get-up-and-go test 
Stair climb power test 
  
CT = Computed tomography, MRI = Magnetic resonance imaging, DXA = Dual-energy X-ray absorptiometry, BIA = bioimpedance 
analysis, SPPB = short physical performance battery.   Adapted from (6). 
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and as a byproduct of its accessibility for muscle biopsy. Very few studies have explored 
the effect of ageing on skeletal muscle fibre size in other muscles, yet there is some 
indication that the reduction in type I fibre size may be more variable outside the VL, with 
no decline observed in the tibialis anterior by Jakobsson et al. (106) and a profound 
decline (21%) described in the biceps brachii by Monemi et al. (107).  
 
Table 1.2. Percentage Changes in Skeletal Muscle Fibre Size in Elderly Cohorts 
Compared to Young Controls. Adapted from Lexell J Gerontol A Biol Sci Med Sci. 




Muscle Type I Fibres (%) Type II Fibres (%) 
Tomonaga 1977 
 
M/F 60-90 VL -7 -52 
Larsson, 1978 
 
M * VL -1 -25 
Scelsi,1980 
 






M 70 VL -15 -19 
 F 70 VL -25 -45 
Lexell, 1991 
 
M 69-84 VL -6 -35 
      
Jakobsson, 1990 M/F 66-77 TA 0 -30 
Monemi 1998 (diameter) M 58-83 Mas. -13 -26 
   BB -21^ -32^ 
Verdijk 2007 M 76±1 VL n.s. -27 
Nilwik 2013 M 71±1 VL n.s. -30 
Kramer 2017 F 79±2 VL n.s. -22 
Fibre size measured as cross-sectional area unless otherwise stated. ^Denotes fibre diameter measurement. VL = vastus lateralis, 
TA = tibialis anterior, Mas. = masseter, BB = Biceps brachii, n.s. = non-significant difference vs controls. Where no age range is 
detailed, mean ± SEM age are quoted. 
 .  
 
1.6.2.2 Skeletal Muscle Fibre Number in Sarcopenia  
Studies of muscle fibre changes with age demonstrate reductions in total muscle cross-
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sectional area (CSA) which exceed those which could be accounted for by reductions in 
muscle fibre area alone; in one study, 80-yr-olds displayed a ~ 33 % reduction in soleus 
CSA compared to young controls, but a reduction of only ~ 20 % in mean muscle fibre 
CSA (108). One possible explanation for such a discrepancy is a reduction in absolute 
fibre number. Indeed it was in the vocal muscles (109) and the pectoralis minor (110) that 
a reduction in fibre number was first demonstrated, with the numbers of type I fibres being 
retained until a more advanced age than type II fibres which declined in number only 
beyond 60 yr in the pectoralis minor and 80 yr in the vocal fold. Subsequent studies by 
Lexell on whole cadaveric VL showed that ageing is associated with a loss of total fibre 
number and that fibre number correlates more strongly with muscle area than does mean 
fibre area, again highlighting the importance of fibre loss in ageing (111,112). Furthermore, 
preferential loss of type II fibres, distinct from alterations in their size has emerged as an 
age-related phenomenon since it was first described (109,110). LMN are lost with 
advancing age, with those innervating type II fibres being disproportionally affected (113). 
This phenomenon is discussed further in Section 1.6.3.3. 
 
1.6.2.3 Skeletal Muscle Fibre Contraction in Sarcopenia 
The decline in individual fibre performance represents an additional potential mechanism 
underlying age-related declines in skeletal muscle performance. Isolated fibres from old 
individuals appear to have reduced shortening velocity (114,115) and force production 
(115,116) in both type I and type IIa fibres compared to those of young controls, although 
no age-related difference in CSA-normalised fibre performance has been shown in 
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sedentary populations (117). An age-associated decline in MHC concentration within 
individual fibres (regardless of their fibre type) is thought to underlie reductions in their 
force production (115). It has been suggested (118) that age-related changes in fibre 
shortening velocity are due to myosin molecule defects that produce a slower myosin-
actin sliding speed (119).  Isolated skeletal muscle fibre performance is modifiable in old 
age. One year of resistance exercise training in elderly women increased the specific force 
of type I and type IIa fibres, as well as the shortening velocity of type I fibres, even in the 
absence of an increase in fibre CSA (118). Immobilisation adversely affects the shortening 
velocity of elderly muscle fibres (115). 
It is clear from the preceding discussion that sarcopenia is characterised by changes in 
skeletal muscle fibre number, size, distribution of type and individual fibre performance. 
However, skeletal muscle exists in proximity to other tissues that alter its mechanical 
function. Adipose tissue mass has generally been found to increase in parallel with 
sarcopenia, a phenomenon termed sarcopenic obesity (3,4), and ageing is in particular 
associated with increased IMAT e.g. frail elderly have increased quantities of IMAT, and 
decreased lean body mass compared to their age-matched non-frail counterparts (120). 
In addition to its proposed inflammatory and atrophic effects (Section 1.7.1), IMAT is 
increasingly thought to mechanically influence skeletal muscle function. Greater 
accumulation of IMAT is associated with poorer physical performance (121,122), and a 
recent finite element analysis model of human skeletal muscle concluded that 
accumulation of IMAT reduces skeletal muscle mechanical performance by altering 
muscle stiffness (123). Pennation angle is the angle at which skeletal muscle fibres insert 
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into a tendon relative to the longitudinal axis of a muscle (124), and this is an additional 
feature of muscle architecture that may influence skeletal muscle performance in the 
elderly. Pennate muscle arrangements allow a greater number of fibres to exist within a 
given muscle volume, at the expense of force production along the longitudinal axis of a 
muscle (124). The elderly have reduced pennation angles within the VL compared to their 
young counterparts (125), perhaps in part due to the age-associated reductions in fibre 
number and area previously discussed. 12 wk of ski training in elderly participants 
significantly increased VL pennation angle and induced a 7.1 % increase in VL thickness 
as measured by ultrasound (126). In one study, obese elderly women had a significantly 
increased pennation angle in the major knee extensor muscles, yet they displayed 
significantly lower knee extension torque normalised to muscle CSA (~ 25 % of normal 
weight controls) (127). Indeed, the accumulation of IMAT described in the obese 
participants may represent an underlying cause of the increased muscle pennation angles 
(123). This, coupled with an insufficient compensatory increase in muscle fibre CSA, may 
compromise longitudinal muscle force production. 
 
1.6.3 Level 3: Cellular and Molecular Determinants of Skeletal Myofibre 
Performance in Ageing 
Having discussed how myofibre changes underpin an age-related decline in skeletal 
muscle performance, an overview of the important determinants of such changes is 
necessary. The inflammatory drivers of sarcopenia are the principal focus of this thesis 
and are considered in detail in Section 1.7.  However, our current understanding is of 
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sarcopenia as a multifactorial pathophysiological process, in which the aetiological factors 
that are often cited as underlying a decline in myofibre and skeletal muscle performance 
span a continuum from the molecular to the integrated physiological.  Indeed, as our 
understanding of the causes of sarcopenia is incomplete, it is often difficult to appreciate 
which factors represent the primary pathophysiological insult and which are merely 
aggravators of sarcopenia. In addition to inflammation, the factors that are most often 
considered include altered SC function, neuromuscular pathophysiology, a decline in 
mitochondrial health, inadequate nutrition, and a decline in physical activity. They are 
considered here, with some attempt being made to infer their importance and 
interdependence as events in the development of sarcopenia.  Their relationship to 
inflammaging is also considered. The accumulation of intramyocellular lipid, insulin 
resistance (IR) and their relationship to sarcopenia are considered briefly in a later section. 
 
1.6.3.1 Skeletal Muscle Satellite Cells and Adult Myogenesis in Sarcopenia 
SC are muscle precursor cells and exist in a niche between the basal lamina and the 
sarcolemma of myofibres (128). They are self-renewing and can give rise to differentiated 
myofibres. Thus SC meet the fundamental definition of a stem cell (129).  
Quiescent SC express high levels of the transcription factor Pax7 (130,131) and in some 
muscles Pax3 (132). Pax7 is essential for normal postnatal skeletal muscle development 
(130). SC proliferate upon activation and daughter cells either commit to a myogenic 
lineage as myoblasts or retain high levels of Pax7 expression and renew the SC pool. 
Those SC committed to myogenesis – the proliferating myoblasts – express MyoD and 
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MYF5. Expression of the differentiation factors myogenin and MRF4 is necessary for 
myoblasts to fuse to each other and to existing myofibres, thus forming mature, multi-
nucleated myotubes (129). 
SC are required for optimal hypertrophic responses of skeletal muscle to stimuli and are 
essential for muscle repair. SC are conditionally depleted by > 90% in tamoxifen-treated 
Pax7-DTA mice (133). When synergist muscles are removed, no difference in the degree 
of initial plantaris hypertrophy is observed compared to vehicle-treated mice (134). 
However, the hypertrophic response to synergist muscle removal plateaus beyond two 
weeks, with vehicle-treated mice displaying a 1.5 times greater increase in muscle size 
than the SC-depleted counterparts after eight weeks (133). Furthermore, it has previously 
been thought that SC remain quiescent in their niche until skeletal muscle is exposed to 
a challenge e.g. exercise or trauma. However recent murine evidence challenges this 
paradigm with 20 % of hindlimb myofibres containing new tdTomato-labelled SC after a 2 
wk lineage-labelling period (135). 
The myonuclear domain (MND) – the volume of cytoplasm regulated by each nucleus in 
an individual myofibre (136) – increased by 32 % in tamoxifen-treated Pax7-DTA mice 
over their controls up to 2 wk (134). Unfortunately, the MND  was not measured in the 
follow-up study, but an inability to expand the domain further may in part explain the 
importance of SC abundance to long-term skeletal muscle hypertrophy (133). Plantaris 
hypertrophy in response to synergist removal was similar in young (five months) and aged 
(25 months) Wistar rats. Yet, the aged rats had 26 % more myonuclei per unit of fibre 
length compared to their younger counterparts. Myonuclear accretion appears to be 
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particularly important in sustaining skeletal muscle hypertrophy in ageing. The importance 
of SC to skeletal muscle repair is further underlined by murine studies of SC depletion, in 
which muscle regeneration in response to cardiotoxin-induced skeletal muscle injury is 
severely impaired (137–139).  
Having established that SC are important in murine skeletal muscle regeneration, 
maintenance and hypertrophy, it is plausible that any impairment of their function in human 
ageing may contribute to sarcopenia. The number of SC within human skeletal muscle 
decreases with age, specifically within the atrophy-prone type II muscle fibres (140–142). 
Animal studies have suggested that SC proliferative capacity is impaired with age (143–
145). Under standard culture conditions, myoblasts derived from young and old 
participants display no differences in terms of growth and differentiation capacity (146). 
The culture of myoblasts from young participants in medium supplemented with elderly 
serum does not affect their desmin expression or differentiation to myotubes (147). 
However, culture of myoblasts from elderly participants in autologous serum adversely 
affects their differentiation to myotubes (148). This literature should be interpreted with 
caution as primary human myotubes were cultured in a variety of media and it is unclear 
which conditions produce the most physiologically representative myotubes (see Section 
1.5). Pertinently, given the alterations in MND observed in SC-depleted mice and in aged 
rats (133,137–139,149), changes in MND have also been seen in the skeletal muscle 
fibres of elderly human participants. In the atrophy-prone type IIa fibres of the VL in 
healthy, sedentary elderly men and women, both nuclear numbers and MND are 
significantly decreased (Nuclear number, 27%; MND, 37%) (136). Only nuclear number 
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appears to be significantly diminished in type I fibres (136).   
The mechanisms underlying the loss of SC in aged skeletal muscle are unclear and their 
discovery is hampered by the requirement to remove SC from their niche in order for a 
comprehensive study to take place. Such removal forces SC to differentiate into 
myoblasts, which are not SC, but an intermediate cell in the development of myofibres 
(150).  As such, assertions that increased reactive oxygen species (ROS) production 
(151,152) and reduced antioxidant activity in myoblasts derived from elderly participants  
(152,153) are representative of SC physiology are inaccurate. However, the idea that 
mitochondrial and metabolic dysfunction might underlie the loss of SC activity in ageing 
has merit, particularly given the evidence of mitochondrial-driven skeletal muscle loss in 
mature myofibres (Section 1.6.3.2). 
The reduction in skeletal muscle SC content appears to be only partially reversible with 
increased physical activity. In young participants, a single bout of resistance training 
increases VL SC in type I and type II fibres at 48 h post-exercise (154). In the elderly, 
resistance training increases SC content in type I fibres at 48 h (155,156) but type II fibre 
SC content is not increased at this time point (155,156), increasing only at 72 h and 
remaining significantly (14 %)  lower than the SC numbers observed in the young (155). 
12 wk resistance training studies in the elderly have shown that SC content increases only 
in type II fibres over the longer term (17,142) and remains ~ 25 % lower than values seen 
in healthy, untrained young adults (142).  
Endurance exercise for increasing skeletal muscle SC content in the elderly is less well 
studied. A single bout of endurance training did not increase type I or type II fibre SC 
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numbers in sedentary older men (156). However, 10 d of increased training load in 
endurance-trained young individuals may increase type II myofibre SC content (35 ± 28%) 
as well as myonuclear density (16 ± 6 %), within type II myofibres (157). Contrastingly, 10 
wk of cycle training in untrained young men increased type II fibre SC content (158). In a 
study of elderly lifelong endurance runners, type II fibres were smaller and had fewer SC 
than the fibres of their young active controls. However, lifelong endurance running 
preserved type II fibre SC number relative to fibre area, a phenomenon not seen in 
sedentary elderly (159).  
It is clear from the above discussion that skeletal myofibres are not static entities with a 
fixed number of myonuclei that simply increase and decrease their myofibrillar content 
over time. They are dynamic cells, in which SC activation and myoblast fusion play an 
important role over the course of an adult lifespan. Primary human myogenic cultures (see 
Section 1.5) offer a useful, if imperfect in vitro model for examining such physiology in the 
context of adipose-derived inflammation.  
 
1.6.3.2 Myofibre Mitochondrial Dysfunction and Sarcopenia 
Outside of the SC niche, within mature skeletal muscle fibres, mitochondrial deficits may 
contribute to declining muscle function and mass with age. Such deficits have been 
suggested to include respiratory chain deficiencies, enhanced ROS production and 
mitochondria-driven skeletal muscle apoptosis (160,161). Mitochondrial mass is 
decreased in sedentary older adults, but habitual physical activity preserves it (162,163), 
along with the expression of peroxisome proliferator-activated receptor gamma 
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coactivator 1-alpha (PCG-1α) (163,164), the so-called ‘master regulator of mitochondrial 
biogenesis’ (161).  
Skeletal muscle mitochondrial DNA content declines with age, with substantial deletions 
being most commonly described. It is thought that these deletions are inherited or 
acquired in early life, with their burden increasing throughout the lifespan by clonal 
expansion. This results in a mixture of respiratory deficient affected (~ 5-14 %) and 
unaffected skeletal muscle fibres (161,165). However, only 5 % of these abnormal fibres 
are atrophied in healthy older adults (166). It is unclear whether respiratory deficient fibres 
are functionally affected in terms of fatigability or force production, although respiratory 
complex IV deficiency in mice does produce a progressive functional decline (167).  
Older studies of rodents, in which mitochondria were mechanically isolated, suggested 
that ageing is associated with an increase in skeletal muscle ROS production (168–170). 
However, recent evidence from saponin-permeabilised fibres suggests that this method 
of mitochondrial isolation exaggerates the difference in skeletal muscle mitochondrial 
function between young and old animals (171). Increased ROS production is not 
consistently demonstrated in permeabilised fibre bundles from aged rodents (171,172), 
and skeletal muscle ROS production does not appear to be predictive of the degree of 
atrophy within individual rodent muscles (172). Furthermore, a recent human study found 
no difference in such ROS production in the skeletal muscle of very old (> 75 yr) 
participants compared to younger elderly (60-75 yr) participants, despite the very old 
having smaller VL myofibres (173).   
Myofibres isolated from the VL of physically active elderly men have enhanced 
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mitochondrial-derived markers of apoptosis, e.g. 3-fold increase in endonuclease G 
compared to their young counterparts (174) and aged human mitochondria are more 
sensitivity to permeability transition, which facilitates the release of mitochondrial pro-
apoptotic proteins (173,174). It is therefore plausible that sarcopenia may in part be 
mediated by apoptosis. Indeed, mitochondria-driven skeletal muscle apoptosis is active 
in aged rats and correlates with the progression of sarcopenia (175), although direct 
evidence of nuclear apoptosis leading to skeletal muscle fibre atrophy or loss in human 
muscle is lacking (160). It would appear that this feature of sarcopenia is not amenable to 
reversal by physical activity (173,174). 
It is difficult to say with any certainty whether the mitochondrial deficits in skeletal 
myofibres that are described here are primary events in the development of sarcopenia. 
Given that physical activity supported by appropriate nutrition (Section 1.6.4.1) is the only 
intervention known to ameliorate sarcopenia, the susceptibility of physically active elderly 
to LMN loss and mitochondria-derived apoptosis must be considered a significant 
indicator of their importance in sarcopenia. It is also challenging to place this mitochondrial 
pathophysiology in the context of inflammaging. If such deficits represent primary events 
in sarcopenia, it is possible that they might, in fact, contribute to the burden of 
inflammation. For example, mitochondrial damage-associated molecular patterns 
(DAMPs), released from damaged mitochondria stimulate the innate immune system 
(176). However, adipokines might also be detrimental to mitochondrial function. This is 




1.6.3.3 Neuromuscular Signalling in Sarcopenia 
Neuromuscular signalling is broadly impaired with age. Loss of LMN was first described 
in human post-mortem tissues 40 yr ago (113), with the number of lumbosacral limb motor 
neurons declining by ~ 20 % by the eighth decade. LMN innervating type II fibres are 
disproportionally affected, with denervated fibres either lost or reinnervated by adjacent 
LMN.  This leads to the phenomenon known as ‘fibre type grouping’ in which motor unit 
size increases and fibres within these larger motor units are restricted to one myosin 
heavy chain isoform (177,178). Such fibre type grouping is not ameliorated by physical 
activity; lifelong runners are similarly affected (179). The mechanisms underlying the loss 
of LMN are incompletely understood. Diminished mitochondrial complex I activity has 
been observed in the spinal neurons of the elderly, compared to foetal controls. Such 
neurons were also smaller and had a reduced mitochondrial DNA content (180). This 
implicates mitochondrial pathology in the loss of LMN with age. Other work in aged rats 
demonstrated morphologically abnormal mitochondria and the apoptosis markers 
caspase 3 and cytochrome c in axon terminals, near the NMJ (181). Caspase 3 
colocalised with dynein in this study, raising the possibility of retrograde caspase 3 
transport to the cell soma, where it may affect neuronal viability (181).  
In addition to the ‘dying back’ phenomenon, in which axonal terminal mitochondrial 
pathology might affect neuronal viability, such pathology may also affect neurotransmitter 
release and synaptic function.  Garçia et al. described axonal terminal mitochondria in 
aged rats that were two to three times larger than elsewhere in the neuron. They were 
electron-deficient, with ruptured mitochondrial matrices and lacked cristae. Furthermore, 
32 
 
the mitochondria displayed an increased tendency towards fusion and thus the formation 
of megamitochondria (181). Crucially, synaptic mitochondria play a role in regulating 
synaptic function, notably by buffering intracellular calcium to regulate exocytosis and 
endocytosis of synaptic vesicles and by providing ATP to facilitate synaptic vesicle 
recruitment from the reserve pool to active zones (182). It is therefore plausible that 
dysfunctional aged mitochondria might affect axonal synaptic signalling and thus skeletal 
muscle function, although this requires further study in humans. In aged rodents, 
fragmentation of the normal, continuous 'pretzel-like' post-synaptic acetylcholine receptor 
pattern occurs (183), and NMJ denervation precedes the development of sarcopenia, 
lending credence to the hypothesis that such NMJ changes drive the muscular changes 
of sarcopenia (184). However, whether the primary event is neurological or muscular 
remains to be seen (183). The relationship between these neural deficits and 
inflammaging remains underexplored (185). 
 
1.6.4 Sarcopenia: Consequences and Management 
Given its complex aetiology, many potential therapeutic strategies and targets exist to 
counteract sarcopenia, but no panacea is likely to be discovered. Therefore, to develop 
an evidence-based, multifaceted approach to the management of sarcopenia. we must 
continue to explore its aetiology. The inflammatory crosstalk between skeletal muscle and 
adipose tissue in ageing – the principal focus of this thesis – is one such avenue of 
exploration. Physical activity, diet and existing pharmaceutical interventions for the 




1.6.4.1 Physical Activity and Diet 
It is evident from the preceding discussion of the cellular and molecular pathophysiology 
driving sarcopenia that physical activity can partially reverse such changes. Indeed, 
decreased physical activity is common in ageing (186,187), and this phenomenon 
represents both a cause of and potential therapeutic intervention for sarcopenia. Cross-
sectional studies have shown that skeletal muscle mass (measured by dual-energy X-ray 
absorptiometry, DEXA) has a strong positive association with self-reported physical 
activity levels in those over age 60 (16,188). Habitual endurance training can increase 
knee extensor peak isometric force, knee extensor one-repetition maximum and peak grip 
strength, albeit without an increase in total lean body mass (189). Some older studies 
found that masters endurance athletes did not have improved skeletal muscle strength, 
power or mass compared to their sedentary counterparts (190–192). It is suggested (189) 
that this may be reflective of the decrease in skeletal muscle fibre size that may be seen 
with marathon training in the young (193).  
Although power and strength decrease at a similar rate in masters weightlifters compared 
to untrained controls, in one study, they generated on average 32 % more absolute peak 
power and 32% greater isometric knee extensor force than their sedentary counterparts. 
Furthermore, they reached their absolute peak power 13 % faster (20). Thus, resistance 
training may represent a useful intervention in the prevention of sarcopenia. Indeed, 
prospective RT interventions (12-24 wk duration) in which daily protein intake exceeds 0.9 
g protein/kg/d have been shown to increase skeletal muscle mass, strength (17,18) and 
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whole body protein mass in the elderly (194). However, the current recommended daily 
intake (RDI) of 0.8 g protein/kg/d appears insufficient to prevent loss of lean body mass 
(LBM) or to facilitate increases in skeletal muscle mass following resistance training in an 
older population. Campbell et al. demonstrated that consuming a euenergetic diet 
containing the RDI of protein for 14 wk did not facilitate increases in whole body muscle 
mass in resistance trained elderly and promoted the accrual of body fat in both resistance 
training and sedentary groups (19). While mid-thigh muscle area was increased by 
resistance training, the sedentary group lost muscle area (19). Such observations in 
longer-term studies are in keeping with acute observations that older individuals require a 
greater quantity of protein than their younger counterparts to maximally stimulate muscle 
protein synthesis (MPS) at rest (195,196) and post-exercise (197). The importance of 
adequate protein intake to support MPS in the elderly is evident. However, the financial 
constraints of living on a fixed income, an inability to prepare meals due to frailty, 
difficulties in chewing and swallowing as well as nutrient malabsorption often conspire to 
prevent sufficient nutritional intake in this population (198). Dietary supplementation with 
vitamin D, ursolic acid and omega-3 fatty acids have also been proposed as strategies 
that might ameliorate sarcopenia (199); detailed discussion of their merits is outside the 
remit of this thesis.  
Maintenance of physical activity, supported by adequate nutrition into old age is therefore 
partially effective at preventing and reversing sarcopenia. Additionally, physically active 
older adults (55 to 64 yr) have reduced fat mass (4.9 kg in men, 2.5 kg in women) 
compared to their sedentary counterparts (200).  This is pertinent to the central hypothesis 
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of this thesis – that adipose-derived inflammation is one aetiological factor in sarcopenia. 
1.6.4.2 Pharmacological Interventions in Sarcopenia 
No effective pharmacological interventions exist for the treatment of sarcopenia. Myostatin 
is a negative regulator of muscle growth (201); its inhibition is therefore of considerable 
interest as a target in anti-sarcopenia drug development. A myriad of potential myostatin 
inhibitors have been developed and trialled to different extents, including anti-myostatin 
antibodies, myostatin propeptide, soluble myostatin receptors as well as follistatin and 
similar proteins (follistatin is an endogenous inhibitor of myostatin) (202). In a phase 2 
clinical trial, the myostatin neutralising antibody LY2495655 significantly increased LBM 
and improved physical performance in elderly who had fallen in the previous year (203). 
Such treatment requires monthly subcutaneous injection of the antibody and is therefore 
unlikely to be a viable preventative intervention for the wider elderly population.  
Growth hormone (GH) and its analogs are often considered as potential interventions for 
sarcopenia. Systemic GH concentrations decline with age (204). GH administration to 
elderly increases LBM and decreases adipose tissue mass (205,206).  GH has been 
approved by the federal drug administration (FDA) for the treatment of the muscle wasting 
associated with chronic human immunodeficiency virus (HIV) infection (207). However, 
the efficacy and safety of GH for the long-term (> 1 yr) treatment and prevention of 
sarcopenia has not been established, despite the fact that it is often used off-label in the 
nebulous discipline of ‘anti-ageing medicine’ (208).  
Systemic testosterone concentrations decline with age (209,210), and testosterone 
administration improves skeletal muscle mass and performance (211–213). However, 
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concerns remain regarding the safety of testosterone, particularly with regard to 
cardiovascular events (214), prostate cancer (215–217) and polycythaemia (218) and 
indeed, that an increased risk of these events exists with testosterone administration 
remains equivocal. SARMs are androgen receptor ligands. Some have shown an ability 
to increase lean body mass in phase I and II clinical trials (219–221). However, none has 
met the criteria for approval.  
It is therefore evident that continued exploration of the mechanisms underlying sarcopenia 
is necessary, to diversify the pharmacological targets at our disposal. 
 
1.7 Sarcopenic Obesity and Inflammaging  
The pro-inflammatory, endocrine function of adipose tissue is particularly pertinent in 
ageing as adipose tissue mass has generally been found to increase with age (3,4). 
Ageing is consistently associated with increases in VAT and IMAT, regardless of sex or 
race (2,4,5,42). Ageing is also associated with chronic low-grade inflammation, referred 
to as “inflammaging” (23). Plasma CRP levels, a biomarker of generalised systemic 
inflammation, increase with age (24); a study of almost 9,000 adults in the USA found the 
median plasma CRP to be 1.4 m/L in those aged 20-29 and 2.7 mg/L in those aged 80 or 
older (24). Importantly, given the association of ageing with adipose tissue accumulation, 
obesity is also independently associated with inflammation (30–33).  
Roubenoff has proposed that loss of LBM and the resulting reduction in energy 
expenditure, promote the gain of adipose tissue that is observed in ageing (222). Such a 
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hypothesis has merit; resting energy expenditure decreases with age (5,223), and this 
decrease can largely be explained by a reduction in LBM (224). Furthermore, low resting 
energy expenditure is associated with an increased risk of obesity (225–227). The 
complexity of the aetiology of sarcopenia has been established in earlier sections of this 
chapter. Thus, the possibility that adipose tissue accumulation might be both a cause and 
a consequence of LBM loss is not surprising. Reduced overall activity levels are also likely 
to play a large part in age-related adiposity (228).  
 
1.7.1 Adipose Tissue Structure and Function 
Adipose tissue is located in two principal anatomical depots throughout the body: 
subcutaneously, between skeletal muscle and the dermis (SAT), and intra-abdominally, 
surrounding the viscera (VAT). Adipose tissue serves to protect underlying tissues and 
provides thermal insulation (229).  
Adipocytes may be subdivided into white and brown adipocytes (229).  White adipocytes 
function as a lipid storage depot, storing fuel as triglycerides when it is in surplus, and 
releasing free fatty acids to facilitate ATP generation in times of fuel scarcity (229). Their 
cytoplasm is dominated by a large unilocular lipid droplet. The storage of triglycerides is 
facilitated by expansion of existing adipocytes (hypertrophy) and formation of new 
adipocytes (hyperplasia) (230). 
Brown adipocytes exist in discrete anatomical areas in both SAT and VAT, and their 
number decreases with age (231). Brown adipocytes are thermogenic cells, under the 
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control of the sympathetic nervous system. They produce heat to maintain temperature 
homeostasis via uncoupled oxidative phosphorylation that is facilitated by uncoupling 
protein 1 (UCP1) (229). Their high rate of fatty acid oxidation is facilitated by triglycerides 
that are stored within many small lipid droplets (229).  
In addition to its energy storage and mechanical protective functions, adipose tissue is an 
endocrine organ that is a prolific source of pro-inflammatory cytokines (adipokines). 
Proteomics approaches have identified over 200 potential adipokines that are expressed 
by human subcutaneous adipocytes (34). Adipokines are now known to have distal effects 
on many tissues, not just skeletal muscle (35) and are implicated in the development of 
insulin resistance, cardiovascular disease and cognitive decline (36–38). 
Hypertrophic adipocytes are associated with a greater secretion of pro-inflammatory 
adipokines (45), but adipokine secretion in obesity is not restricted to adipocytes 
themselves. Other cell types reside within adipose tissue, (e.g. mesenchymal stem cells, 
preadipocytes, endothelial cells, pericytes, T cells, and M2 macrophages) and are 
collectively termed the SVF. In vitro, the SVF is a more prolific secretor of pro-inflammatory 
cytokines (e.g. IFNγ, IL-1β, TNFα) than mature adipocytes (46). Notably, co-culture of the 
SVF with mature adipocytes produces a unique highly inflammatory cytokine profile (46). 
Thus, the cytokine secretion by adipose tissue as a whole, not just that by its individual 
cellular components would appear to be of the most physiological relevance. Increased 
numbers of resident macrophages have been found in the obese adipose tissue of both 
mice (232,233) and humans (234); furthermore, obesity may induce a switch from the M2 
anti-inflammatory macrophage state to the M1 proinflammatory state (235,236). A study 
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of mice has suggested that absolute numbers of adipose tissue macrophages do not 
increase in lean elderly, but there is a relative increase in M1 macrophages (235).   
Gross anatomical depots display different adipokine secretory profiles. VAT accumulation 
is associated with an increased risk of adverse cardiovascular and metabolic outcomes 
(39,40), a phenomenon that is often attributed to its prolific secretion of pro-inflammatory 
cytokines (41). In obese participants, portal vein (which drains VAT) IL-6 concentrations 
are 1.5 times those of the systemic circulation, although leptin concentrations are 
significantly lower (237). Adipocyte hypertrophy (238,239) and macrophage accumulation 
(234,240) are two important determinants of adipose tissue inflammation and are more 
prominent in VAT than SAT. Unfortunately, little is known about adipokine secretion by 
IMAT due to the technical difficulties associated with its biopsy in adequate quantities for 
study. This is an area which requires further study, given the proximity of IMAT to skeletal 
muscle fibres. 
Lipids may also accumulate within skeletal muscle myofibres (intramyocellular lipid; 
IMCL). Fatty acids are transported into skeletal muscle fibres and are channelled towards 
1) storage as triacylglycerols (TAG); 2) mitochondrial oxidation; or 3) conversion to 
signalling molecules (including eicosanoids, phospholipids and ceramides). Dysfunctional 
intramyocellular fatty acid handling and IMCL accumulation have a well-established if 
incompletely understood association with skeletal muscle insulin resistance (SKM-IR). 
Particularly, the accumulation of specific lipid intermediates, namely diacylglyerol (DAG) 
and ceramides has been suggested to mediate SKM-IR. Dysfunctional fatty acid uptake 
by skeletal muscle and IMCL lipid accumulation is – at least in part – an age-related 
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phenomenon, having been observed to occur in lean and overweight non-diabetic men 
(241). In addition to their effects on skeletal muscle insulin sensitivity, IMCL may contribute 
to sarcopenia. Diet-induced obesity and IMCL accumulation inhibit rodent skeletal MPS 
(242–244); furthermore, lipid infusion in healthy young men inhibits MPS (245).  
Both insulin and amino acids promote MPS via mammalian target of rapamycin complex 
1 (mTORC1) signalling, raising the possibility that insulin resistance in ageing might 
reduce MPS (246–248). However, considerable evidence exists to suggest that it is the 
vasodilatory effects of insulin, which most affect MPS. In healthy young adults, nitric oxide 
synthase inhibition prevents insulin-induced increases in MPS (249). In one study, femoral 
amino acid-glucose infusion increased MPS in the young, but not in the elderly; following 
the infusion, plasma arterial insulin concentrations were significantly lower in the elderly 
(250). It must be remembered that amino acid ingestion alone is capable of enhancing 
MPS in the elderly (251,252) (Section 1.6.4.1). Despite this, under conditions of combined 
carbohydrate and protein feeding – an experimental condition that better reflects real-
world nutrient consumption and allows for an endogenous insulin response – MPS rates 
are diminished in the elderly compared to their young counterparts (250,253). Pertinently, 
leg blood flow does not increase in response to hyperinsulinaemia in older people (254). 
Additionally, insulin-induced inhibition of whole body (255) and leg proteolysis (256) is 
diminished in the elderly. 
 
1.7.2 Adipokines and Skeletal Muscle Mass 
Having described the phenomena of sarcopenic obesity and inflammaging and having 
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highlighted the prolific production of pro-inflammatory cytokines by adipose tissue, it is 
important to outline broadly what is known about the effect of such adipokines on skeletal 
muscle mass. 
In sarcopenia, the multifaceted nature of LBM loss leads to a substantial and therefore 
easily detectible change in LBM. If adipokines indeed represent one facet of the 
sarcopenic process, then one might expect to see a decrease in LBM in younger obese 
individuals, although the magnitude of the LBM loss in the young is likely to be 
considerably smaller given the multifactorial nature of sarcopenia. Additionally, skeletal 
muscle loss may not be as great in young obese individuals, as obesity represents an 
overload stimulus acting on anti-gravity muscles, promoting increased absolute muscle 
mass and strength (257). However, skeletal muscle strength relative to total body mass is 
reduced in the obese, indicating that the increase in total strength is functionally 
inadequate (257).  
Despite the confounding factor of obesity being an overload stimulus on skeletal muscle, 
limited cross-sectional studies exist to suggest that visceral fat area (VFA) correlates 
negatively with skeletal muscle mass in the young. In one study of healthy young men of 
normal BMI, a significant negative correlation existed between VFA and total skeletal 
muscle mass (R=-0.57, P < 0.001); a negative correlation with skeletal muscle mass also 
existed for subcutaneous fat area (SCFA) (R=-0.55, P < 0.001) (258). In a slightly older, 
largely middle-aged population, those with coexisting visceral obesity and low muscle 
mass had a larger VFA than those with visceral obesity or low muscle mass alone, 
although this did not reach significance (259). Genetic factors may play a role in such a 
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phenomenon, with Asian-American young women being particularly prone to coexistent 
obesity and low BMI (260).  
In the elderly, the association between systemic inflammation, adipose tissue mass and 
sarcopenia is more pronounced. The cross-sectional Health, Aging, and Body 
Composition (Health ABC) Study of 3075 men and women aged 70–79 years 
demonstrated that those with high systemic concentrations of TNFα and IL-6 had a smaller 
mid-thigh muscle cross-sectional area and decreased grip strength (27). Furthermore, 
longitudinal studies of large elderly cohorts have positively associated high systemic 
concentrations of IL-6, CRP and TNFα and with loss of skeletal muscle mass (25,26). 
Indeed, the risk of losing 40 % of grip strength over 3 yr was increased 2 to 3-fold in those 
with a combination of increased serum IL-6 (> 5 pg/mL) and CRP (> 6.1 µg/mL) (25). 
Cross-sectional studies of the body composition of individuals across the lifespan found 
that total adipose tissue mass (28) and VAT mass (29) negatively correlated with skeletal 
muscle mass. A 2 yr prospective study of 379 Korean men and women also demonstrated 
that VAT area, as measured by DEXA, predicted appendicular lean soft tissue area at 2 
yr (r2 = -0.203, p < 0.001) (259). Caution must be exercised in inferring causation from 
such correlative data, but the consistent finding of a negative association between adipose 
tissue mass and skeletal muscle mass/LBM adds considerable weight to the validity of 
exploring adipokine-mediated sarcopenia.  
Indeed, the anti-myogenic and pro-atrophic actions of some adipokines are now well 
established. High systemic concentrations of widely produced cytokines such as IL-6 and 
TNFα, which are also adipokines, contribute to the substantial loss of skeletal muscle 
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mass in the cachexia of chronic disease (261,262). While inflammation-driven sarcopenia 
and cachexia undoubtedly have mechanisms in common, the degree of inflammation in 
cachexia is far greater than that seen in ageing and obesity (263,264), and thus cachexia 
is not considered in detail here, for fear of conflating the two phenomena.  
A large study of adults aged 19-80 has shown that plasma IL-6 levels increase with age, 
independently of BMI (264). Interestingly, correction for VAT mass eliminates such age-
associated differences in plasma IL-6 concentration (265). Although IL-6 appears 
necessary for normal skeletal muscle hypertrophy. (266–269), higher concentrations of 
IL-6 have been reported to induce skeletal muscle atrophy (270,271), and IL-6 has been 
shown to inhibit myogenic differentiation of C2C12 cultures (272). 14 d of local IL-6 
infusion into rodent tibialis anterior muscle can induce a significant decrease in total and 
myofibrillar TA content (273). The dose of IL-6 infusion in this study was 0.7 pg·muscle-
1·h-, This is equivalent to plasma concentrations observed in the elderly (264).  
TNFα is another cytokine which is well established as an inducer of myofibre atrophy. In 
chapter 5 of this thesis, recombinant TNFα (rTNFα) stimulation of primary human 
myogenic cultures is employed a pro-inflammatory stimulus that impairs myotube 
formation in vitro. Thus, its effects on skeletal muscle mass are considered in some detail 
below. This section also serves as a case-study, highlighting the breadth of evidence 
supporting a role for a better-studied adipokine in the aetiology of sarcopenia. While 
adipokines like IL-6 and TNFα are well established as promoting loss of skeletal muscle 
mass, there exist many adipokines within the adipose inflammatory milieu that are less 
well characterised. The function of several such cytokines is explored in this thesis and 
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consideration is given in the following sections to the limited existing evidence of their 
effect on skeletal muscle mass. 
1.7.3 TNFα and Skeletal Muscle Mass 
In a study of ~550 adults aged 19-80, plasma TNFα levels increased significantly with 
age, independent of BMI (264). Plasma TNFα is also significantly increased in obese 
participants, independent of age (32). Adipose tissue is an important source of TNFα; its 
adipose tissue expression increased 2.5-fold in aged mice (33). A similar increase in 
subcutaneous adipose tissue TNFα (TNFA) gene expression has been described in obese 
mice and humans (274,275). A study comparing the systemic (radial arterial blood) and 
visceral (portal venous blood) concentrations of adipokines in the obese found that their 
TNFα concentrations did not differ significantly (276), although VAT TNFA expression 
increased with non-alcoholic fatty liver disease severity in a study of those with class III 
obesity (BMI > 40 kg/m2) (277). 
In considering the possible effects of adipose-derived TNFα on skeletal muscle size, 
quality and function, it is useful to consider studies that have explored the effect of 
exogenous TNFα on skeletal muscle, both in vitro and in vivo.  
Strong evidence exists to suggest that TNFα activates muscle catabolic pathways, 
including the 28S ubiquitin proteasome. In vitro, stimulation of C2C12 myotubes with 
rTNFα induced myotube atrophy and increase the expression of the ubiquitin E3 ligases 
MAFbx and MURF-1 (65,278). Furthermore, such rTNFα stimulation (100 ng/mL) can also 
increase the protein expression of unphosphorylated forkhead box protein O1 (FOXO1) 
and forkhead box protein O3 (FOXO3); when myotubes are transfected with FOXO1 
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siRNA, the rTNFα-induced increase in MAFbx and MURF-1 protein expression is 
attenuated (65). In vivo, Intravenous (IV) rTNFα administration (100 µg/kg) to rats 
increases skeletal muscle ubiquitin gene expression, as well as increasing the 
ubiquitination of skeletal muscle proteins (279,280).  The same dose of rTNFα, delivered 
intraperitonally to mice can induce increases in both the mRNA and protein expression of 
MAFbx and MURF-1 at 24 hours post-injection (281).  Furthermore, ex-vivo soleus muscle 
force production was reduced by 25 % in such mice, and ubiquitinylation of troponin T 
increased significantly. Identical TNFα administration to MURF-1 knockout (MURF-1-/-) 
mice does not affect ex-vivo soleus force production or the proportion of ubiquitinylated 
troponin T (281). In certain circumstances, TNFα appears to also have anti-myogenic 
actions. While physiological concentrations of rTNFα (5 pg/mL) have been shown to 
enhance the differentiation of C2C12 cultures and TNFα expression is increased in 
regenerating murine skeletal muscle (282), concentrations of rTNFα above 50 pg/mL 
appear to inhibit myogenic differentiation in vitro (282,283). 
The absolute concentrations of TNFα that myotubes and skeletal muscle are exposed to 
in the studies detailed here generally far exceed those concentrations seen in the plasma 
of elderly individuals (interquartile range 13.73 to 20.54 pg/mL in (264)). Local resting 
skeletal muscle interstitial concentrations of TNFα, as measured by microdialysis appear 
to be similar to plasma concentrations (284–286). However, we are unaware of 
measurements having been made in the elderly or the obese. Interstitial concentrations 
of TNFα in areas of skeletal muscle lying adjacent IMAT may be higher, given that SCAT 
and VAT are known to secrete TNFα. Furthermore, the magnitude and rapidity of the 
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effects seen with rTNFα on skeletal muscle in vivo and in vitro (e.g. 25% reduction in 
soleus force production at 24 h after a single TNFα IP injection (281)) may suggest that 
lower concentrations of TNFα might have important effects on skeletal muscle mass and 
function over time.  
 
1.7.4 Resistin and Skeletal Muscle Mass 
Resistin is a pro-inflammatory adipokine that is produced predominantly by monocytes 
and macrophages in humans, with a smaller proportion produced by adipocytes (287). 
However, given the importance of M1 macrophage accumulation in ageing and obesity 
(Section 1.7.1), adipose tissue secretion of resistin may be of some consequence in 
sarcopenic obesity. It has been suggested that resistin may initiate a pro-inflammatory 
‘feed-forward loop’ by inducing the expression of TNFα and IL-6, a phenomenon that has 
been observed in leukocytes (288). In turn, interleukin 1β (IL-1β), TNF-α and IL-6 can 
induce resistin expression by leukocytes (288). However, it is unclear whether this 
phenomenon occurs in adipose tissue or skeletal muscle. Plasma and serum resistin 
concentrations are positively correlated with BMI (289,290) although no independent 
effect of age has been reported (289). Surgical removal of half of the total VAT in rats 
leads to systemic reductions (26 %) in resistin concentrations (28).  
The effect of resistin on sarcopenic muscle is understudied, but limited evidence suggests 
that it might have an important effect on skeletal muscle mass and quality. Plasma resistin 
concentrations have been reported to have an inverse relationship with quadriceps torque 
in old (69-81 yr), but not in young (18-30 yr), participants (291). Transfection of a human 
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resistin eukaryotic expression vector into C2C12 cells was reported to increase myoblast 
proliferation, but reduced the expression of desmin and resulted in thinner myotubes 
(292). However, this study used a murine cell line and did not investigate the effect of 
exogenous resistin on myotube formation. Notably, human resistin displays only 59 % 
amino acid sequence homology to murine resistin. Thus, mouse models may be 
inadequate for the investigation of its human physiology (293).  
 
1.7.5 Leptin and Skeletal Muscle Mass 
Leptin is an adipocyte-derived cytokine. Its plasma concentrations are largely determined 
by adipose tissue mass and food intake. Leptin secretion increases in response to energy 
intake and decreases during periods of fasting. Leptin crosses the blood-brain barrier, 
suppressing food intake via its actions in the arcuate nucleus (294).  
Unsurprisingly, plasma leptin concentrations are greater in obese participants (10.4 ± 1.3 
ng/mL) compared to non-obese controls (7.6 ± 0.5 ng/mL) (32). Interestingly, murine 
models suggest that leptin may exert hypertrophic effects on skeletal muscle and thus 
have the potential to reverse sarcopenia. 10 d of subcutaneous leptin injection (10 µg/d) 
in old mice significantly increased quadriceps mass and extensor digitorum longus fibre 
area (c. 20%) (295). In another study leptin deficient (ob/ob) mice with a body weight 2.5 
times that of lean controls displayed a 40 % reduction in quadriceps mass (296).   
However, studies in human participants suggest that such dramatic hypertrophic effects 
are not seen with plasma leptin fluctuations within the physiological range. In adults under 
48 
 
50 yr, serum leptin concentrations are positively correlated with fat free mass (FFM) in 
men, but not in women (297). However, men in the highest quintile for FFM also displayed 
the highest BMI and fat mass (FM); the resulting anti-gravity overload stimulus represents 
an important confounder. Indeed, when multiple linear regression analyses were carried 
out, FFM explained only 6 % of the variation in serum leptin, independent of FM (297). In 
late middle-aged and elderly participants, sarcopenia with coexistent visceral obesity has 
been associated with significantly greater plasma leptin concentrations than in those with 
sarcopenia alone (2.6 ng/mL ± 2.3 vs 5.7 ng/mL ± 2.3) (298). None the less, skeletal 
muscle atrophy, as measured by thigh muscle CSA corrected for body weight does not 
differ between the groups (298). However in another study, when appendicular skeletal 
muscle mass was measured by DEXA in a healthy elderly population, plasma leptin was 
negatively associated with skeletal muscle mass, even after correction for FM (299). Such 
a relationship may not hold true in very frail elderly who have low absolute plasma leptin 
levels and muscle mass compared to healthy controls (300).  Work to date has drawn 
correlations between plasma leptin concentrations and measurements of skeletal muscle 
mass. We are unaware of any work demonstrating a clear causative effect of leptin on 
human skeletal muscle growth and development (e.g. using an in vitro myotube model). 
 
1.7.6 Visfatin and Skeletal Muscle Mass 
Visfatin (also known as Nicotinamide phosphoribosyltransferase – Nampt) is a relatively 
recently discovered pro-inflammatory adipokine/biosynthetic enzyme. As with resistin, 
visfatin upregulates production of IL-1β, TNF-α and IL-6 by monocytes (301). Visfatin 
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plasma concentrations correlate positively with BMI (302–304), but the effect of age 
(independent of BMI) is unclear. Endurance exercise training increases skeletal muscle 
visfatin activity in mice (305) and humans (306). In chicken myoblasts, recombinant 
human visfatin decreased their expression of the MRFs MyoD and MRF4, while increasing 
MYF5 expression, but myogenesis was not examined (307). 
 
1.7.7 Adipokines and Skeletal Muscle Metabolism 
Sarcopenia describes a loss of skeletal muscle mass and quality. It is clear from the 
previous discussion that alterations in myofibre metabolism, may in part underpin the loss 
of skeletal muscle mass and performance and that adipokines such as IL-6 (Section 1.7.2) 
and TNFα (Section 1.7.3) are capable of altering skeletal muscle protein turnover. 
Little evidence exists to suggest what effect other, less well-studied adipokines e.g. leptin 
and resistin might have on skeletal muscle protein turnover. Limited evidence exists to 
suggest that such adipokines may alter energy substrate uptake and metabolism. For 
example, resistin – which features prominently in this thesis – inhibited glucose uptake 
and impaired glycogen synthesis during a 24 h stimulation of rat L6 myotubes (308,309). 
Another study found that resistin inhibited palmitate uptake by L6 myotubes (310). 
However, whether primary human myotubes or human skeletal muscle behave in a similar 
fashion to an immortalised rat cell line is unknown. Indeed, certain adipokines are better 
studied with regard to energy substrate uptake and metabolism, but their study has 
highlighted that caution is advisable when extrapolating studies in rodent cell lines to 
human physiology. For example, TNFα infusion in healthy humans induces skeletal 
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muscle insulin resistance (311), yet TNFα has been found by different investigators to 
increase (312), decrease (313) and not influence (314,315) glucose uptake by L6 
myotubes.  IL-6 infusion in human participants increases whole-body and skeletal muscle 
lipolysis, without affecting glucose turnover (316–318), yet IL-6 suppresses glucose 
uptake by L6 myotubes (319).  
 
1.8 IL-15 
Given the dearth of pharmacological therapeutic interventions in sarcopenia (Section 
1.6.4), it is important to explore additional avenues for the development of such 
interventions. To that end, IL-15 is a myokine that is known to promote the formation of 
C2C12 myotubes in culture and can prevent the loss of skeletal muscle mass in mice 
exposed to systemic inflammation (49,50). Its biological role in human skeletal muscle is 
not fully understood. 
 
1.8.1 IL-15 Background  
IL-15 was first identified as a 14 kDa four-helix bundle cytokine with T-cell stimulatory 
activity (320,321). It is similar in structure to IL-2 and IL-6 (322). The human and murine 
forms of IL-15 have a homology of 73 % at both the nucleotide and amino acid levels; it 
has been suggested that such homology is sufficient for IL-15 function to be largely 
conserved between the species (323,324). 
Two mRNA isoforms of IL15 are generated. Long signal peptide IL-15 (LSP-IL15) is 
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encoded by exons 3-5 of the gene (325). The short signal peptide IL-15 (SSP-IL15) 
transcript encodes an identical mature IL-15 peptide. However, the signal peptide portion 
of SSP-IL-15 lacks the first exon of the LSP-IL15 transcript, with additional alternative 
exons discovered in both the human and murine forms of SSP-IL15 (326–329). SSP-IL15 
is highly transcribed in the heart, with prominent expression also in thymus and testes 
(325). LSP-IL15 expression is high in skeletal muscle, placenta, heart, lung, liver, thymus, 
and kidney (320,325). The presence of upstream AUGs in the 5' UTR of a transcript 
impairs translation (330,331). The 5' UTR of IL15 contains multiple such AUGs (320).  
Eliminating many of these AUGs improves IL15 translation (332). Indeed, SSP-IL15 is 
more efficiently translated and this is thought to be due to translation initiation occurring 
at its alternative exon, thus avoiding the AUG-containing 5' UTR (333). However, it is the 
protein generated by the inefficiently translated LSP-IL15 which is better secreted 
(325,334,335). Such secretion of IL-15 is facilitated by its specific alpha receptor (IL-15rα) 
(336). 
 
1.8.2 IL-15 Receptor Complexes and Subunits 
The IL-15 receptor is a heterotrimeric complex which consists of two signalling subunits - 
the gamma cytokine receptor (γc) and the interleukin 2 receptor beta subunit (IL-2Rβ) and 
one non-signalling subunit (interleukin 15 receptor alpha subunit, IL-15rα) which confers 
IL-15 specificity on the receptor complex (336). The γc subunit forms part of receptors for 
multiple cytokines, including IL-2, IL-4, IL-7 and IL-9 (337). IL-15rα contains an exon 2-
encoded sushi domain that facilitates the high-affinity binding of IL-15 to IL-15rα via 
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extensive ionic interactions (338,339). Multiple isoforms (generated through alternative 
splicing) of IL-15rα have been described (323,339); the first three to be characterised are 
equally capable of binding IL-15 (323). These isoforms of IL-15rα are expressed across 
multiple human cell types (339) and have a broad intracellular distribution. Notably, IL-
15rα is prominently expressed at the nuclear membrane, and its co-localisation with p300 
suggests that a portion of IL-15rα is located inside the membrane (339). The presence of 
an abundant intracellular receptor for IL-15 may suggest an intracellular function for the 
poorly secreted SSP-IL-15 (339).  
IL-15rα facilitates the secretion of IL-15. Transfection of human embryonic kidney 293 
(HEK 293) cells with IL-15 DNA in conjunction with an IL-15rα expressing plasmid 
enhances IL-15 secretion (335). This mechanism is conserved in murine myotubes – 
primary myotube cultures from IL-15rα knockouts do not secrete IL-15 (52). IL-15rα also 
exists in soluble isoforms (sIL-15rα), which bind IL-15 and may act as either agonists or 
antagonists at the cell membrane IL-15rα/β/γ receptor complex (340). Intracellular IL-15 
signal transduction has been characterised in immune cells, but nothing is known about 
such intracellular signalling in skeletal muscle. In lymphocytes janus kinase 1/ signal 
transducer and activator of transcription 3 (JAK1/STAT3) activation takes place via IL-15rβ 
and JAK3/STAT5 activation occurs via the γc subunit (341). The phosphoinositide 3-
kinase/protein kinase B (PI3k/Akt) and MAPK pathways are also activated (341). The 
functional importance of IL-15 activation of these pathways remains to be established in 




1.8.3 IL-15 in Skeletal Muscle 
A role for IL-15 in skeletal muscle myogenesis and hypertrophy was first suggested 20 
years ago when it was discovered that IL-15 stimulation of murine C2C12 myoblast 
cultures is as effective as insulin-like growth factor 1 (IGF-1) stimulation in increasing MHC 
accumulation at the myoblast and myotube stages (49). Additionally, IL-15 stimulation 
promoted the development of larger myotubes (49). In another study, stimulation of rat 
extensor digitorum longus muscle with human rIL-15 (100 ng/mL) decreased its proteolytic 
rate, but did not affect protein synthesis (342). Furthermore, stimulation of murine C2C12 
myotubes with IL-15 can ameliorate the increase in cathepsin L activity seen with TNFα 
and dexamethasone stimulations (50). In mice with experimentally-induced sepsis, 
intraperitoneal pre-treatment with IL-15 (10 μg/kg) reduced mRNA expression of the E3 
ligases MAFbx and MURF-1 at 24 h (50). IL15 expression has been shown to be 
increased in the unloaded, atrophic limbs of old rats and quail (51). Such an increase in 
IL15 mRNA expression might be a physiological attempt to counteract atrophic stimuli 
(51). Aged mice (28 months) have been observed to display a non-significant decrease in 
LBM and lower muscle and serum IL-15 levels than their younger controls (343). Our 
limited knowledge of IL-15 biology suggests that an age-related reduction in skeletal 
muscle IL-15 might contribute to this murine ‘sarcopenia’. However, definitive mechanistic 
evidence is lacking.  
In addition to its apparent role in the maintenance of skeletal muscle mass, IL-15 may play 
a metabolic role within skeletal muscle. The observation that an increase in IL-15 
expression (soleus and gastrocnemius) accompanied improved glucose tolerance in 
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endurance-trained Zucker Diabetic Fatty Rats led to speculation that IL-15 may promote 
enhanced insulin sensitivity (344). Co-incubation of rIL-15 (10 and 100 ng/mL) with rat 
muscle strips and endoplasmic reticulum stress inducers (dithiothreitol or tunicamycin) 
reduced the expression of ERS markers (345). ERS is known to impair insulin signalling 
(345). Definitive evidence of anti-diabetic actions of IL-15 remain to be presented. 
Additionally, IL-15 may promote enhanced oxidative metabolism in skeletal muscle and 
thus improved endurance capacity. Stimulation of murine C2C12 myoblasts with rIL-15 
(50 µg/mL) reduced the activity of the non-oxidative metabolism enzymes creatine kinase 
and lactate dehydrogenase and attenuated the hydrogen peroxide (H2O2) induced 
increase in cellular ROS (346). Furthermore, mice that overexpress IL-15 can run for twice 
as long as their wild-type counterparts; expression of mediators of oxidative metabolism, 
(peroxisome proliferator activated receptor delta [PPAR δ], sirtuin 1, peroxisome 
proliferator activated receptor gamma coactivaror 1 alpha [PGC1α]), is increased in the 
skeletal muscle of such mice (347).  
Studies characterising the biological actions of IL-15 in human skeletal muscle are lacking.  
We are unaware of any studies demonstrating the secretion of IL-15 by primary human 
myotubes cultured from healthy muscle. Endurance training has been demonstrated to 
increase basal IL-15 protein expression, without a change in IL-15 mRNA or plasma IL-
15 (348). In another study, an acute bout of resistance exercise increased IL-15 protein 
expression, yet its basal expression was unaffected by resistance training (349). 
Furthermore, following an acute bout of resistance exercise, the myofibrillar protein 
synthesis rate has been observed to display a significant and substantial positive 
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relationship with skeletal muscle IL-15rα expression (350).  Interestingly, single nucleotide 
polymorphisms (SNPs) in exons 7 and 4 of the IL-15rα gene are associated with an 
enhanced hypertrophic training response (351). The physiological basis for these changes 
is unknown. It is clear from animal studies that IL-15 may have important functions in 
skeletal muscle. Such functions implicate IL-15 as a potential therapeutic target in 
sarcopenia and skeletal muscle metabolic dysfunction. However, the biological actions of 
IL-15 in human skeletal muscle remain to be characterised. 
 
1.9 Hypotheses and Aims  
 
The two central hypotheses of this thesis are: 
 
1. That there exist understudied adipokine constituents of the adipose inflammatory 
milieu that are differentially secreted by lean and non-lean adipose tissue and that 
the enhanced secretion of these adipokines is detrimental to myogenesis and is in 
part responsible for sarcopenia. 
2. That the pro-myogenic and hypertrophic actions of IL-15 previously described in 
rodent studies would be retained in human myogenic cultures, but that cultures 
derived from the skeletal muscle of elderly individuals would be more resistant to 
the hypertrophic effects of IL-15 than those of young individuals. 
 
Therefore, the objectives of this work were as follows: 
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1. To determine the effect of the adipose inflammatory milieux secreted by lean and 
non-lean adipose tissue on primary human myogenesis and to identify 
understudied adipokine constituents that may be consequential in mediating such 
effects (Chapter 3). 
2. To identify in the adipose inflammatory milieux a candidate adipokine of apparent 
myogenic consequence and detail its myogenic actions and the mechanism of such 
action (Chapter 4). 
3. To consider whether the candidate adipokine has metabolic effects on primary 
human myocytes (Chapter 5). 
4. To detail the myogenic actions of IL-15 in primary human myogenic cultures derived 
from young and old participants and to establish whether its purported pro-
myogenic and hypertrophic actions can be sustained in a pro-inflammatory 
environment.  
 
The specific objectives that were identified to address these aims are outlined in the 




























2. Materials and Methods 
All procedures were carried out at room temperature unless otherwise stated.  
2.1 Ethical Approval and Subject Recruitment 
Samples obtained from healthy participants were obtained and used under approval 
granted by the University of Nottingham Medical School Ethics Committee. The 
participants were volunteers, recruited through poster advertising that was approved by 
the ethics committee. Young participants were aged 18-30 yr; elderly participants were > 
65 yr. Potential participants with no history of cardiovascular disease or diabetes were 
invited to a medical screening at the University of Nottingham Human Physiology Unit, 
comprising a 12-lead electrocardiogram, blood pressure monitoring and blood sampling 
for routine haematology and biochemistry analyses (full blood count, urea and 
electrolytes, clotting factors). Informed consent was obtained from participants during this 
visit and the participants were advised that they were free to withdraw at any time. The 
results of medical screening were reviewed by a clinician before participants were invited 
to attend for the main study visit.  
Adipose tissue samples were obtained from participants with knee and hip osteoarthritis 
were obtained intra-operatively from middle-aged and elderly patients undergoing total 
joint replacement surgery under the approval of the University of Birmingham Research 
Ethics Committee. The demographics of this population is presented in Chapter 3. All 
patients gave informed consent before surgery. Those with a known secondary cause of 
osteoarthritis were excluded, as were patients who had ever received IV or oral 
immunosuppressive medications or those who had received any intra-articular steroid 




2.2 Subject Data and Sample Collection 
Healthy participants attended the University of Nottingham Human Physiology Unit for the 
main study visit. 12 young (age 22.2 ± 0.6 yr, BMI 21.9 ± 0.9) and 6 older (age 70.3 ± 1.9 
yr, BMI 23.5 ± 1.9) participants were recruited. Three biological replicates were used for 
each cell culture experiment and participant details for each experiment are outlined in 
Appendix Table 1. Participants were asked to abstain from alcohol consumption and 
exercise training for 48 h prior to the visit and to arrive having fasted for a minimum of 6 
h. Each subject underwent a DEXA scan to determine their body composition, for which 
they gave separate informed consent. Subject height and weight were recorded, and BMI 
was calculated as weight (kg) divided by height (m) squared.  A single blood sample (30 
mL) was collected by venipuncture in the antecubital fossa, using a butterfly needle and 
syringe. The blood was divided between serum separating blood tubes and tubes 
containing EDTA. The tubes were placed on ice until further processing could take place 
(within 3 h). A VL biopsy was obtained under local anaesthetic by the Unit clinician, using 
the suction-modified Bergström technique (352). The biopsy was placed in sterile 
phosphate-buffered saline (PBS) and was kept on ice; subsequent processing took place 
within 3 h.  
Skeletal muscle and SAT samples obtained from participants with knee and hip 
osteoarthritis were obtained intra-operatively by the lead surgeon, placed in sterile 





2.3 Blood Sample Processing 
Serum separating blood tubes were centrifuged at 3000 rpm for 10 min, and the serum 
was aliquoted into 1 mL cryovials, snap frozen in liquid nitrogen and stored at -80 °C. 
EDTA blood tubes were snap-frozen in liquid nitrogen and stored at - 80 °C. 
 
2.4 Tissue Culture 
All reagents used were from Sigma-Aldrich, St. Louis, MO, USA, unless otherwise stated. 
Tissue culture was carried out under sterile conditions in a class II safety cabinet. 
 
2.4.1 Primary Human Myoblast Isolation and Culture 
Primary human skeletal myoblasts were isolated from skeletal muscle using a protocol 
provided by Dr Andrew Bennett (FRAME laboratory, University of Nottingham). Muscle 
samples were minced for 10 min with a scalpel, digested with 5 mL 1x trypsin-EDTA and 
placed on an orbital rotator for 15 min at 37 °C. An equal volume of growth medium 
(Ham's F10 with 2 mM L-glutamine, 100 μg/mL penicillin/streptomycin, 20 % heat-
inactivated FBS) was added and muscle digests centrifuged at 460 g for 5 min.  The 
resulting pellets were resuspended in growth medium and then incubated for 20 min at 
37 °C, 5 % CO2 in an uncoated 75 cm2, vented tissue culture flask. The cell suspensions 
were then removed to vented flasks or plates coated with 0.2 % gelatin and cultured in 
an appropriate volume of medium (Table 2.1). Our isolation technique has consistently 
produced cultures in our lab that produce desmin positive multinucleated myotubes that 
are negative for the fibroblast marker TE7(86) (Appendix Fig. 2.1). 
Commercially available primary human myoblasts (Thermo Fisher cat. No. A12555), 
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isolated from a female aged 21 yr were used for some of the work described in this thesis. 
They were cultured in the same media and conditions as the cultures that we isolated in-
house. 
 
Table 2.1 Tissue Culture Vessels and Media Volumes. 
Culture Vessel Type Medium Volume (mL) 
Flask - 75 cm2 12 mL 
Flask - 25 cm2 4 mL 
Plate – 6 well 2 mL 
Plate – 12 well 1.5 mL 
Plate – 24 well 1 mL 
 
 
Cultures were fed with growth medium at 48 h and every 48-72 h thereafter. If necessary, 
myoblasts were subcultured (1:3) at 70 % confluence by trypsin-induced dissociation from 
their vessel. Briefly, the growth medium was removed from the vessel and replaced with 
an equal volume of PBS. The PBS was aspirated and replaced with 0.05 % Trypsin-EDTA. 
The culture vessel was placed in an incubator at 37 °C for 5 -10 min until > 80 % of cells 
were observed to be detached by light microscopy. An equal volume of growth medium 
was added to neutralise the trypsin-EDTA. The cell suspension was centrifuged at 460 g 
for 5 min and the resulting pellet resuspended in growth medium and transferred to new 
0.2 % gelatin-coated flasks or plates.  
For cryopreservation, myoblasts were detached from their vessel as described above and 
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resuspended in a medium containing 65 % growth medium, 25 % FBS and 10 % Dimethyl 
sulfoxide (DMSO) (Adapted from (73)). Following transfer to a freezing container, (Mr 
Frosty, Thermo Scientific, MA, USA) samples were stored at - 80 °C overnight before 
being moved to long-term liquid nitrogen storage.  
Myoblasts and Myotubes were used experimentally between passages two and five.  
 
2.4.2 Differentiation of Primary Human Myoblasts to Myotubes 
Myoblasts were grown to 90 % confluence before switching to culture medium that 
promoted their differentiation to myotubes (Ham's F10 with 2mM L-glutamine, 100 μg/mL 
penicillin/streptomycin, 6 % heat-inactivated horse serum). The cells were maintained in 
this differentiation medium for 8 d, after which time multinucleated myotubes were 
predominant in the culture.   
 
2.4.3 Recombinant Cytokine Stimulation of Primary Human Myoblasts and 
Myotubes 
Much of the work presented in this thesis involves the stimulation of myoblasts and 
myotubes with recombinant cytokines. The details of cytokine concentrations, as well as 
the timing and duration of such stimulations, are described in the relevant data chapters. 
Broadly, stimulations were achieved by the addition of the relevant cytokine to an 
appropriate medium. The details of the cytokines used in this work are outlined in Table 





Table 2.2. Recombinant Cytokines Used in this Work. 
Recombinant 
Protein 
Source Sequence Manufacturer Catalogue No. 
Resistin E. Coli Full length (aa 




Leptin E. Coli Full length (aa 




Visfatin E. Coli Full length (AA 
1-491 and N-




IL-15 E. Coli 114 AA Cambridge 
Bioscience 
GFH86 








2.4.4 Generation of Adipose Conditioned Medium  
SAT was obtained intraoperatively from patients of varying BMI undergoing total hip and 
total knee replacement surgery. SAT was incubated in myotube differentiation medium at 
a ratio of 1 g tissue to 10 mL medium for 24 h. Larger samples were divided into segments 
of ~ 1 g to ensure that the surface area of adipose tissue exposed to medium remained 
approximately constant. At 24 h the adipose conditioned medium (ACM) was removed, 
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aliquoted into 5 mL sample containers and stored at - 80 °C. For experimental use, the 
ACM was diluted 1:2 with differentiation medium, to ensure a sufficient nutrient 
composition to sustain myogenic differentiation.  
 
2.5 Isolation of Total Protein from Primary Human Myoblasts and Myotubes 
For protein extraction, myotubes were lysed in ice-cold radioimmunoprecipitation assay 
(RIPA) buffer (50 mM Tris HCl, 150 mM NaCl, 1.0 % (v/v) NP-40, 0.5 % (w/v) Sodium 
Deoxycholate, 1.0 mM EDTA, 0.1 % (w/v) sodium dodecyl sulfate [SDS], 0.01 % (w/v) 
sodium azide, protease inhibitor cocktail, phosphatase inhibitor cocktail, pH of 7.4). 15 
μL/cm2 growth surface of RIPA was used. A cell scraper was used to aid dissociation of 
cells from the culture plate. Cell lysates were then removed to a microcentrifuge tube and 
sonicated on ice for 1 min before being centrifuged at 14,000 g for 10 min at 4 °C to pellet 
cell debris.  The total protein concentration of each cell lysate supernatant was quantified 
by a bicinchoninic acid assay (Thermo Scientific), according to the manufacturer's 
instructions. Lysates were stored at - 80 °C 
 
2.6 SDS Polyacrylamide Gel Electrophoresis and Immunoblotting 
Total protein lysates of known concentration (see Section 2.5 above) were mixed 3:1 with 
4x Laemmli sample loading buffer (0.5M Tris-HCl pH 6.8, 20 % (v/v) Glycerol, 10 % (w/v) 
SDS, 0.1 % (w/v) bromophenol blue, 10 % (v/v) beta-mercaptoethanol [βME]) and water 
to generate polyacrylamide gel loading stocks of known concentration. Samples were 
boiled for 5 min.  
SDS polyacrylamide gel electrophoresis (SDS-PAGE) gels were cast in empty gel loading 
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cassettes (Thermo Fisher) using 37.5:1 Acrylamide:Bisacrylamide ProtoGel 30 % 
(National Diagnostics). The volume of ProtoGel used was calculated as Vp = (X x Vt)/30 
where, Vp = Volume of 30 % ProtoGel, X = % Monomer desired in gel, Vt = Total volume 
of gel casting solution. For resolving gels, Vt comprised the volume of ProtoGel required, 
4x ProtoGel resolving buffer (1.5M Tris-HCl pH 8.8, 10 % SDS) diluted to 1x, and 
deionised water. Stacking gels comprised the volume of ProtoGel required for a 4 % gel, 
4x ProtoGel stacking buffer (0.5M Tris-HCl pH 6.6, 0.4% SDS) diluted to 1x, and deionized 
water. An appropriate gel percentage was chosen according to the size of the protein of 
interest. In general, proteins < 20 kDa were run on gels of 14 % (w/v) acrylamide, proteins 
> 60 kDa were run on gels of 10 % (w/v) acrylamide. All other gels were 12 % (w/v) 
acrylamide.  
Equal amounts of total protein were loaded onto SDS-PAGE gels; when samples were 
run across multiple gels, an internal control sample was run. Proteins were separated by 
electrophoresis (50 mA) in 1x Tris-Glycine SDS-PAGE Buffer (0.025M Tris base, 0.192M 
glycine, and 0.1 % (w/v) SDS).  Proteins were then transferred onto polyvinylidene 
difluoride (PVDF) membrane (Amersham Hybond-P, GE Healthcare, Buckinghamshire, 
UK) in an electroblotting buffer (0.025M Tris base, 0.192M glycine, 20 % (v/v) methanol 
at pH 8.4) using the 'Standard SD' program of the Trans-Blot Turbo semi-dry transfer 
system (Bio-Rad, CA, USA). Membranes were blocked for 1 h and agitated overnight with 
primary antibody diluted in TBS-T at 4 °C (Table 2.3). The membranes were washed for 4 
x 5 min in 1xTBS-T (50 mM Tris hydrochloride [Tris-HCl], 150 mM sodium chloride [NaCl], 
0.1% (v/v) Tween 20 at pH 7.5) and agitated for 1 h at room temperature with horseradish 
peroxidase-conjugated secondary antibody (Table 2.3). TBS-T washes were repeated and 
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the membranes incubated with ECL Prime Western blotting detection reagents 
(Amersham Biosciences, Amersham, UK) according to the manufacturer's instructions. 
Bands were visualised on the ChemiDoc MP imaging system (Bio-Rad). An open-source, 






















Table 2.3. Immunoblotting Antibody Details. 





GAPDH MC Rabbit CST 5174 5% milk 1:2000 
Histone H3 MC Mouse CST 3638 5% milk 1:2000 
IL-15 MC Rabbit Generon EPR1542Y 5% milk 1:1000 
NF-κB p65 MC Mouse CST 6956 5% BSA 1:2000 
Phospho – 
NF-κB p65 
MC Rabbit CST 3033 5% BSA 1:2000 
β-actin MC Mouse Sigma A4700 5% milk 1:5000 





PC Rabbit CST 9102 5% BSA 1:1000 




PC Rabbit CST 9271 5% BSA 1:1000 
Myogenin MC Rabbit Abcam ab124800 5% BSA 1:1000 
MyoD1 MC Rabbit Abcam ab126726 5% milk 1:1000 
MAFbx MC Rabbit Abcam ab168372 5% BSA 1:1000 
MURF-1 MC Rabbit ECM 
Biosciences 




MC Rabbit R&D Systems MAB4470 5% BSA 1:1000 
Puromycin MC Mouse Millipore MABE343 5% BSA 1:1000 
       
Secondary antibodies diluted 1:15000 in TBS-T.  Sigma Aldrich, sheep anti-mouse IgG HRP-linked 






2.7 Isolation of Total RNA 
All work involving ribonucleic acids (RNA) was carried out on surfaces treated with a 
nuclease control reagent (RNaseZap®, Thermo Fisher). Dedicated RNA pipettes, which 
were cleaned regularly with the nuclease control solution were used in conjunction with 
sterile DNase and RNase free filter pipette tips. DNase and RNase free microcentrifuge 
tubes were also used. All reagents were used exclusively for RNA extractions. 
For RNA extraction, 1 mL TRIzol® Reagent (Life Technologies, CA, USA) was added to 
myoblasts and myotubes grown in 12-well plates or to 100 mg skeletal muscle. The 
TRIzol® lysates were homogenized by pipetting up and down several times, transferred 
to microcentrifuge tubes and 200 µL chloroform was added. Following incubation for 2-3 
min, the samples were centrifuged for 15 min at 12,000 g and 4 °C. The upper aqueous 
phase was removed to a new tube and 500 µL isopropanol added. Following a 10 min 
incubation the samples were centrifuged for 30 min at 12,000 g and 4 °C. The 
supernatants were removed, the pellets washed with 1 mL 75 % ethanol and the samples 
were centrifuged for 5 min at 7500 g and 4 °C. The wash was removed and the RNA 
pellets were vacuum dried for 30 min. The pellets were resuspended in 30 µL RNase-free 
water and the samples placed in a heat block set at 60 °C for 5 min to ensure complete 
solubilisation. The RNA yield and quality was determined using a microvolume 
spectrophotometer (NanoDrop 2000, Thermo Fisher). A 260/280 nm ratio of > 1.7 was 
considered acceptable for sample use in RT-qPCR. RNA samples were stored at - 80 °C. 
 
2.8 Real-Time Quantitative PCR 
A one-step master mix pre-mixed with SYBR green (Primerdesign, Southampton, UK), 
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was used and 5 μL reaction volumes were prepared in triplicate, in 384 well plates (Table 
2.4). One-step RT-qPCR was carried out on a Light-Cycler 480 (Roche, Basel, 
Switzerland) using the following cycler conditions: 1) Reverse transcription - 10 min, 55 
°C; 2) Polymerase activation – 8 min, 95 °C; 3) Denaturation, annealing and extension – 
10 s, 95 °C plus 60 s, 60 °C, repeated for 45 cycles; 4) Melting curve – stepwise 
temperature increase to 95 °C.  Non-template controls were run for each primer used and 
a reference gene was quantified on each plate (See Table 2.5 for primer details). For 
analysis, the threshold fluorescence was set using a logarithmic view of the curve and 
was placed in the linear phase of the reaction, above the background signal. Cycle 
threshold (Ct) values for each sample were defined by the cycle number at which the 
curve crossed the threshold (see Appendix Table 2). Relative quantities of RNA were 
calculated as: 
 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑞𝑢𝑎𝑛𝑡𝑖𝑡𝑦 𝑅𝑁𝐴 =
2𝐶𝑡 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 𝑡𝑎𝑟𝑔𝑒𝑡 𝑔𝑒𝑛𝑒−𝐶𝑡 𝑠𝑎𝑚𝑝𝑙𝑒 𝑡𝑎𝑟𝑔𝑒𝑡 𝑔𝑒𝑛𝑒




Table 2.4. SYBR green RT-qPCR Reaction Volumes. 
Reagent Volume per Reaction (μL) 
One-step SYBR green master mix 2.5 
Primer mix 0.25 
RNA Equivalent to 10 ng 




Table 2.5. RT-qPCR Primer Details. 
Gene Manufacturer Primer Sequences 
IL15 Primerdesign F: 5’-GGAAACCCCTTGCCATAGC-3’ 
R: 5'-GATGGAAATACTTCTCAAATGTGGT-3' 










MYF5 Primerdesign F: 5’-CACCTCCAACTGCTCTGATG-3’ 
R: 5’-TAAGGAGTTTTTATCTGTGGCATATAC-3’ 
MYOD1 Primerdesign F: 5’-CGCCTGAGCAAAGTAAATGAG-3’ 
R: 5’-GCCCTCGATATAGCGGATG-3’ 








Primerdesign F: 5’-GACGCCCTGAGCCATT-3’ 
R: 5’-CCTCTTCCTGATCTTCTTCTTCAAT-3’ 
PPARG Primerdesign F: 5’-GAATAAAGATGGGGTTCTCATATCC-3’ 
R: 5’-AACTTCACAGCAAACTCAAACTT-3’ 




ACACB Primerdesign F: 5’-ATGGCCTCCACCGTTGTC-3’ 
R: 5’-CTTCTGTCCACTCCACTGTCA-3’ 
PDK1 Primerdesign F: 5’-CCAAAGCATCAGAGCCATCATT-3’ 
R: 5’-AGGATTACTTGAGCCCAGAAGAT-3’ 
UCP2 Primerdesign F: 5’-CTCTCCCAATGTTGCTCGTA-3’ 
R: 5’-ATGAGGTTGGCTTTCAGGAG-3’ 




Primerdesign F: 5’-ATGGCTGTGGCTGGTTTCT-3’ 
R: 5’-AGCAGGAGGACCGCAAATA-3’ 
PPARGC1A Primerdesign F: 5’-TTGCTAAACGACTCCGAGAAC-3’ 
R: 5’-GACCCAAACATCATACCCCAAT-3’ 
ACTB Primerdesign Proprietary  
GAPDH Primerdesign Proprietary 
TMEM8C 
(Myomaker) 
Primerdesign F: 5’-AACTCAAATACAAAATAGGACGCTTT-3 
R: 5’-CCTTCGCCTTCTCAAAACAAAC-3’ 
F = Forward primer, R = reverse primer 
 
2.9 Enzyme-Linked Immunosorbent Assay 
Enzyme-linked immunosorbent assays (ELISAs) were used, according to manufacturer’s 
instructions for the quantification of human IL-15 (Human IL-15 Quantikine ELISA Kit; R&D 
Systems, Minneapolis, MN, USA; sensitivity 2 pg/mL) in myotube culture supernatants 
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and human resistin (Human Resistin Quantikine ELISA Kit; R&D Systems; sensitivity 55 
pg/mL) in ACM. Standards were prepared by a series of 2-fold dilutions of the top standard 
in accordance with the manufacturer’s instructions. No blocking step is required with 
Quantikine ELISA kits. The prescribed amount of sample or standard was added – in 
duplicate – to microplates pre-coated with a monoclonal antibody against the target 
protein. Eight standards were included, including a blank (0 pg/mL) standard. Plates were 
incubated at room temperature for 2 h, the samples aspirated from the plate and the wells 
washed four times with the wash buffer provided. 200 μL of the provided monoclonal 
antibody, conjugated to horseradish peroxidase was added to each well for the prescribed 
time. The wells were washed as before and 200 μL of tetramethylbenzidine (TMB) 
substrate solution added for 30 min. Finally, 50 μL 2 N sulfuric acid was added to each 
well and plates were read with an absorbance microplate reader (ELx808, Biotek, 
Winooski, VT, USA) at the wavelengths prescribed by the kit manufacturer. The mean of 
duplicate standard and sample values were calculated and corrected for the mean blank 
value. A standard curve was generated using the standard values (Microsoft Excel, 2016). 
A coefficient of determination (R2) value of > 0.99 was considered acceptable. The slope 
equation of the curve was used to calculate the sample concentrations. Any sample for 
which the calculated concentration was below the published sensitivity of the ELISA was 
considered to be negative (0 pg/mL).  
 
2.10 Multiplex Immunoassay 
Cytokine and chemokine concentrations were quantified in ACM by multiplex magnetic 
bead-based immunoassay (Luminex® Screening Assay, R&D Systems) according to the 
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manufacturer’s instructions. 50 µL of a 1x antibody magnetic bead stock (Adiponectin, 
Serpin E1, Aggrecan, Amphiregulin, CCL11, CCL2, CCL3, CCL20, Chemerin, CXCL10, 
Dkk1, Galectin-1, gp120, IL-1β, IL-10, IL-15, IL-7, visfatin, TNFα, Galectin-3BP, Lipocalin-
2, CCL4, FABP4, LIF, Leptin, IL-6, Resistin, MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, 
MMP-9, MMP-10, MMP-12, MMP-13) was added to each well of a flat bottom black plate. 
50 µL of undiluted sample or standard were added in duplicate to the plate. The plate was 
sealed with foil and incubated for 2 h at room temperature on an orbital rotator at 800 rpm. 
The plate was washed three times with a magnetic plate washer (Bio-Plex Pro™ Wash 
Station, Bio-Rad) using the wash buffer provided. 50 µL of a biotinylated antibody cocktail 
was added to each well; the plate was resealed and incubated for 1 h on the orbital rotator. 
The wash steps were repeated as before and 50 µL of the provided streptavidin-PE was 
added to the wells. The plate was incubated on the orbital rotator for 30 min and the wash 
steps repeated for a final time. Finally, the beads were resuspended in 200 µL wash buffer 
and the analytes were quantified by the Luminex® 200 multiplex analyser (Luminex® 
Corporation, Austin, Texas, USA). 
 
2.11 Free Fatty Acid Assay  
A colourimetric free fatty acid (FFA) quantification assay (Abcam, Cambridge, UK) was 
used to measure ACM FFA concentrations. The assay converts FFA to their CoA 
derivatives which are then oxidised, with colour formation occurring in proportion to their 
concentration. Briefly, a standard curve was prepared as described in the kit protocol and 
50 µL acyl-CoA synthase reagent was added to an equal volume of sample or standard 
in a 96 well plate and incubated for 20 min at 37 °C. The oxidation reaction mix was then 
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added for 30 min at 37 °C in the dark. The absorbance of each well was read at 570 nm 
using an absorbance microplate reader (ELx808, Biotek).   
 
2.12 HDL and LDL/VLDL Assay 
A colourimetric HDL and LDL/VLDL cholesterol assay kit (Abcam, Cambridge, UK) was 
used to measure cholesterol concentrations in ACM. Cholesterol oxidase oxidises free 
cholesterol to produce a product that reacts with a probe to provide a colour change in 
proportion to free cholesterol concentration. Cholesterol esters can be hydrolysed to free 
cholesterol separately, allowing the separate quantification of free cholesterol and total 
cholesterol. In brief, a standard curve and the reaction mix were prepared according to 
the manufacturer’s instructions. 50 µL reaction mix was added to an equal volume of 
sample or standard in a 96 well plate and incubated for 60 min at 37 °C in the dark. The 
absorbance of each well was read at 570 nm using an absorbance microplate reader 
(ELx808, Biotek).   
 
2.13 Cell Proliferation Assay 
A colourimetric tetrazolium salt-based cell proliferation assay (CellTiter 96® Aqueous 
One Solution; Promega, Madison, WI, USA) was used. This assay uses 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner 
salt (MTS), which is reduced to a coloured formazan product by metabolically active 
cells. Thus, the assay indicates the number of metabolically active cells in culture at any 
given timepoint. Myoblast growth medium was replaced with 100 μL serum-free Ham’s 
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F10 base medium to prevent FBS interference with absorbance readings (354). 20 μL 
MTS reagent was added to each well the plate was incubated at 37 °C, 5 % CO2 for 3 h. 
Each condition was assayed in quadruplicate. The absorbance of each well was read at 
450 nm using an absorbance microplate reader (ELx808, Biotek).   
 
2.14 Immunofluorescence Staining of Primary Human Myotubes 
Myotubes were differentiated for 8 d in 24-well culture plates (See Section 2.4). The 
culture medium was removed and the cells fixed with 2 % (v/v) formaldehyde in PBS for 
30 min. Following permeabilisation in 100 % methanol for 10 min, wells were washed 
three times with 500 μL PBS and then blocked with 5 % (v/v) goat serum in PBS for 30 
min. An anti-desmin primary antibody (Thermo Fisher, MA5-13259) was diluted in 1 % 
(v/v) BSA/PBS and 150 μL was added per well for 1 h.  Wells were washed as before and 
incubated with 150 μL/well secondary antibody (Goat anti-Mouse IgG Secondary 
Antibody, Alexa Fluor 488, Thermo Fisher, R37120) for 1 h in the dark. Each well was 
washed once with PBS and 150 μL/well DAPI (4',6-diamidino-2-phenylindole)/PBS 
(1:5000, Cell Signalling Technology) was added for 5 min in the dark. Wells were washed 
with PBS, a drop of mountant added to each well (ProLong Diamond Antifade, Thermo 
Fisher) and a coverslip applied.  
 
2.15 Quantification of Myotube Thickness, Myotube Number and Nuclear Fusion 
Index 
24-well plates of immunofluorescence (IF) stained (desmin/DAPI) myotubes were imaged 
on an epifluorescence/brightfield microscope (Leica DMI6000). Triplicate wells were 
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stimulated for each biological replicate. Multiple images were taken in each well for the 
quantification of myotube thickness (MTT), myotube number and nuclear fusion index 
(NFI).  For the quantification of MTT, 15 images of each well were obtained using the 63x 
objective, the first image being obtained at a fixed starting point and subsequent images 
selected by moving to the next field of view in a predefined pattern. For assessment of 
myotube number and NFI, five images of each well were obtained in the same fashion, 
using the 20x objective. Image analysis was carried out by a blinded researcher, using 
Image J software (353) (Figure 2.1). A myotube was defined as a desmin positive object, 
containing 3 or more nuclei. The MTT was calculated by taking the average of five 
measurements obtained along its length, and the centremost myotube in each field of view 
was chosen for measurement (Fig. 2.1, A).  The NFI was defined as the number of nuclei 
incorporated into myotubes, expressed as a proportion of the total visible nuclei in each 
field of view (Fig. 2.1, B). In order to calculate a NFI that is closer to the true NFI of the 
cultures, the measurement was made inside a fixed grid superimposed on each image. 
This allowed nuclei outside of the grid to be considered in defining a desmin positive 
structure as a myotube, without considering them for nuclear counting purposes. The true 
NFI of our cultures is still likely to be higher than the values quoted in this thesis, as some 
desmin positive structures containing fewer than 3 nuclei likely had additional nuclei 
outside of the field of view and/or the focal plane of the microscope. MTT data in this thesis 
comprises 450 total measurements from 90 myotubes per treatment condition for each 
subject (n), n=3 participants.  NFI comprises values from 45 images per treatment 
condition for each subject, n = 3 participants.  This strategy is comparable to previously 
published work (146,147,355–357) although a higher magnification was chosen for our 
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2.16 Immunoprecipitation of Resistin from Adipose Conditioned Media 
All procedures were carried out in a class II safety cabinet, and all reagents were sterile. 
70 μL Protein A Sepharose® beads (Abcam, ab193256) were incubated with 1 μg anti-
resistin primary antibody (polyclonal rabbit IgG, Thermo Fisher PA1-1049) or 1 μg rabbit 
IgG isotype control (Sigma, 12-370). The antibody-bead mixture was incubated for 4 h at 
4 °C on a shaker. The beads were centrifuged at 3,000 g for 2 min at 4 °C and the 
supernatant was discarded. 1 mL PBS was added. This wash step was repeated twice. 5 
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mL ACM was added to each bead-antibody conjugate and the ACM-bead-antibody 
mixture was incubated for 24 h at 4 °C under rotary agitation. The mixture was centrifuged 
at 3,000 g for 2 min at 4 °C and the supernatant (ACM) was retained and stored at - 80 
°C. The antibody-bead conjugates were washed in PBS as before. The antigen-antibody 
complexes were eluted from the sepharose beads by the addition of 50 μL 2x Laemmli 
sample loading buffer (see Section 2.6). The elutes were incubated at 50 °C for 10 min. 
The mixture was centrifuged at 3,000 g for 2 min at 4 °C and the supernatant (elute 1) 
was retained and stored at – 80 °C. 50 μL 2x Laemmli sample loading buffer was again 
added to the beads and the procedure repeated (elute 2). Both elutes were stored at – 80 
°C in advance of their use in immunoblotting for the detection of resistin (see Section 2.6). 
 
2.17 Oil Red O Staining 
Oil Red O staining was carried out on 24-well plates of myotubes that had been previously 
IF stained using a protocol adapted from Koopman et al. (358). 500 μL PBS was added 
to each well and the plate incubated at 37 °C for 30 min. The coverslips were carefully 
removed with forceps, and the wells washed three times in PBS. Microscopic examination 
of the wells and detached coverslips confirmed that no cellular detachment from the plate 
occurred.  An Oil Red O stock solution (0.5 % (w/v) Oil red O in 60 % triethyl-phosphate 
in ddH2O) was diluted 3:2 in ddH2O. This working solution was filtered through a 0.22 µM 
syringe filter to remove Oil Red O precipitate. 150 μL Oil Red O working solution was 
added to each well for 1 h. The wells were washed as before in PBS, a drop of mountant 
(ProLong Diamond Antifade, Thermo Fisher) added to each well and a coverslip applied. 
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Brightfield imaging was carried out on a microscope (Leica DMI6000, Fig. 2.2, A). The Oil 
Red O positive area was quantified by Image J analysis. Briefly, each image was 
converted to a grayscale 8-bit format (Fig. 2.2, B) and the threshold was adjusted to 
highlight pixels of intensity between 90 and 110 (Fig. 2.2, C). The total Oil Red O area of 





2.18 Mitotracker® Stain 
Primary human myotubes were stained with Mitotracker® Green FM, which stains 
mitochondria independent of their membrane potential and Mitotracker® Orange CM-
H2TMRos which accumulates in mitochondria in a membrane-dependent fashion 
(Thermo Fisher). Both reagents were reconstituted at 1 mM and diluted together in 
myotube differentiation medium (Green 1:10,000, Orange 1:5000). Culture medium was 
removed from the myotubes and the wells washed once in PBS. 500 µL Mitotracker® stain 
medium was added to each well, the plate wrapped in foil and incubated for 45 min at 37 
°C. The wells were washed three times with 500 µL PBS; the final wash was not removed. 
The plates were imaged immediately on an epifluorescence microscope (Leica DMI6000). 
Five images were taken in each well using the 20x objective, with triplicate wells imaged 
for each treatment condition in each independent experiment. Image acquisition settings 
were fixed throughout. The mean fluorescence intensity of the green and red channels of 
each image was quantified using Image J software. Mitotracker® Orange intensity was 
corrected for the Mitotracker® Green FM intensity – a surrogate for total mitochondrial 
mass.  
 
2.19 Seahorse XFe96 Analysis of Myotube Metabolic Function 
The Seahorse XFe96 analyser (Agilent Technologies, Santa Clara, California, United 
States) measures oxygen consumption rate (OCR) and the extracellular acidification rate 
(ECAR) of cells in 96 well plates to assess their metabolic function. A mitochondrial stress 
test (Seahorse XF Mito Stress Test) was used; oligomycin, Carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone (FCCP) and a mixture of rotenone and antimycin A are 
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serially injected by the analyser to assess aspects of mitochondrial function. Oligomycin 
inhibits ATP synthase (mitochondrial complex V), reducing OCR. The remaining OCR 
represents proton leak and non-mitochondrial respiration. Basal ATP production may be 
calculated by subtraction of this OCR from basal OCR. FCCP uncouples respiration, 
producing unfettered maximal oxygen consumption by complex IV. Rotenone (complex I 
inhibitor) and antimycin A (complex III inhibitor) completely inhibit mitochondrial 
respiration, enabling calculation of proton leak by subtraction from oligomycin OCR 
values. Baseline ECAR values, indicative of lactate production and thus non-oxidative 
metabolism, are also obtained during a Mito Stress Test. The test was carried out in 
accordance with the manufacturer’s recommendations. 25,000 myoblasts per well were 
seeded to 0.2 % gelatin-coated Seahorse XFe96 Cell Culture Microplates. At 24 h the 
cells were differentiated. Treatment conditions were assayed in quadruplicate – further 
details can be found in the relevant data chapter. The assay was run at differentiation day 
8. An XFe96 sensor cartridge was hydrated in Seahorse XF Calibrant Solution (Agilent 
Technologies) overnight at 37 °C in a non-CO2 incubator. On the day of the assay, XF Cell 
Mito Stress Test assay medium was prepared (XF base medium, 5.5 mM glucose, 1 mM 
sodium pyruvate, 1 mM glutamine, pH 7.4, filter sterilised). Myotube differentiation 
medium was replaced with 175 µL/well assay medium and the plate was incubated for 1 
h at 37 °C in a non-CO2 incubator. Oligomycin, FCCP and Rotenone/antimycin A were 
reconstituted according to the Mito Stress Test Kit instructions and 25 µL of each added 
to the appropriate wells of the Seahorse utility plate. The utility plate is loaded into the 
analyser with the cell microplates to facilitate drug delivery during the stress test. The 
analyser was calibrated and the plate loaded. The assay configuration for each of the four 
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test phases (basal, oligomycin injection, FCCP injection, rotenone/antimycin A injection) 
was as follows: mix 3 min, wait 2 min, measure OCR/ECAR 3 min, repeated for three 
cycles. 
The XF Cell Mito Stress Test may also be modified to allow the measurement of 
endogenous and exogenous fatty acid oxidation and this procedure was carried out 
according to the manufacturer’s instructions. Briefly, the protocols for the seeding of 
myoblasts and for carrying out the Mito Stress Test were repeated as described above. 
However, 24 h before the assay, the growth medium was replaced with a substrate limited 
medium (DMEM: 0.5 mM glucose, 1 mM glutamine, 0.5 mM carnitine, 1 % FBS) to deplete 
endogenous substrates within the cell. 45 min prior to the assay the medium was replaced 
with assay medium (111 mM NaCl, 4.7 mM KCl, 1.25 mM CaCl2, 2 mM MgSO4, 1.2 mM 
NaHPO4, 2.5 mM glucose, 0.5 mM carnitine, 5 mM HEPES, pH 7.4 at 37 °C). For each 
treatment condition, four assay conditions were utilised to allow endogenous and 
exogenous fatty acid oxidation to be calculated: BSA controls (added to wells just prior to 
assay commencement as per the manufacturer) with and without the CPT-1 inhibitor 
etomoxir (400 μM in FAO assay medium added 15 min prior to the assay) and palmitate-
BSA (added to wells just prior to assay commencement as per the manufacturer) with and 
without the CPT-1 inhibitor etomoxir (400 μM in FAO assay medium added 15 min prior 
to the assay). Endogenous and exogenous fatty acid oxidation were calculated from the 






2.20 Non-Radioactive Surface Sensing of Translation (SUnSET) Protein 
Synthesis Assay 
A SUnSET protein synthesis assay was employed in myogenic cultures that had been 
stimulated with recombinant cytokines. On the day of the assay, the culture medium was 
removed and replaced with differentiation medium containing 1 μM puromycin (Sigma 
Aldrich) for 30 min. Cultures were then prepared for immunoblotting (Section 2.6), and the 
resulting blots were probed with an anti-puromycin primary antibody (Table 2.3). Protein 
synthesis was estimated by Image J densitometric analysis of each lane (Section 2.6), 
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corrected for ponceau stain densitometry values. Immunoblots were stained with ponceau 
S (0.5 % (w/v) ponceau S in 1 % acetic acid) for 5 min, washed for 1 min in 1x TBS-T. The 
blots were then imaged on the ChemiDoc MP imaging system (Bio-Rad). Image J v1.47 
was used for the densitometric quantification of each lane.  
 
2.21 Data Handling and Statistical Analysis 
A brief description of the data analysis strategy used is intended here. Details of the every 
tests used for each data set may be found in the appropriate figure legend. All data 
analysis was carried out using SPSS Statistics 21 (IBM, NY, USA) and GraphPad Prism 
v5.03 (GraphPad Software, CA, USA). Shapiro-Wilk tests were used to evaluate the 
normality of data sets and the Levene test was employed to assess the equality of 
variances within data groups. If possible, data were transformed so that a normal 
distribution and equal variances were achieved. For parametric data involving two 
treatment conditions unpaired t-tests were used. Such non-parametric data were analysed 
by Mann-Whitney U tests. For parametric data involving multiple treatment conditions, 
one-way analysis of variance (ANOVA) with post-hoc Bonferroni correction was preferred, 
to limit type I error. Where data violated the assumptions of ANOVA, Mann-Whitney U 
tests were used, with post-hoc Holm’s sequential Bonferroni adjustment to limit the type I 
error associated with multiple comparisons.  
A p value of < 0.05 was considered statistically significant although this should not be 
confused with the biological significance of a finding, which is considered in the discussion 
of each data set. In general, data are presented as mean ± standard error of the mean 
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The Subcutaneous Adipose 

















Adipose tissue mass typically accumulates from middle age at a rate of 0.21 kg/yr in men 
and 0.14 kg/yr in women, peaking in old age (4). The coexistence of sarcopenia with this 
increase in adipose tissue mass is termed sarcopenic obesity (8).  
Cross-sectional studies of body composition across the lifespan have found that total 
adipose tissue mass (28) and VAT mass (29) are negatively correlated with skeletal 
muscle mass. Furthermore, a prospective study of 379 Korean men and women also 
demonstrated that VAT area, (measured by DEXA) predicted 20 % of the variance in 
appendicular lean soft tissue area at 2 years (r2 = -0.203, p < 0.001) (259).  
Ageing is also accompanied by an increased systemic inflammatory burden (264).  This 
inflammation has been associated with the loss of LBM with age. Indeed, longitudinal 
studies of elderly cohorts have positively correlated high systemic concentrations of IL-6, 
CRP and TNFα and with loss of skeletal muscle mass (25,26). Adipose tissue is now 
known to be a prolific secretor of pro-inflammatory cytokines. Proteomic approaches have 
identified hundreds of potential adipokines that are expressed and likely secreted by 
human subcutaneous adipocytes (34). The association of adipose tissue accumulation 
and systemic inflammation with sarcopenia, coupled with the status of adipose tissue as 
an endocrine organ, suggest that there is substance to the hypothesis that sarcopenia is 
– in part – an adipokine-driven phenomenon. This chapter uses a broad definition of the 
term adipokine, to encompass all molecules that are secreted by adipose tissue and which 




A lone study has examined the effect of an inflammatory milieu secreted by human SAT 
and VAT adipocytes on primary human myotubes, demonstrating that VAT adipocytes 
from OB individuals induce myotube atrophy (47). However, the SVF of adipose tissue, 
which includes preadipocytes and macrophages, is a more prolific secretor of pro-
inflammatory cytokines than mature adipocytes (46). Consequently, adipokine secretion 
by human adipose tissue – not just that by adipocytes – must be characterised and its 
effect on human myofibre size and function determined. It must also be ascertained 
whether obesity alters this adipose tissue inflammatory milieu as well as its myogenic, 
atrophic and metabolic effects on skeletal muscle. 
The prolific secretion of pro-inflammatory cytokines by VAT is addressed in Section 1.7.1. 
We have noted that SAT also secretes pro-inflammatory adipokines (45–47) and that VAT 
represents a small proportion of total adipose tissue mass (12.7 % in endurance runners 
aged 27 to 69 years (48)). Thus, SAT may be underestimated as a contributor to the 
systemic inflammatory burden and is the focus of this work.  
The anti-myogenic and pro-atrophic actions of some adipokines are now well established. 
TNFα and IL-6 are well studied in this respect (270,271,273,279,281,359). However, such 
effects of many other adipokines are not well characterized, and it is not known which 
components of the subcutaneous adipose inflammatory milieu are most consequential in 
the pathogenesis of sarcopenic obesity.  
Therefore, the objectives of this chapter were as follows:  
1. To quantify the secretion of prominent known adipokines from the SAT of middle-
aged and elderly participants and to identify whether the inflammatory milieux differ 
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between lean (normal weight; NW) and non-lean (overweight; OW and obese; OB) 
elderly individuals. 
2. To identify the adipokine constituents of these milieux which may be most 
consequential in the pathophysiology of sarcopenic obesity.  
3. To determine whether these inflammatory milieux alter the development of 
myotubes in primary myogenic cultures derived from young and old participants.  
4. To ascertain whether these inflammatory milieux alter myotube oxidative 
metabolism. 
 
3.2  Methods 
Subcutaneous adipose tissue samples from subjects (aged 45 – 89 yr) of varying BMI 
(Table 3.1) were maintained in myoblast differentiation medium for 24 h (1 g adipose tissue 
per 10 mL medium). The media were aliquoted and stored at -80 °C. The concentrations 
of known adipokines were determined in lean (BMI < 25, n = 13), and non-lean (BMI > 25; 
overweight, n = 17, obese, n = 15) ACM by multiplex magnetic bead-based human 
cytokine assays. The concentrations of fatty acids, total cholesterol and free cholesterol 
were determined in ACM by using enzyme-based colorimetric assay kits (Abcam, UK). 
Next, the effect of the NW and OB adipose inflammatory milieux on young and old 
myotube formation was examined. Subconfluent myoblasts from young and old lean, 
healthy participants (n = 3 per group) were switched to unconditioned differentiation 
medium, NW ACM or OB ACM. Each young biological replicate was paired with one from 
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the old experimental group, with both replicates being stimulated with the same NW and 
OB ACM sample. NW and OB ACM samples were chosen from the small pool of such 
samples with sufficient media available to facilitate an experiment in which media were 
renewed every 2 d. A combination of inadequate OW ACM samples of sufficient volume 
and limitations on the number of available myogenic culture wells led us to eliminate OW 
ACM from these experiments. At 8 d, myotubes were fixed, IF stained for desmin and with 
DAPI and imaged on an epifluorescence microscope. These images were used to quantify 
MTT and NFI. To examine the effect of ACM on myotube mitochondrial metabolism, 
commercially available primary human myoblasts from a 21 yr old female were used in 
conjunction with a Seahorse® XFe96 analyser XF Mito Stress Test. We demonstrate in 
Chapter 4 that such myogenic cultures behave similarly to the ones that we routinely 
isolate. Four independent experiments were conducted, using genetically identical 
myotubes that had been derived from four different manufacturer vials and were cultured 
separately. Myotubes were stimulated with NW (n = 5), OW (n = 7) and OB (n = 7) ACM 



















Table 3.1. Population Demographics.  Subcutaneous adipose tissue samples were 
obtained from participants undergoing total hip and knee replacement surgery.  
 Normal weight Overweight Obese 
Gender (n, M/F) 4/7 7/10 9/6 
Hip/Knee (n) 7/4 11/6 11/4 
Age (yr) 68.1 ± 3.3 a 72.3 ± 2.2 a 68.1 ± 2.0a 
BMI 23.8 ± 0.3a 27.3 ± 0.4b 33.1 ± 0.7c 
WHR 0.88 ± 0.02 a 0.92 ± 0.01a 0.95 ± 0.02 b 
Different symbols indicate that values are significantly different (p < 0.05) one-way 
ANOVA with post-hoc Bonferroni adjustment. Values are mean ± SEM. Normal weight 
age range = 49 to 81 yr, overweight age range = 56 – 85 yr, obese age range = 55 – 81 




3.3.1 Characterising the Inflammatory Milieu Secreted by Subcutaneous Adipose  
The concentrations (mean ± SEM) of ACM adipokines in lean (NW) and non-lean (OW 
and OB) ACM are represented in Fig. 3.1 and Table 3.2. The data are presented in both 
table and dot plot formats to allow the absolute values and the true spread of the datasets 
to be appreciated. The concentrations of resistin (lean 1207 ± 225 pg/mL, non-lean 1778 
± 109 ng/mL; p = 0.01 by unpaired t test) and serpin E1 (lean 4033 ± 967 pg/mL, non-lean 
13328 ± 3110 pg/mL; p = 0.02 by Mann Whitney U test) were significantly elevated in non-
lean ACM.  There was a trend for the concentrations of fatty acid binding protein 4 (FABP4) 
to be lower in non-lean ACM (lean 56 x 104 ± 12x104 ng/mL, non-lean 33 x104 ± 37x104 










Lean (BMI < 25) 
(Mean ± SEM, 
pg/mL) 
Non-Lean (BMI > 
25) 






Adiponectin        28716 ± 4524 
 
28841 3779 0.18  
Aggrecan 579 ± 15 513 ± 23 0.07¶  
Amphiregulin 532 ± 137 703 ± 67 0.22  
Chemerin-1 2655 ± 673 3450 ± 583 0.44  
Eotaxin 95 ± 41 61 ± 12 0.81  
FABP4 56 x104 ± 12 x104 33 x104 ± 4 x104 0.06¶  
Galectin-1 5.3 x104 ± 0.6 x104 5.2 x104 ± 0.3 x104 0.85  
IL-10 2.25 ± 0.56 2.59 ± 0.39 0.62  
IL-15 1.81 ± 0.52 2.32 ± 0.37 0.45  
IL-1β 12.02 ± 1.59 11.94 ± 1 0.96  
IL-6 968 ± 220 2438 ± 495 0.12¶  
IL-7 3.02 ± 0.27 3.04 ± 0.29 0.96  
Leptin 11335 ± 2592 12210 ± 2467 0.83  
MCP-1 2372 ± 924 1540 ± 406 0.34  
MIP1a 363 ± 54 303 ± 32 0.33  
MIP1b 101 ± 37 125 ± 24 0.58  
MIP3a 85 ± 25 164 ± 51 0.97  
Resistin 1207 ± 225 1778 ± 109 0.01  
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Serpin E1 4033 ± 967 13328 ± 3110 0.02¶  
TNFα 10.43 ± 1.57 10.43 ± 1.17 0.99  
Visfatin 2420 ± 507 2077 ± 212 0.91¶  
Data analysed as lean vs non-lean by unpaired t-test except values marked ¶, 




The variable nature of the concentrations of each cytokine between individuals is 
somewhat evident in Fig. 3.1. However, such a graphical representation of the data does 
not adequately communicate the degree to which each ACM differs from that of the 
average NW individual. In Fig. 3.2, the data are expressed as a log10 transformation of 
their fold change from the NW mean for each cytokine so that the distance of a given point 
from 0 on the y-axis scale represents an equivalent change in adipokine concentration 
when compared to a mirrored point on the other side of the 0 line. It is evident that OW 
ACM (Fig. 3.2, A) and OB ACM (Fig. 3.2, B) adipokine concentrations are highly variable 
with respect to the NW mean value. It is also evident that lesser variability exists in the 
adipokine concentrations found in the ACM of NW individuals, with respect to the NW 






To quantify the degree to which the ACM of each subject in this study differs from that of 
the standard NW individual, an Adipokine Variability Score (AVS) was designed (see 
Appendix Fig. 3.1 and the associated text). It is evident from these data that it should not 
be assumed that the ACM concentration of a given adipokine is predictive of an adipose 
secretory pattern for all the adipokines that were measured.  
Linear regression analyses were performed, comparing BMI with the concentrations of 
adipokines that were significantly different or approached such significance in 
comparisons of lean and non-lean ACM (Fig. 3.1, Table 3.2). These analyses indicate that 
BMI is responsible for – at most – a small proportion of the variance in ACM adipokine 




The multiplex magnetic bead-based immunoassay was supplemented by the use of 
colourimetric assays, designed to quantify free fatty acids, total cholesterol and free 
cholesterol. No significant differences in their concentrations were observed between the 
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lean and non-lean ACM samples (Fig. 3.4).  
 
 
3.3.2 The Effect of Adipose Conditioned Medium on the Differentiation of Primary 
Human Myotubes from Young and Old Participants 
Myotubes from elderly participants that were stimulated with OB ACM (See Table 3.3) 
were significantly thinner (30% ± 5%, p = 0.009) than their NW ACM counterparts (Fig 3.5, 
B).  The NFI of elderly myogenic cultures was also diminished (42 ± 6%, p = 0.0003) by 
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OB ACM compared to NW ACM (Fig. 3.5, C).  Young myotubes were not significantly 
affected by stimulation with the same ACM samples (Fig. 3.5 B, C).  
 
 
Table 3.3. Adipokine Concentrations (pg/mL) for the Adipose Conditioned 
Media that were Selected for Use in the Differentiation of Primary Human 
Myotubes.  













Adiponectin 21150 26398 15944 15939 18021 7995 
FABP4 151x104 31 x104 46 x104 22 x104 11 x104 10 x104 
IL-10 0.01 4.7 5.3 5.4 4.6 0.73 
IL-1β 23.9 17.1 16.2 14.8 2.4 5.4 
IL-6 475 1564 527 7621 488 309 
Leptin 1553 8942 416 23426 1270 17923 
Resistin 1417  1465 483 1742 1586 2020 
TNFα No read No read 3.9 No read 5.9 9.5 








3.3.3 The Effect of Adipose Conditioned Medium on the Mitochondrial Metabolism 
of Primary Human Myotubes 
Basal respiration (17 ± 8 %, p = 0.0003), maximal respiration (17 ± 6 %, p = 0.01), ATP 
production (9 ± 8 %, p = 0.0005), and spare capacity (22 ± 6 %, p = 0.0003), were 
significantly elevated by OB ACM compared to NW ACM; the NW values did not differ 
from unstimulated controls. (Fig. 3.6). OW ACM similarly increased spare capacity, but no 








3.4.1 The Differential Expression of Adipokines in Lean and Non-Lean 
Subcutaneous Adipose Conditioned Medium  
Resistin and Serpin E1 ACM concentrations were significantly elevated in the OW/OB 
group compared to their NW counterparts, with FABP4 concentrations being diminished 
(p = 0.06). Resistin is a pro-inflammatory adipokine that is produced predominantly by 
monocytes and macrophages in humans, with a smaller proportion being produced by 
adipocytes (287). However, given the importance of adipose tissue M1 macrophage 
accumulation in ageing and obesity (232,234–236), adipose secretion of resistin may be 
of some consequence in sarcopenic obesity. Plasma and serum resistin concentrations 
have been positively correlated with BMI (289,290). Indeed, previous work from our group, 
using the same patient population from which ACM was generated, (Philp AM, PhD thesis) 
demonstrated that serum resistin concentrations in the OW and OB are significantly 
elevated compared to NW individuals (NW, 9818 ± 7325 pg/mL; OW/OB, 13041 ± 9013 
pg/mL; p = 0.03).  
Few studies describe the effect of resistin on sarcopenic muscle. Plasma resistin 
concentrations have been reported to have an inverse relationship with quadriceps torque 
in old (69-81 yr), but not in young (18-30 yr), participants (291). C2C12 myoblast 
proliferation is increased by the transfection of a human resistin eukaryotic expression 
vector, and such transfection reduces the expression of desmin and results in thinner 
myotubes (292). We are unaware of any studies that have used primary human myotubes, 
coupled with exogenous resistin to investigate the effects of this adipokine on skeletal 
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muscle. Notably, human resistin displays only 59 % amino acid sequence homology to 
murine resistin. Thus, extrapolation of the effects of murine resistin to human physiology 
are particularly problematic (293).  
Fatty acid binding proteins, including FABP4, are cytosolic proteins that bind hydrophobic 
molecules and act as lipid chaperones to facilitate fatty acid metabolism (360). ACM 
concentrations of FABP4 tended (p = 0.06) to diminish in non-lean ACM. Previous work 
from our lab (Philp AM, PhD thesis) measured the serum adipokine concentrations of 174 
patients recruited to the same study from which the SAT was sourced for ACM generation; 
17 of the 45 SAT ACM donors were included in the serum analyses. FABP4 serum 
concentrations were significantly elevated in non-lean individuals. This paradox between 
the diminished expression of FABP4 in non-lean adipose tissue and its elevated serum 
concentration in the same population has been described in the literature and may 
perhaps be explained by a significantly higher expression of FABP4 in the hepatic tissue 
of obese individuals (361). Elevated serum FABP4 is well established as a predictor of 
pre-eclampsia (362), gestational diabetes mellitus (363) and cardiovascular disease 
(364,365). However, circulatory FABP4 has not been established as being mechanistically 
important in the pathogenesis of such conditions and may simply act as a biomarker for 
dysfunction within individual tissues.  
Serpin E1 (plasminogen activator inhibitor-1) – concentrations of which were elevated in 
non-lean ACM –  is a protease inhibitor that inhibits the activation of plasminogen via 
tissue plasminogen activator (tPA) and urokinase (uPA) (366,367). The plasminogen 
activation system facilitates the remodelling of the skeletal muscle extracellular matrix 
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(368). Serpin E1 is an acute phase reactant of which macrophages and adipocytes are 
prolific producers (366). It is therefore unsurprising that non-lean adipose tissue displays 
increased serpin E1 secretion. Serpin E1 has been implicated in the development of 
atherosclerosis and favourable tumour microenvironments (366). Extravascular Serpin E1 
can alter extracellular matrix deposition as well as activate intracellular signalling 
pathways (e.g. the NFκB and ERK pathways) via interaction with urokinase plasminogen 
activator receptor (uPAR) and low-density lipoprotein-like receptor-1 (LRP-1) receptors 
(366,369,370). Thus, it is biologically plausible that adipose-derived serpin E1 could exert 
biological effects in distal tissues, including skeletal muscle. Indeed, it is well established 
that activation of plasminogen supports skeletal muscle regeneration. uPA-/- and 
plasminogen -/- mice display severe defects of skeletal muscle regeneration; tPA-/- mice 
are unaffected, therefore uPA-mediated plasminogen activation appears to be important 
in skeletal muscle regeneration (371,372). In mice (male C57BL mice with a heterozygous 
mutation in the insulin II gene; Akita mice), with systemically elevated serpin E1, the serpin 
E1 inhibitor PAI-039 rescues skeletal muscle regeneration in response to cardiotoxin injury 
(373). Pertinently, the SC of human participants with Duchenne muscular Dystrophy 
secrete more serpin E1 than healthy control cells (374). Thus, there is some evidence to 
suggest that the elevated secretion of serpin E1 by non-lean adipose tissue could have a 
detrimental effect on skeletal muscle myogenesis.  
The composition of the ACM generated for this work is representative of adipokine 
secretion by a fixed weight of adipose tissue. However, OB and OW individuals have a 
greater adipose tissue mass than their NW counterparts thus the effect of secreted factors 
from obese adipose tissue on skeletal muscle could be under-represented in our ACM in 
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vitro model. Furthermore, it is important to note that BMI is an imperfect, if convenient 
surrogate for adiposity, that is useful in predicting risk (e.g. of cardiovascular disease 
(375,376)) at a population level, but is less useful for individuals, e.g. elite rugby union 
forwards may often be classified as OB, despite having low body fat percentages (377). 
However, dissection studies of elderly cadavers have suggested that about 80 % of the 
variance in total adiposity can be predicted by BMI (378). The predictive value of BMI for 
SAT mass is lower, at 61 % for women and 78 % for men (378). Such values are consistent 
with DEXA validations of BMI as a marker of adiposity (379). Therefore, for a given 
adipokine secretion profile and a given BMI classification, an individual with a low body 
fat percentage will have a lower systemic burden of adipose-derived inflammation than an 
individual with a higher body fat percentage. This is an important consideration. Of the 
adipokines that we measured in ACM, only resistin and serpin E1 were differentially 
secreted by a fixed mass of adipose tissue between lean and non-lean individuals. 
However, these differences are likely to be magnified both locally and systemically by 
increased adiposity in the non-lean. For this reason, our observations of ACM composition 
do not preclude other adipokines from playing an important role in the aetiology of 
sarcopenia or indeed other pathologies. For example, no difference in IL-6 ACM content 
was observed between lean and non-lean participants. However, systemic concentrations 
of IL-6 increase with age (264) and despite low concentrations of IL-6 appearing to support 
skeletal muscle hypertrophy (266,268,380), higher concentrations of IL-6 induce skeletal 
muscle atrophy (270,271). Thus, adipokines that were not observed to be differentially 
expressed by lean and non-lean adipose tissue may still be important contributors to the 
aetiology of sarcopenia.  
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Adipose tissue is located primarily in two anatomical depots, SAT and VAT.  In this study, 
we were limited to using SAT for the generation of ACM.  VAT is considered to be the more 
prolific secretor of adipokines (41,276). Adipocyte hypertrophy (201,202) and macrophage 
accumulation (234,240) – which drive AT inflammation – are more prominent in VAT than 
SAT. VAT is also more often associated with an increased risk of cardiovascular disease 
and the metabolic syndrome (39,40). VAT mass has frequently been shown to have a 
substantial negative correlation with skeletal muscle mass (29,258), and VAT area can 
predict 20 % of the variance in appendicular lean soft tissue area after 2 yr (259).  Indeed, 
Pellegrinelli et al. generated conditioned medium from human SAT and VAT adipocytes. 
Although they do not describe the composition of these media in sufficient detail, it is 
evident that OB VAT conditioned medium contained greater concentrations of adipokines 
such as IL-6, granulocyte colony-stimulating factor (G-CSF) and IL-7 than OB SAT 
conditioned medium (47). 
However, the importance of VAT as a source of inflammation does not preclude SAT from 
playing a prominent role in inflammation-mediated sarcopenia. Negative correlations have 
also been described between total AT mass (28), SAT mass (258) and skeletal muscle 
mass. SAT mass does not appear to increase with age in men for a given BMI (44), 
however, when younger and older cohorts are not BMI matched, an absolute gain of SAT 
in conjunction with increased body weight and BMI is evident with advancing age (45). 
Importantly, VAT represents a small proportion of total AT mass. Thus, SAT is likely to also 
be an important contributor to the systemic inflammatory burden.  
IMAT mass also increases with age (42,120). Given the proximity of IMAT to skeletal 
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muscle, it may be an important local contributor to sarcopenic obesity.  However, little is 
known about adipokine secretion by IMAT due to the technical difficulties associated with 
its biopsy in adequate quantities for study. In frail elderly, IMAT accumulation positively 
correlates with IL-6 protein expression within the skeletal muscle (120). Surprisingly little 
is known about the mechanisms underlying the development of IMAT. A population of 
skeletal muscle non-myogenic progenitor cells, widely termed fibro-adipogenic progenitor 
cells (FAP) have been identified as one possible source of adipocytes within skeletal 
muscle (381). FAP were simultaneously identified in mice by two research groups as Sca-
1+ CD34+ PDGFRα+ cells with both adipogenic and fibrogenic, but not myogenic potential 
(382,383). More recently, FAP have been identified in human skeletal muscle (381). 
Notably, adipocytes formed by FAP display a disordered metabolism compared to 
subcutaneous adipose stroma cell-derived adipocytes e.g. they are insensitive to insulin-
induced glucose uptake (384). Thus, some evidence exists to suggest that FAP-derived 
adipose tissue differs from SAT. Should FAP be definitively identified as contributors to 
IMAT, their in vitro culture may offer a method of profiling the IMAT secretome. 
 
3.4.2 The Composition of Adipose Conditioned Medium is Highly Variable, 
Irrespective of Body Mass Index  
One of the observations from our profiling of the cytokine content of ACM is the degree of 
variability that exists within individuals and between individuals. It is evident in Fig. 3.2 
that individual NW, OW and OB ACM samples display considerable deviation of their 
adipokine content from the NW group mean. This visualisation also highlights that the 
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degree of such variability is less in NW ACM. This phenomenon was quantified by the 
design of the AVS (Appendix Fig. 3.1). The AVS clearly illustrates that the OW and OB 
ACM are on average significantly different in their constituents than NW ACM. 
Furthermore, a plot of OB ACM adipokine concentrations, in which four OB ACM with 
similar resistin concentrations are highlighted (Appendix Fig. 3.1) illustrates that such 
clustering for one adipokine is not predictive of those samples containing similar 
concentrations of other adipokines. Thus, while BMI clearly alters the composition of the 
milieu secreted by adipose tissue, the degree to which particular adipokines are affected 
is unpredictable.   
Here, the AVS score is representative of 21 adipokines that we measured using multiplex 
magnetic-bead human cytokine assays. Proteomics approaches have identified hundreds 
of potential adipokines that are expressed by human subcutaneous adipocytes (34,385). 
Thus, the potential for adipose tissue secretome variability between individuals is 
substantial. Most proteomic profiling has thus far utilised primary human adipocytes 
(34,385,386) or adipose tissue (387), rather than adipose tissue conditioned media and 
has thus been limited to predicting whether individual proteins are likely to be secreted by 
adipose tissue.  
As noted previously, Pellegrinelli et al. examined the effect of an inflammatory milieu 
secreted by human SAT and VAT on myotubes, but used adipocytes alone, rather than 
adipose tissue to generate conditioned medium (47).   The results of their multiplex 
cytokine analysis of those conditioned media is provided in insufficient detail to draw 
meaningful conclusions as to the differences between their NW and OB subcutaneous 
adipocyte conditioned medium (47). Thus, although we quantified a limited panel of 
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adipokines in our ACM, it represents a substantial contribution to our knowledge of the 
adipose tissue secretome and how it is altered by obesity. This work will benefit from 
expansion. First, by expanding the numbers of participants, particularly in the NW group. 
Adipose tissue was obtained from patients undergoing total hip and knee replacement 
surgery for osteoarthritis. Osteoarthritis is more common in non-lean individuals (388).  
Thus, our recruitment in the NW category lagged behind that in the OW and OB categories 
over the lifetime of this project. Second, by carrying out metabolic phenotyping of the 
participants to ascertain whether measures of insulin resistance better explain the 
variability in SAT adipokine secretion than BMI. Finally, this work should be developed by 
the use of proteomic approaches to expand on our adipokine profiling of ACM.  
Excessive exogenous delivery of free fatty acids can have detrimental effects on skeletal 
muscle, including insulin resistance and altered skeletal muscle lipid partitioning 
(241,389–391). Thus, the multiplex magnetic bead-based immunoassays of ACM were 
supplemented by colourimetric assays designed to quantify free fatty acids, total 
cholesterol and free cholesterol. No significant difference in their ACM concentrations was 
observed.  It is again evident from these data that we recruited far fewer individuals in the 
NW category than in the OW and OB categories. Increasing the sample size in the NW 
category – which will be possible in our laboratory in the coming years – would increase 
the statistical power of such assays.  Furthermore, the assays detailed here detect total 
fatty acid and cholesterol content of the ACM. It is possible that the fatty acid and 
cholesterol species present in ACM differ between lean and non-lean individuals. 
Lipidomic profiling of such ACM, in addition to the proteomic work proposed, would be a 
worthwhile endeavour.  
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3.4.3 Obese Adipose Conditioned Medium has a Detrimental Effect on the 
Formation of Elderly Myotubes 
Primary human myogenic cultures were differentiated to form myotubes in the presence 
of ACM. Six ACM were used in this work, three NW and three OB. Adipose tissue donor 
participants were those undergoing joint replacement surgery; the skeletal muscle donor 
participants were healthy recruits. The timing of subject recruitment in those studies 
precluded an experimental design in which each primary myogenic culture was treated 
with a panel of the same NW and OB ACM. Thus, each young myogenic culture donor 
was paired with an elderly donor, and those cultures were treated with the same NW and 
OB ACM.  
Myotubes from elderly participants that were stimulated with OB ACM were 30 % thinner 
than their NW ACM counterparts, and the NFI of elderly myotubes was diminished by 
more than 40 % (Fig 3.5, B).  The same ACM samples had no significant effect on the 
formation of myotubes by myogenic cultures derived from young participants.  
 The ACM used were chosen primarily because there was sufficient ACM available to 
conduct the experiment. It is evident from Table 3.3 that overall the OB ACM had higher 
IL-6, leptin, resistin and visfatin concentrations as well as lower FABP4 concentrations 
than their NW counterparts. It is biologically plausible that these differences in ACM 
composition, acting in concert could have a profound effect on myotube development. The 
discrepancy in leptin concentration between these NW and OB ACM is not representative 
of the lean and non-lean populations as a whole (Table 3.2). It is also possible that other 
unmeasured factors – some perhaps undiscovered – within OB ACM contributed to the 
considerable declines in MTT and NFI observed in elderly cultures. Despite the variability 
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in ACM composition, these effect sizes are large, with relatively small SEM values 
observed for the three myogenic cultures in each age group (~5-6%). While three 
biological replicates were sufficient to detect these changes in elderly myotubes, it is 
possible that our assay is underpowered to detect lesser, but none the less real and 
physiologically important decreases in MTT and NFI in young cultures. Ways in which the 
assay might be improved are considered in Chapter 7.  
Our finding that OB ACM significantly reduced MTT and NFI in elderly myotubes, whereas 
young myotubes treated with the same ACM were not affected to the same extent is both 
remarkable and novel. Previous work in this area has shown that conditioned medium 
from SAT adipocytes derived from lean individuals does not alter the MTT or NFI of 
myotubes in myogenic cultures isolated from a neonate (47). In the same study, 
conditioned medium from VAT adipocytes significantly diminished MTT and NFI. However, 
the SVF of adipose tissue, which includes preadipocytes and macrophages, is a more 
prolific secretor of pro-inflammatory cytokines than mature adipocytes (46); the work 
presented here considers the inflammatory milieu secreted by adipose tissue as a whole. 
In the 3D adipocyte and myotube co-culture system used by Pellegrinelli et al., they 
observed that VAT adipocytes modified myokine secretion by myotubes, creating a unique 
inflammatory milieu that was more than the sum of its adipocyte and myotube parts (47).  
In future work, quantification of adipokine concentrations in ACM after 24 h in culture with 
myotubes from young and old participants might yield additional useful information about 
the inflammatory environment that detrimentally affects myotube formation.  
The mechanisms underlying the differential responses of young and elderly myotubes to 
OB ACM were not explored in this study, yet plausible avenues of enquiry exist. Primary 
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human myogenic cultures are known to retain some of the characteristics of their donors 
(76–78). Whether the differentiation of primary human myogenic cultures diminishes with 
age is controversial (146,147), although culture of myoblasts from older individuals in 
autologous serum has been reported to adversely affect their differentiation (148). 
Definitively establishing whether such a difference in differentiation capacity exists under 
physiologically relevant culture conditions is necessary, only then can a detailed 
examination of the molecular differentiation program (e.g. myogenic regulatory factor 
expression) be made to elucidate the mechanisms that underlie an age-related decline in 
differentiation capacity in the presence of OB ACM.  
Differential expression of cytokine receptors between young and elderly individuals has 
been widely described, including in the brain (392), spleen (392) and NK cell population 
(393). Indeed, in a later chapter of this thesis (Chapter 6), diminished expression of the 
IL-15 receptor IL-2Rβ is described in elderly skeletal muscle. We are unaware of any 
comprehensive profile of cytokine receptor gene or protein expression made in aged 
human skeletal muscle. It is possible that altered cytokine receptor expression levels leave 
elderly myogenic cultures more susceptible to the detrimental effects of OB ACM on 
culture differentiation.  
 
3.4.4. Obese Adipose Conditioned Medium Increases Myotube Oxidative 
Metabolism Without Altering Glycolytic Activity  
24 h stimulation of myotubes with OB ACM (n = 7) increased basal respiration, maximal 
respiration, ATP production and spare capacity compared to NW ACM (n = 5). Baseline 
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extracellular acidification rate (ECAR) — a surrogate measurement of glycolytic activity –  
did not differ with BMI classification, although ECAR was slightly elevated by OB ACM 
compared to unstimulated myotubes. Thus, the increase in oxygen consumption observed 
in myotubes stimulated with OB ACM is unlikely to be due to a high rate of glycolysis in 
the presence of an excess of oxygen (the ‘Warburg effect’) (394,395). Thus, OB ACM 
appears to increase the energetic demand of primary human myotubes, with that demand 
being fulfilled by oxidative metabolism. The mechanism by which OB ACM increases 
myotube energetic demand remains to be determined.  
It is possible that the inflammatory milieu of OB ACM may increase muscle protein 
turnover and indeed alter the balance between muscle protein synthesis and breakdown.  
For example, evidence exists to suggest that TNFα activates muscle catabolic pathways. 
In vitro, stimulation of C2C12 myotubes with rTNFα induces myotube atrophy and 
increases the expression of the ubiquitin E3 ligases MAFbx and MURF-1, which target 
proteins for proteasomal degradation (65,278). In vivo, rTNFα administration (IV, 100 
µg/kg) to rats increases skeletal muscle ubiquitin gene expression, as well as increasing 
the ubiquitination of skeletal muscle proteins (279,280).  However, a study of 4 h human 
rTNFα infusion in healthy young men – which raised plasma TNFα concentrations to ~17 
pg/mL (similar to our most concentrated ACM) – did not observe any alterations in skeletal 
muscle protein turnover (396). A similar study of recombinant IL-6 infusion in healthy men 
achieved plasma concentrations of 140 pg/ml, far lower than the IL-6 content of ACM 
(Table 3.2). A 50 % decrease in muscle protein turnover was observed, with a small 
increase in net muscle protein breakdown (397). Little evidence exists to suggest what 
effect other adipokines, e.g. resistin might have on skeletal muscle protein turnover. 
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Primary human myotubes represent a useful in vitro model for the preliminary explorations 
of such effects. L-[2,6-3H] phenylalanine might be used to measure muscle protein 
synthesis and breakdown in the presence of ACM and individual recombinant cytokines 
(67,398). It is anticipated that such studies will be possible in our lab, following the 
generation of additional ACM. 
Finally, although the increased basal respiration in OB ACM-treated myotubes was 
accompanied by an increase in ATP production, the presence of energy sinks in such 
cells, e.g. futile substrate cycles such as the one between fructose-6-phosphate and 
fructose 1,6-biphosphate that is known to be induced by TNFα (399) cannot be 
discounted. 
24 h stimulation of rat L6 myotubes with resistin, concentrations of which were increased 
in OB ACM has been found to inhibit glucose uptake and impair glycogen synthesis 
(308,309). Resistin has also been observed to inhibit palmitate uptake by L6 myotubes 
(310). It is therefore unlikely that resistin, (should it suppress both glucose and fatty acid 
uptake in human myotubes – a considerable assumption) is in large part responsible for 
the increased oxidative metabolic activity observed in OB ACM stimulated cells. However, 
this assumes that primary human myotubes behave similarly to an immortalised rat cell 
line. Furthermore, the concentrations of resistin used in such studies were up to 250 times 
greater than those found in ACM. The metabolic effects of resistin on human myotubes 
are explored in Chapter 5. Other prominent components of the adipose inflammatory 
milieu could also influence myotube metabolism in those ACM with elevated 
concentrations. For example, TNFα and IL-1β increase glucose uptake by L6 myotubes 
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(400); a separate study found that TNFα increased L6 myotube glycolytic activity. IL-6 
infusion in human participants increases whole-body and skeletal muscle lipolysis, without 
affecting glucose turnover (316–318). To summarise, many adipokines are known to alter 
myotube and skeletal muscle metabolism. However, the variability in the composition of 
adipose inflammatory milieux is such that discussion of which adipokines are most 
consequential in producing the metabolic changes observed with OB ACM stimulation falls 
within the realms of informed speculation.  
 
3.5 Limitations and Future Directions 
The limitations of and the opportunities for development of this work have been outlined 
above and are summarised here. Firstly, recruitment of NW participants for SAT biopsy 
was limited. Recruitment of patients undergoing joint replacement surgery is ongoing. 
Thus, the potential exists for our laboratory to generate additional NW ACM in the future. 
Furthermore, while myogenic cultures from three individuals were sufficient to detect a 
significant OB ACM-induced decrease in MTT and NFI in elderly cultures, it is possible 
that smaller, but important decreases were not detected in cultures derived from the 
young. It is evident in subsequent chapters of this thesis that three biological replicates 
are sufficient for such assays when recombinant cytokine stimulations are used, but ACM, 
perhaps due to the variability in its adipokine composition requires the power of additional 
replicates. This work establishes a statistical precedent (e.g. standard deviations) for the 
planning of future studies. 
Resistin and serpin E1 are identified here as adipokines that are differentially secreted by 
the adipose tissue of lean and non-lean individuals. It is clear from the discussion above 
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that both may influence skeletal muscle mass. There is also limited evidence to suggest 
that resistin might alter skeletal muscle metabolism. Further exploration of both adipokines 
in this regard is warranted. Resistin has emerged as the adipokine with the potential to be 
of most consequence in the aetiology of sarcopenia. Its effects in skeletal muscle are 
therefore considered further in Chapters 4 and 5 of this thesis. The inflammatory milieux 
secreted by VAT and IMAT are of great interest in understanding the pathogenesis 
sarcopenic obesity. Given the prolific inflammatory profile of VAT and the proximity of IMAT 
to skeletal muscle, these milieux should be comprehensively characterised.  
The variability in ACM adipokine concentrations, irrespective of BMI is notable. 
Comprehensive proteomic and lipidomic profiling of SAT, VAT and IMAT ACM with respect 
to BMI/adiposity would, therefore, be of great utility to researchers interested in the 
mechanisms underlying sarcopenic obesity.  
This chapter has presented an overview of the effects of ACM on myotube oxidative 
metabolism. There remains a need to determine which adipokines are most consequential 
in driving the increase in such metabolism by OB ACM. The possibility that OB ACM 
causes an increase in muscle protein turnover should be considered.  
Finally, work such as ours would benefit from establishing the most physiologically 
relevant culture conditions for human primary myogenic cultures. Subsequently, the issue 
of whether myogenic cultures derived from older individuals differ from those of their 








• Quantifying the secretion of prominent known adipokines by the adipose tissue of 
elderly participants with respect to BMI. 
• Determining whether these inflammatory milieux alter the development of 
myotubes in primary myogenic cultures derived from young and old participants.  
•  Ascertaining whether the inflammatory milieux alter myotube oxidative 
metabolism.  
• Identifying candidate adipokine/s for further study which may be most 
consequential in the pathophysiology of sarcopenic obesity.  
 
The secretion of resistin was significantly increased in non-lean adipose tissue. It is 
evident from the preceding discussion that that resistin might have detrimental myogenic 
and metabolic actions in skeletal muscle. Thus, subsequent chapters examine these 







































It was established in Chapter 3 that OB ACM has a detrimental effect on the differentiation 
of myogenic cultures derived from elderly participants. It was further established that 
resistin is differentially secreted by the adipose tissue of lean and non-lean individuals and 
thus represents a plausible candidate for mediating – at least in part –  these anti-
myogenic effects. Notably, the OB ACM used in these experiments had elevated 
concentrations of visfatin and leptin compared to the NW ACM that were used (Table 3.3); 
this was not representative of the NW and OB populations as a whole (Table 3.2). 
Furthermore, visfatin and leptin are understudied with respect to their effects on 
myogenesis. Thus, we identified resistin, leptin and visfatin for further study in this regard.  
NFκB pathway signalling (Fig. 4.1) has in the past, been implicated as both a positive and 
negative regulator of myogenesis (401). Genetic approaches to this problem have now 
clearly established the classical NFκB pathway as a negative regulator of myogenesis. 
Myotube formation has been demonstrated to be enhanced in primary cultures derived 
from p65 knockout (p65-/-) mice (402) and in mice with the deletion of one NFκB p65 allele 
(p65+/-) (403). p65-/- mice have also displayed a 76 % increase in tibialis anterior fibre 
number (402). Furthermore, IKKβ-deficient mice are protected against denervation-
induced skeletal muscle atrophy (3). Resistin has been shown to activate NFκB signalling 
in the human liver cancer cell line HepG2 (404), human coronary artery endothelial cells 
(405) and human macrophages (406). Thus, we hypothesised that resistin might impair 
primary human myogenesis by activating NFκB signalling.  
Therefore, the objectives of this chapter were as follows:  
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1. To determine whether resistin, leptin and visfatin alter primary human myogenesis 
in vitro, and to establish whether they are – at least in part – responsible for the 
detrimental effects of OB ACM on primary human myogenesis.  
2. To determine whether resistin activates classical NFκB pathway signalling in 
primary human myogenic cultures. 
3. To ascertain if such NFκB pathway signalling mediates any detrimental effect of 











Subconfluent myoblasts from young (n =3) and elderly (n = 3) participants were switched 
to differentiation media containing recombinant leptin (0 ng/mL or 5 ng/mL). Media were 
renewed every 2 d. At 8 d, cultures were fixed, IF stained for desmin and with DAPI, 
imaged on an epifluorescence microscope and MTT and NFI were quantified as previously 
described. A concentration of 5 ng/mL leptin was chosen as it represents the upper end 
of the concentrations observed in ACM (Fig. 3.1). The experiment was repeated with 
recombinant resistin and visfatin. For much of the mechanistic work that follows these 
experiments, the primary myogenic cultures that we isolated from skeletal muscle biopsies 
are supplemented by commercially available primary human myoblasts. We first sought 
to establish that the myogenic responses of these cells under OB ACM and resistin 
stimulation conditions reflect the responses that we observed in our in-house cultures. To 
that end, commercially available primary human myoblasts from a 21 yr old female were 
differentiated in media containing 0 ng/mL or 5 ng/mL recombinant human resistin or in 
OB ACM. Three independent experiments were conducted, using genetically identical 
myotubes that had been derived from three different manufacturer vials and that had been 
cultured separately. The OB ACM used were the same as those detailed in Chapter 3 
(Table 3.3). To confirm the anti-myogenic role of resistin in ACM, resistin was 
immunoprecipitated from OB ACM using resistin antibody-agarose bead conjugates. IgG 
isotype antibody-agarose bead conjugates were used on the same samples as a control. 
Subconfluent commercially available myoblasts were differentiated in these ACM as 
previously described. Resistin is known to activate classical NFκB signalling in other cell 
types (404–406). Therefore, similar signalling activity was examined in our primary human 
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myotubes. Myogenic cultures were differentiated for 48 h in the presence of 5 ng/mL 
recombinant resistin, with or without the IKKβ inhibitor 5-(p-Fluorophenyl)-2-
ureido]thiophene-3-carboxamide (TPCA-1) and serine 536 phosphorylation of p65 (p-p65) 
was measured by immunoblotting. Myogenic cultures were also differentiated for 8 d (in 
media containing 0 ng/mL or 5 ng/mL recombinant resistin ± 40 nM TPCA-1) to examine 
the effect of such conditions on MTT and NFI.  
 
4.3 Results 
4.3.1 The Effect of Recombinant Adipokines on the Differentiation of Primary 
Human Myotubes from Young and Old Participants 
Recombinant leptin reduced MTT (23 ± 6 % p = 0.04) in old myogenic cultures only (Fig. 






Visfatin did not alter MTT or NFI (Fig. 4.3).   
 
 
Resistin significantly reduced MTT in both young (18 ± 5 %, p = 0.04) and old (24 ± 6 %, 
p = 0.04) myogenic cultures (Fig. 4.4, A). NFI was significantly diminished in old cultures 





4.3.2 Resistin and Obese Adipose Conditioned Media are also Detrimental to the 
Differentiation of Commercially Available Primary Human Myoblasts 
MTT was significantly reduced by both resistin (26 ± 6 %, p = 0.04) and OB ACM (26 ± 4 
%, p = 0.02) compared to unstimulated control myotubes (Fig. 4.5, A). Additionally, NFI 
was significantly diminished by resistin (23 ± 6 %, p = 0.01) and OB ACM (73 ± 13 %, p = 






4.3.3 Immunoprecipitation of Resistin from Obese Adipose Conditioned Medium 
Improves Myogenesis 
The success of the immunoprecipitation of resistin from ACM was confirmed by elution of 
antibody-antigen complexes from the agarose beads, and detection of resistin in these 
elutes by immunoblotting (Fig. 4.6, A). All control elutes were negative for resistin. To 
further confirm the success of the immunoprecipitation, ACM resistin concentrations were 
quantified by an ELISA which employed a different anti-resistin antibody than the 
immunoprecipitation procedure. Resistin concentrations in OB ACM were diminished 
following resistin immunoprecipitation (Fig. 4.6, B). In these commercially available cells, 
NFI was previously shown to be substantially inhibited by OB ACM (Fig. 4.5, B). Thus, NFI 
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was chosen as a reliable outcome to determine whether a reduction in OB ACM resistin 
concentration rescues myogenesis. Resistin immunoprecipitation from OB ACM 
increased NFI by 60 ± 16 % (p = 0.03; Fig. 4.6, C). Linear regression analysis of resistin 
concentration and NFI indicates a possible negative association between the two, but this 






It was confirmed that classical NFκB signalling was suppressed during myogenesis (Fig. 
4.7, A). Myogenic cultures differentiated for 48 h in the presence of 5 ng/mL recombinant 
resistin displayed a significant increase in serine 536 phosphorylation of p65 (p-p65); such 
phosphorylation was inhibited by the presence of the IKKβ inhibitor 5-(p-Fluorophenyl)-2-
ureido]thiophene-3-carboxamide (TPCA-1) (Fig. 4.7 B, C). An uncropped version of the 
blot presented in Fig. 4.7, B is included in Appendix Fig. 4.1 to demonstrate the detection 
of a distinct dominant band at the appropriate molecular weight (~ 65 kDa).  
Having established that resistin activates the classical NFκB signalling pathway during 
myogenesis, the ability of TPCA-1 to rescue myotubes from the anti-myogenic actions of 
resistin was explored. As before (Fig. 4.4, 4.5), 8 d resistin stimulation of differentiating 
myogenic cultures significantly diminished MTT and NFI (Fig. 4.8), a phenomenon that 
was completely reversed by co-incubation with TPCA-1. Activation of the classical NFκB 
signalling pathway is often associated with increased expression of the E3 ubiquitin 
ligases MAFbx and MURF-1 (407,408); indeed, recombinant resistin stimulation of 
differentiating myogenic cultures induced a variable increase in their expression – this was 















4.4.1 The Effect of Recombinant Adipokines on In Vitro Human Myogenesis. 
In Chapter 3 of this thesis, resistin was identified as a potentially important mediator of the 
anti-myogenic effects of OB ACM. Having established a clear rationale for examining the 
myogenic effects of resistin, it was demonstrated in this chapter that exogenous 
recombinant resistin – at the concentrations found in OB ACM – does indeed inhibit 
myogenesis. 5 ng/mL recombinant resistin significantly and similarly reduced MTT in both 
young and old myogenic cultures; NFI was significantly diminished in old cultures only 
(Fig. 4.4). Furthermore, immunoprecipitation of resistin from OB ACM rescued 
myogenesis (Fig. 4.6). NFI had previously been shown to be substantially inhibited by OB 
ACM in these cells (Fig. 4.5, B).Thus, NFI was chosen as a reliable outcome to determine 
whether a reduction in OB ACM resistin concentration rescues myogenesis. Indeed, a 
substantial (R2 = 0.4), but not statistically significant (p = 0.09) negative relationship was 
observed between ACM resistin concentration and NFI (Fig. 4.5).  
Despite the considerable variability in OB ACM adipokine composition described in 
Chapter 3, resistin is an adipokine that is enriched in the adipose inflammatory milieu of 
many OB individuals (Fig. 3.1), and it has a demonstrable negative effect on myogenesis.  
The dearth of evidence regarding the effect of resistin on skeletal muscle growth, 
maintenance and regeneration has previously been noted (Sections 1.7.4, 3.3.1). 
However, our results concur broadly with the few relevant studies that exist. One study 
showed that plasma resistin concentrations had an inverse relationship with quadriceps 
torque, but not handgrip strength in old (69-81 yr), but not in young (18-30 yr), participants 
(291). In a separate study, C2C12 myoblast proliferation was increased by the transfection 
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of a human resistin eukaryotic expression vector, and such transfection reduced the 
expression of desmin and resulted in thinner myotubes (292). Our use of a human in vitro 
model is of particular importance, given that human resistin displays poor amino acid 
sequence homology to murine resistin (293).  
The OB ACM used to differentiate myoblasts (described in the previous chapter, Section 
3.2.3) had elevated concentrations of visfatin and leptin compared to the NW ACM that 
were used (Table 3.3); this was not representative of the NW and OB populations as a 
whole (Table 3.2). Additionally, visfatin and leptin are understudied with respect to their 
effects on myogenesis. Thus, it was decided that further study of their myogenic effects 
was warranted. 5 ng/mL recombinant leptin reduced MTT in old myogenic cultures only, 
NFI was not affected (Fig. 4.1). 5 ng/mL recombinant visfatin did not alter myogenesis 
(Fig. 4.2). It is therefore likely that leptin contributed to the anti-myogenic effects of OB 
ACM in the experiment described in Section 3.2.3. The known effects of leptin on skeletal 
muscle growth, maintenance and regeneration were reviewed in the first chapter of this 
thesis (Section 1.7.5). It was established that while large alterations of systemic leptin 
concentrations in mice suggest that the adipokine has a positive relationship with skeletal 
muscle mass (295,296), studies in human participants suggest that large hypertrophic or 
atrophic effects are not seen with plasma leptin fluctuations within the physiological range. 
For example, serum leptin concentrations have been positively correlated with FFM in 
men, but not in women (297). However, men in the highest quintile for FFM also displayed 
the highest BMI and fat mass; the anti-gravity overload stimulus of their fat mass is an 
important confounder. In contrast, studies of late middle-aged and elderly participants, 
have noted significant, if small (β = ~ -0.2) negative associations between plasma leptin 
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and skeletal muscle mass (298,299). Our finding that 5 ng/mL recombinant leptin reduced 
MTT in cultures derived from elderly participants compliments these observations. 
We utilised commercially available primary human myoblasts from a 21 yr old female for 
some of our mechanistic work and first established that the myogenic responses of these 
cells under OB ACM and resistin stimulation conditions reflected the responses that we 
observed in our in-house cultures (Fig. 4.5). It is notable that both resistin and OB ACM 
reduced the NFI of such cultures, a phenomenon that was not observed in our in-house 
young myogenic cultures (Fig. 3.5, Fig. 4.4). The lack of biological variability in 
experiments conducted with primary cells from one individual is likely to be responsible 
for this observation; although myogenic cultures isolated from young skeletal muscle are 
overall clearly less susceptible to the effects of OB ACM and resistin on NFI (Fig. 3.5, Fig. 
4.4), individual variability in this response is to be expected.  
 
4.4.2 Resistin Inhibits Human Myogenesis by Activating the Classical NFκB 
Signalling Pathway 
Having established the effects of resistin on the differentiation of primary human myogenic 
cultures, a mechanism of its action was sought. Mouse receptor tyrosine kinase-like 
orphan receptor (ROR) (409) and decorin (410) are thought to be receptors for murine 
resistin. Toll-like receptor 4 (TLR4) has been suggested as a receptor for human resistin 
(411), and TLR4 are found in primary human myogenic cultures (412). Adenylyl cyclase-
associated protein 1 (CAP1) is also a known receptor for human resistin (413), but only 
CAP2 is expressed in human skeletal muscle (414). While the receptor/s for resistin in 
skeletal muscle remain to be definitively identified, it is clear that resistin activates NFκB 
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signaling widely, such activation having been demonstrated in the human liver cancer cell 
line HepG2 (404), human coronary artery endothelial cells (405) and human macrophages 
(406). Indeed, bioinformatic analysis in HepG2 cells suggested that resistin might also 
activate the 5' AMP-activated protein kinase (AMPK) and extracellular signal-regulated 
kinases 1 and 2 (ERK 1/2) signalling pathways, but molecular investigations determined 
that it signalled via the NFκB pathway alone (404). The canonical wnt signalling pathway 
is an important additional pathway that supports myogenesis (415–418), but work in 
primary human osteoblasts in our lab demonstrated that resistin promotes its activation 
rather than inhibition (419). Such activation would be expected to facilitate myogenesis. 
Thus, activation of the classical NFκB pathway by resistin remains the most plausible 
mechanism by which it might inhibit myogenesis.  
Until recently, it was unclear whether activation of the classical NFκB pathway is a positive 
or a negative regulator of myogenesis (401). Many early studies relied upon 
electrophoretic mobility gel shift assays (EMSA), which are subject to considerable 
technical variability between labs (401,420,421). Additionally, NFκB activity appears to be 
sensitive to culture conditions, with C2C12 cultures displaying transient NFκB activity 
upon their first exposure to differentiation medium (422). More recently, genetic 
approaches have definitively established the classical NFκB pathway as a negative 
regulator of myogenesis. Myogenesis has been shown to be enhanced in p65-/- myoblasts; 
in the same study, 4 wk old p65-/- mice displayed a 76 % increase in tibialis anterior fibre 
number, although mean fibre diameter was reduced by 39 % (402). In another study, IKKβ-
deficient mice were protected against denervation-induced skeletal muscle atrophy (3). 
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Furthermore, inhibition of classical NFκB pathway signalling with IKKβ inhibitor IV 
enhanced the myogenic differentiation of primary murine cultures from wild-type mice 
(403). A recent study used a bi-allelic Cre-lox transgenic mouse in which NFκB can be 
activated specifically in muscle SC following administration of tamoxifen (423). It 
demonstrated that NFκB activation in the SC of aged mice inhibits skeletal muscle 
regeneration in response to cryoinjury.  
In our primary human myogenic cultures, classical NFκB pathway activity (as measured 
by p65 phosphorylation) was diminished at 48 h post-differentiation (Fig. 4.7, A); this 
concurs with previous observations made in C2C12 cultures (402). The addition of 5 
ng/mL recombinant resistin to such cultures resulted in persistent p65 phosphorylation at 
48 h, a phenomenon that was reversed by the addition of 40 nM TPCA-1 (Fig. 4.7, B). 
TPCA-1 alone did not further diminish p-p65 expression, likely due to the small magnitude 
of its expression in differentiating myotubes beyond 24 h (Fig. 4.7, A).  
This work has focused on identifying a central cell signalling pathway that is responsible 
for resistin-induced inhibition of myogenesis. We present compelling evidence that the 
classical NFκB pathway is such a pathway. What remains to be definitively established is 
which NFκB target genes mediate this inhibition. Activation of the classical NFκB signalling 
pathway is often associated with increased expression of the E3 ubiquitin ligases MAFbx 
and MURF-1 (407,408); these genes are binding targets of the p50 subunit of the classical 
pathway and its transcriptional co-activator Bcl-3 (408,424). Given that MAFbx and 
MURF-1 are well documented as mediators of mature myofibre atrophy, and have also 
been specifically implicated in the inhibition of myogenesis (425,426), they were chosen 
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as NFκB target genes for further molecular corroboration of our observations of improved 
MTT and NFI. Resistin induced a variable and non-significant increase (across three 
independent experiments) in MAFbx and MURF-1 expression (Fig. 4.8); this was 
eliminated by co-stimulation of myogenic cultures with resistin and TPCA-1.  
Cyclin D1 is a transcriptional target of NFκB and is a known inhibitor of myogenesis 
(403,427,428). Furthermore, p65 directly interacts with Cyclin D1 and is thought to 
stabilise its expression (429). Indeed, we observed a small increase in total p65 
expression in myoblasts that were stimulated with resistin for 24 h (Appendix Fig. 4.2) 
suggesting that exposure to resistin prior to differentiation might leave such myoblasts 
unprepared for successful differentiation. The transcription factor, Ying-Yang 1 (YY1) is 
regulated by p65 and acts as a transcriptional repressor of many genes (e.g. troponins, 
myosin heavy chains and α-actin) that are key to mature myofibre development (430). p65 
and YY1 are also known to interact with the microRNA miR-29. miR-29 expression 
enhances myogenesis (431) such expression is repressed by YY1 (432). At the onset of 
differentiation, the decrease in classical NFκB pathway activity releases miR-29 
expression from the inhibitory effects of YY1. miR-29 also exerts negative feedback on 
YY1 via binding to its 3’UTR (432). The effect of NFκB activity on growth factor and 
cytokine expression by myotubes and myofibres must also be considered. For example, 
skeletal muscle regeneration is improved in p65+/- mice post cardiotoxin injury, compared 
to wild-type controls. Skeletal muscle hepatocyte growth factor (HGF) expression was 
found to be elevated during such regeneration and silencing this expression with a small 
hairpin RNA targeting HGF eliminated the improvement in regeneration conferred by the 
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p65+/- genotype (433). Delineating the downstream mediators of classical NFκB pathway 
activity in the inhibition of myogenesis will be crucial to the development of pharmaceutical 
interventions to enhance skeletal muscle regeneration not just in instances of catastrophic 
skeletal muscle injury, but also in ageing skeletal muscle. The relevance of SC activation 
and myogenesis to skeletal muscle growth and maintenance over the lifespan was 
considered in Chapter 1 and is considered again in Chapter 7. 
NFκB signalling is central to many cellular processes, including immunity, cell proliferation 
and apoptosis as well as embryonic and neuronal development (434). Thus, many existing 
pharmacological agents that are known to inhibit the NFκB pathway have significant side 
effects, such that they are unsuitable for the prevention of sarcopenic obesity. Thalidomide 
is one such drug. When used as a chemotherapeutic agent it causes thrombo-embolic 
events, peripheral neuropathy and increases infection rates (435). Similarly, the 26S 
proteasome inhibitor bortezomib – which inhibits NFκB by preventing the degradation of 
IκBα – also has serious side effects, including peripheral neuropathy, thrombocytopenia 
and reactivation of herpes zoster (435,436).  
However, there exists one drug class with few side effects that may prevent sarcopenia 
by inhibiting the NFκB pathway. Non-steroidal anti-inflammatory drugs (NSAIDs) are 
known principally as cyclooxygenase (COX) inhibitors (437). However, NSAIDs are also 
known to inhibit the classical NFκB pathway by suppressing IκBα degradation (438), a 
mechanism that might be expected to facilitate myogenic adaptations to exercise. Some 
studies have found that NSAIDs impair SC proliferation responses to exercise in young 
healthy participants (439,440) and that low doses of ibuprofen, coupled with short-term 
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resistance training (6 wk) had no beneficial effect on skeletal muscle mass (441). 
However, in a more recent study, more severe skeletal muscle injury was induced by 
electrical stimulation and NSAIDs promoted SC activation (442). Furthermore, standard 
doses of paracetamol (4 g/day) and ibuprofen (1.2 g/day) appear to significantly increase 
muscle volume and strength acquisition during a 12 wk resistance training program in 
elderly (443). Thus, it may be that cost-effective pharmaceutical interventions for the 
amelioration of NFκB-induced loss of skeletal muscle mass already exist; ibuprofen used 
in conjunction with a proton pump inhibitor to prevent NSAID-induced upper 
gastrointestinal mucosal damage (444) might represent a good starting point.  
Our work used TPCA-1, an inhibitor of IKKβ (IC50 = 18 nM) that is also capable of inhibiting 
IKKα and thus the alternative NFκB pathway at much higher concentrations (IC50 = 400 
nM) (445). The concentration of TPCA-1 used in this work (40 nM) was chosen to produce 
a robust inhibition of IKKβ and is 10-fold lower than the concentration that would produce 
any consequential inhibition of IKKα. In any case, the alternative NFκB pathway (Fig. 4.1) 
does not appear to regulate myogenesis. IKKα expression is induced late in the myogenic 
program and myogenesis is normal in primary murine myoblasts lacking IKKα (401,402). 
However, IKKα does appear to facilitate mitochondrial biogenesis in differentiating 
myotubes and is essential for the survival of mature myotubes under starvation conditions 
(402).   
 
4.5 Limitations and Future Directions 
Importantly, this work has established that resistin activates classical NFκB pathway 
signalling and that reversing this inhibition ameliorates the deleterious effects of resistin 
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on in vitro primary human myogenesis. However, the receptor/s by which resistin initiates 
such signalling remain to be definitively established. Furthermore, the significance and 
interdependence of the NFκB target genes which mediate its inhibition of myogenesis are 
not fully understood. It appears that NFκB interactions with YY1 and cyclin D1 might play 
a central role, with the expression of many genes that are key to mature myofibre 
maintenance and development (e.g. troponins, myosin heavy chains, α-actin, MAFbx, 
MURF-1) known to also be affected. The delineation of these events is crucial to our wider 
understanding of the myogenic program, not just that under conditions of resistin 
stimulation.  
Given that standard doses of paracetamol and ibuprofen can enhance strength and 
muscle volume acquisition during a 12 wk resistance training programme, it would be 
valuable to confirm their pro-myogenic utility and to determine whether such an 
intervention is effective and safe in a population with sarcopenic obesity.  
 
4.6 Conclusions 
This chapter has established that: 
• Resistin and leptin have a deleterious effect on in vitro human myogenesis.  
• Resistin – at least in part – mediates the detrimental effects of OB ACM on primary 
human myogenesis.  
• Resistin activates classical NFκB pathway signalling in primary human myogenic 
cultures. 
• Such NFκB pathway signalling mediates the detrimental effect of resistin on 
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5.1  Introduction 
The preceding data chapters have established a rationale for the study of resistin with 
respect to ageing skeletal muscle.  In Chapter 4, an anti-myogenic effect of resistin was 
established, and the classical NFκB pathway was identified as a central signalling 
pathway through which resistin acts to exert these effects. The interdependence of 
skeletal muscle mass, function and metabolism in ageing was established in the 
introductory chapter of this thesis (e.g. see Sections 1.6.3.2 and 1.7.7).  
Resistin is understudied regarding its metabolic effects on skeletal muscle. In one study, 
resistin inhibited glucose uptake and impaired glycogen synthesis during a 24 h 
stimulation of rat L6 myotubes (308,309). Another study found that resistin inhibited 
palmitate uptake by L6 myotubes (310). However, such studies are few, limited in scope 
and it is unknown whether primary human myotubes or human skeletal muscle behave 
similarly to immortalised rodent cell lines. In completing the experiments described in 
Chapter 4, the appearance of prominent intramyocellular structures – which were thought 
to be lipid droplets – was noted in myotubes formed under resistin stimulation conditions. 
This observation appeared to agree with reports of lipid accumulation in resistin-
stimulated human macrophages (446) and of hepatic steatosis in resistin-treated mice 
(404). Thus, confirmation of such lipid accumulation in our myotubes, as well as 
quantification of their fatty acid oxidative capacity, was identified as an experimental 
priority for subsequent studies investigating the effect of resistin on myotube metabolism.  
The rationale for hypothesising that resistin exerted its anti-myogenic effect via activation 
of the classical NFκB signalling pathway (Chapter 4) was clear; resistin had been shown 
to activate NFκB signalling in other human cell types, and such signalling is now well-
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established as anti-myogenic. It is less clear whether such signalling might mediate any 
metabolic effects of resistin on primary human myotubes.  
 
Therefore, the objectives of this chapter were as follows:  
1. To determine whether resistin alters oxidative metabolism in primary human 
myotubes.   
2. To investigate whether resistin stimulation of developing myotubes promotes the 
accumulation of intramyocellular lipids. 
3. To quantify the free fatty acid oxidative capacity of resistin-stimulated myotubes.  
4. To ascertain if inhibition of NFκB pathway signalling reverses any metabolic 
alterations induced by resistin.  
 
5.2 Methods 
To screen for a metabolic effect of resistin on primary human myotubes, differentiated 
myotubes were maintained for 24 h in differentiation media supplemented with or without 
5 ng/mL recombinant resistin. At 24 h myotubes were stained with Mitotracker® Green 
FM, which stains all mitochondria and Mitotracker® Orange CM-H2TMRos which 
accumulates in mitochondria in a membrane-potential dependent fashion. 15 
immunofluorescent images at 20x magnification were captured from each independent 
experiment (n = 3 independent experiments). The mean fluorescence intensity of the 
green and red channels of each image was quantified using Image J software. We used 
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a Seahorse® XFe96 analyser, in conjunction with an XF Mito Stress Test to more fully 
characterise the effects of resistin on myotube mitochondrial metabolism. Commercially 
available primary human myoblasts from a 21 yr old female were used, and four 
independent experiments were conducted, using genetically identical myotubes that had 
been derived from four different manufacturer vials and were cultured separately. Firstly, 
fully differentiated myotubes were stimulated for 24 h with differentiation media (containing 
0 ng/mL or 5 ng/mL recombinant resistin ± 40 nM TPCA-1). It was established in Chapter 
4 that resistin signals via the classical NFκB pathway and that inhibiting this pathway with 
the IKKβ inhibitor TPCA-1 reverses the detrimental effects of resistin on in vitro human 
myogenesis. Given that TPCA-1 restores normal myogenesis, we sought to establish 
whether it could also normalise any metabolic effects of resistin in such myotubes. The 
Seahorse® XF Mito Stress Test was repeated on myotubes that had been differentiated 
for 8 d in the presence of 0 ng/mL or 5 ng/mL recombinant resistin ± 40 nM TPCA-1. 
In completing the work described in Chapter 4, we observed the accumulation of 
intramyocellular structures in resistin-stimulated myotubes. We hypothesised that these 
were lipid droplets. Here, we sought to confirm this. As before, myogenic cultures (n = 3 
independent experiments) were differentiated for 8 d in the presence of 0 ng/mL or 5 
ng/mL recombinant resistin ± 40 nM TPCA-1. The resulting myotubes were stained with 
Oil Red O, imaged, and the staining was quantified using Image J software. 
Having observed considerable myotube lipid accumulation under resistin stimulation 
conditions, we sought to quantify the capacity of such myotubes to oxidise endogenous 
and exogenous fatty acids using an XF Palmitate-BSA FAO Substrate Mitochondrial 





5.3.1 Mitotracker® Orange CM-H2TMRos Staining of Mitochondria in Resistin-
Stimulated Myotubes 
Mitotracker® Green FM intensity was not altered by resistin stimulation, indicating that the 
total number of mitochondria did not differ between stimulation conditions. Mitotracker® 
Orange intensity was reduced by 11 ± 3 % in resistin-stimulated myotubes (p = 0.09 by 
unpaired t-test). When the Mitotracker® Orange intensity in each image was corrected for 
the corresponding Mitotracker® Green FM intensity (a surrogate for total mitochondrial 
mass), the reduction in Mitotracker® Orange intensity (10 ± 3 %) approached significance 







5.3.2 Resistin is a Metabolic Stressor of Primary Human Myotubes   
Basal respiration, maximal respiration, ATP production, spare capacity and baseline 
ECAR measurements were unaffected by any 24 h stimulation condition (Fig. 5.2, A-F). 
However, proton leak was significantly increased (26 ± 14 %, p = 0.03) by resistin 
stimulation. Furthermore, this phenomenon was reversed by co-stimulation with TPCA-1 







Longer-term (8 d) stimulation of developing myotubes induced more profound metabolic 
changes than those described above (Fig. 5.3 A, B). Resistin increased basal respiration 
(36 ± 7 %, p < 0.0001) and ATP production (114 ± 12 %, p <0.001) and on average 
increased proton leak (91 ± 21 %), although this did not reach statistical significance (p = 
0.055); Maximal respiration, spare capacity and baseline ECAR were unaffected (Fig. 5.3, 
C-H). In all instances, co-stimulation of the cultures with TPCA-1 reversed these effects. 
Notably, TPCA-1 independently increased ATP production compared to unstimulated 
controls (Fig. 5.3, E), but no other outcome was significantly altered. Fig. 5.3, B visualises 
the relative contribution of mitochondrial and non-mitochondrial oxygen consumption as 
well as that of proton leak, to the baseline OCR. Non-mitochondrial respiration 
represented 46 ± 1 % of OCR in unstimulated myotubes, with mitochondrial respiration 
being responsible for 45 ± 1 % of OCR. Resistin stimulation increased basal OCR (see 
above) but did not substantially alter the relative contributions of mitochondrial and non-











5.3.3 Resistin Promotes Myotube Lipid Accumulation 
Resistin significantly increased both the Oil Red O area in each field of view (57 ± 16 %, 
p = 0.004; Fig. 5.4, A) and the average Oil Red O particle size (36 ± 9 %, p = 0.0003; Fig. 
5.4, B). Co-stimulation of the myogenic cultures with resistin and TPCA-1 reversed this 




5.3.4 Resistin Increases the Capacity of Primary Human Myotubes to Oxidise Fatty 




Endogenous fatty acid oxidation was not detected in unstimulated myotubes. Resistin 
significantly increased both endogenous and exogenous fatty acid oxidation (Fig. 5.5). 
Surprisingly, however, TPCA-1 stimulation alone also enhanced exogenous fatty acid 
oxidation.  Furthermore, co-stimulation of developing myotubes with resistin and TPCA-1 
did not reverse the effects of resistin alone (Fig. 5.5).  
 
 
5.3.5 Resistin Does Not Induce Substantial Changes in Metabolic Gene 
Expression 
Despite the profound changes in oxidative metabolism (Section 5.2.2) and lipid 
accumulation (Section 5.2.3) induced by myotube differentiation in the presence of 
resistin, no significant alterations in metabolic gene expression were observed (Fig. 5.6). 
A non-significant (0.66-fold, p = 0.09) decrease in GLUT4 expression was found (Fig. 5.6, 
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A). The rationale for quantifying each of the genes presented is detailed in the discussion 








5.4  Discussion 
5.4.1 In Myotubes, Resistin Promotes Enhanced ATP Production, Increased Fatty 
Acid Oxidation and Lipid Accumulation 
In Chapter 3, resistin was established as an adipokine that has a detrimental effect on 
primary human myogenesis in vitro.; a clear rationale for its prioritisation for such study 
was established in Chapter 2. Resistin is also understudied regarding its metabolic effects 
on skeletal muscle. This chapter establishes that resistin has profound metabolic effects 
on primary human myotubes in vitro. It characterises some aspects of this dysfunction, 
and although important questions remain as to how and why such metabolic adjustments 
evolve, this work is distinct in illuminating the breadth of such dysfunction and in doing so 
in primary human cultures.  
Staining of myotubes with Mitotracker® Green FM and Mitotracker® Orange CM-
H2TMRos was employed as a method for detecting differences in mitochondrial mass or 
mitochondrial membrane potential following 24 h resistin stimulation. Mitotracker® Green 
FM staining indicated that the total number of mitochondria did not differ between 
myotubes stimulated with or without resistin. When the Mitotracker® Orange intensity in 
each image was corrected for the corresponding Mitotracker® Green FM intensity, the 
reduction in Mitotracker® Orange intensity in resistin-stimulated myotubes approached 
significance. This finding, in addition to pilot data from the first independent experiments 
detailed in Fig. 5.2 and Fig. 5.3 confirmed to us the utility of pursuing the study of the 
metabolic effect of resistin on myotubes in vitro.  
Indeed, short-term (24 h) resistin stimulation of fully differentiated myotubes (Fig. 5.2, G) 
and longer-term (8 d) stimulation of myogenic cultures during differentiation (Fig. 5.3, H; 
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p = 0.055) induced an increase in proton leak (although this did not quite reach statistical 
significance in the 8 d stimulated cultures). The IKKβ inhibitor TPCA-1 prevented this 
enhanced proton leak. These findings are in accordance with the apparent resistin-
induced fall in mitochondrial membrane potential indicated by reduced Mitotracker® 
Orange staining intensity. 24 h resistin stimulation of myotubes did not induce any 
changes in the other outcomes measured by the Seahorse® XF Mito Stress Test, with 
more profound metabolic changes being observed in myotubes formed for 8 d under such 
stimulation conditions (Fig. 5.3). In addition to proton leak, resistin induced a marked 
increase in basal respiration and ATP production; co-stimulation of the cultures with 
TPCA-1 reversed these effects. Such resistin stimulation of developing myotubes also 
promoted lipid accumulation (Fig. 5.4), a phenomenon that again, was reversed by the 
presence of TPCA-1. Both endogenous and exogenous fatty acid oxidation were 
enhanced in such lipid-laden myotubes (Fig. 5.5). Surprisingly, however, TPCA-1 
stimulation alone also enhanced exogenous fatty acid oxidation, and co-stimulation with 
resistin and TPCA-1 did not reverse the effects of resistin alone. Thus, while inhibition of 
resistin signalling via the classical NFκB pathway normalised myotube basal respiration, 
ATP production, proton leak and lipid content, it did not do so by altering fatty acid 
oxidation.  
 
5.4.2 Resistin as a Metabolic Stressor of Myotubes – Possible Mechanisms of 
action 
With resistin stimulation of myotubes, the metabolic picture that we describe is one of 
increased ATP production, increased basal OCR, increased fatty acid oxidation and lipid 
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accumulation. The data presented in Fig. 5.5, B demonstrate that resistin-stimulated 
myotubes display an enhanced capacity to oxidise exogenous fatty acids. The notion that 
enhancement of fatty acid uptake is largely responsible for resistin-induced myotube lipid 
accumulation is supported by the small contribution of de novo lipogenesis to skeletal 
muscle lipid storage (447–449) coupled with the large (~ 60 %) increase in myotube lipid 
accumulation described here (Fig. 5.4). The combination of resistin and TPCA-1 did not 
alter either endogenous or exogenous fatty acid oxidation, compared to stimulation with 
resistin alone, suggesting that the normalisation of myotube lipid content by TPCA-1 is 
not due to an enhancement of myotube fatty acid oxidative capacity. It may be that 
inhibition of the classical NFκB pathway by TPCA-1 reduces myotube fatty acid uptake, 
thus allowing a larger proportion of such fatty acids to be oxidised.  
Indeed, some evidence exists to support this hypothesis. Resistin stimulation of human 
macrophages has been shown to promote intracellular lipid accumulation, with a 
concomitant increase in the cell surface expression of the fatty acid transporter CD36 
(446). A search of the ArrayExpress database (450) yielded microarray data from a study 
(E-GEOD-64060) of mice lacking brown adipose tissue (BAT) CD36 expression. Resistin 
gene expression was detected only in CD36 null mice; in the context of the other studies 
discussed here, this may represent a compensatory response to the absence of CD36 
expression. Evidence that fatty acid transporters such as CD36 and the fatty acid transport 
proteins (FATPs) are direct transcriptional targets of NFκB is lacking. However, some 
evidence of their interdependence does exist. In mice with hepatic steatosis, NFκB gene 
expression correlated closely with the expression of FATP genes (R2 = 0.77, p < 0.01) 
(451). Another study described a substantial reduction in NFκB expression in human 
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macrophages following inhibition of CD36 activity with Sulfo-N-succinimidyl oleate (452). 
It is unclear from the manuscript which NFκB subunit was detected by the antibody used. 
The possibility that enhanced fatty acid uptake might itself activate NFκB transcriptional 
activity must also be considered and indeed, this has been demonstrated in L6 myotubes 
(453). Thus, while the promotion of fatty acid uptake via resistin-mediated NFκB activation 
is plausible, the current evidence is tenuous and requires further study. Such a mechanism 
would, however, explain our observation that co-stimulation of myogenic cultures with 
resistin and TPCA-1 prevents lipid accumulation without altering fatty acid oxidation rates. 
The substantial enhancement of exogenous fatty acid oxidation by TPCA-1 alone, while 
not necessarily indicative of increased fatty acid uptake, represents an additional reason 
for caution in considering this hypothesis.  
Small amounts of de novo lipogenesis occur in skeletal muscle, yet such lipogenesis might 
be of consequence in resistin-stimulated myotubes. Resistin is certainly capable of 
inducing lipogenesis in the liver. Resistin-null Ob/Ob mice have been reported to be 
protected from hepatic steatosis and displayed decreased hepatic expression of enzymes 
involved in de novo lipogenesis, including acetyl-coA carboxylase (ACC) and fatty acid 
synthase (FAS) (454). In our myotubes, resistin stimulation increased the expression of 
the ACC gene ACACB 1.5-fold (Fig. 5.6, D), but this did not reach statistical significance. 
Other work has described the stimulation of the human HepG2 hepatocyte cell line with 
resistin (50 ng/mL). Increased expression of the master regulators of fatty acid synthesis 
– the sterol regulatory element-binding proteins (SREBP1, SREBP2) was observed (455). 
SREBP1 and SREBP 2 are well-established promotors of lipogenic gene expression (456) 
and indeed, resistin also promoted the expression of ACC, Stearoyl-CoA desaturase 
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(SCD, the rate-limiting enzyme in monounsaturated fatty acid synthesis) and diglyceride 
acyltransferase (DGAT1, which catalyses the formation of triglycerides) in the HepG2 cells 
(455). In mice, the SREBP1 gene contains an NFκB promotor sequence 
(GGGRNNYYCC; (457)), to which NFκB binds (458) and NFκB may act in concert with 
SP1 to promote SREBP1 gene expression and thus lipogenesis (459). This particular 
murine NFκB promotor sequence is not conserved at the same position in humans (458), 
but a search for the GGGRNNYYCC sequence in the promotor regions of human 
SREBP1, SREBP2 (Ensembl release 89; (460)) yielded possible NFκB promotor 
sequences within close proximity to the first SREBP exon  (SREBP1: -91 bp, 5’-
GGGGTCCCC-3’; SREBP2:  +11 bp, 5’- GGGAATCCC-3’). The database of 
transcriptional start sites (DBTSS) contains tissue-specific transcriptional start site 
positions for human genes (461,462). The true transcriptional start site for human skeletal 
muscle SREBP2 is 15 bp distal to the NFκB promotor sequence (Appendix Figure 5.1), 
and thus the NFκB promotor sequence that we identified at +11 bp lies immediately 
upstream of the first SREBP2 exon, rather than within it. Thus, while direct evidence of 
NFκB binding and activation of human SREBP expression is lacking, it represents a 
plausible mechanism by which resistin might activate lipogenesis and warrants further 
exploration. 
Indeed, enhanced fatty acid uptake, fatty acid oxidation and lipogenesis might co-exist in 
resistin-stimulated myotubes. If resistin is a potent direct activator of both fatty acid uptake 
and lipogenesis in skeletal muscle, such processes might also exert positive feedback 
upon one another. Enhanced fatty acid uptake and thus substrate oversupply to the TCA 
cycle could reasonably be expected to produce an excess of mitochondrial citrate, which 
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upon transport to the cytoplasm would allosterically activate ACC, thus facilitating malonyl-
CoA production. Malonyl-CoA acts as the substrate for fatty acid synthesis, thus renewing 
the fatty acid pool and mitochondrial substrate oversupply. This positive feedback, coupled 
with direct activation of the lipogenic program by resistin might amplify the usual small 
contribution of de novo lipogenesis to skeletal muscle lipid content (Fig. 5.7). Similar futile 
substrate cycling between de novo lipogenesis and fatty acid oxidation had been 
demonstrated with leptin stimulation of ex vivo murine skeletal muscle and is essential for 
leptin to stimulate thermogenesis in such muscle (463). The synthesis of one molecule of 
palmitate in skeletal muscle would theoretically cost 14 molecules of ATP (448), and thus 
should facilitate the dissipation of intracellular lipid as has been suggested with regard to 
leptin (448,464). Indeed, we stimulated developing myotubes for 8 d with 5 ng/mL leptin 
and demonstrated a substantial decrease in myotube lipid content (Appendix Figure 5.2). 
However, if resistin is a direct activator of both fatty acid uptake and lipogenesis in skeletal 
muscle, enhanced fatty acid oxidation (Fig. 5.5) coupled with such futile substrate cycling 
might be insufficient to dissipate the intramyocellular fatty acid burden. Inhibition of 
carnitine palmitoyltransferase 1 (CPT-1, which is rate-limiting for long-chain fatty acid 
transport into mitochondria) by malonyl CoA might be expected to prevent such a 
substrate cycle but the absolute requirement for both de novo lipogenesis and fatty acid 
oxidation to facilitate leptin-induced skeletal muscle thermogenesis suggests that this is 
not necessarily the case (463). Indeed, it has been noted that malonyl-CoA independent 
regulation of CPT-1 has tended to be overlooked (465) and fatty acids can directly induce 





In addition to the above, resistin-stimulated (24 h and 8 d) myotubes displayed an increase 
in proton leak, and this phenomenon was reversed by co-stimulation with TPCA-1 (Fig. 
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5.2, 5.3). Proton translocation across the inner mitochondrial membrane via routes other 
than the ATP synthase complex uncouples oxidative phosphorylation from respiration and 
is termed proton leak. Proton leak is principally facilitated by the adenine nucleotide 
translocase (ANT) and uncoupling proteins (UCP). ANT activity is induced by fatty acids 
(469,470), and this phenomenon appears to preserve skeletal muscle insulin sensitivity in 
the presence of excess fatty acids (471).  Controversies still exist regarding the 
mechanism of proton transport by UCP, although such activity is undoubtedly promoted 
by fatty acids and may occur via their acute activation of UCP or via their chronic alteration 
of UCP expression (472).  The UCP2 and UCP3 genes are expressed in skeletal muscle, 
although these isoforms are understudied in contrast with UCP1 and their importance to 
mitochondrial bioenergetics remains unclear (472). Detailed discussion of such 
controversies in the study of UCP biology is beyond the scope of this thesis (see (472) for 
a recent review). UCP2 and UCP3 gene expression was not altered by resistin (Fig. 5.6, 
B,C), although the observation that resistin is capable of inducing proton leak in myotubes 
at 24 h (Fig. 5.2) would suggest any contribution by ANT or UCP to such proton leak takes 
place via their activation rather alteration of their expression. Future work should focus on 
establishing whether resistin’s effects on myotube fatty acid metabolism is responsible for 
ANT and UCP activation and thus enhanced proton leak. Such proton leak may be a 
further adaptation intended to dissipate the intramyocellular fatty acid burden in resistin-
stimulated myotubes.  
The apparent decrease in GLUT4 expression (Fig. 5.6, A) in resistin-stimulated myotubes 
is broadly in keeping with the general principle of the glucose-fatty acid cycle proposed by 
Randle et al. (473) i.e. that use of one nutrient (fatty acids) inhibits the use of another 
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(glucose). However, an integrated examination of glucose and fatty acid uptake and 
oxidation will be necessary in resistin-stimulated myotubes to properly delineate any 
alterations in metabolic fuel utilisation. Any future work designed to further detail the 
metabolic effects of resistin in myotubes should consider the possibility that ROS 
overproduction might contribute to proton leak. ROS activate UCPs and ANT (474–476), 
and activation of such proton leak appears to protect against further ROS formation. For 
example, UCP3-/- mice produce an excess of skeletal muscle ROS (477,478) and 26 
weeks of high-fat feeding in such mice lowers mitochondrial capacity, suggesting that 
UCP3 may play a role in compensating for conditions of chronic free fatty acid excess 
(479).  
 
5.5 Limitations and Future Directions 
 
This chapter has described substantial and important effects of resistin on young primary 
human myotubes in vitro. The picture that has emerged is one of resistin as a metabolic 
stressor of myotubes, specifically one of increased ATP production, basal OCR, fatty acid 
oxidation, proton leak and lipid accumulation. While this work is novel and represents an 
advancement in our knowledge of the metabolic effects of resistin on human myocytes, it 
has several important limitations and highlights important areas of future investigation. 
First, the measurement of glucose and fatty acid uptake, as well as their oxidation, would 
establish a clearer picture of metabolic fuel utilisation in such myotubes. Second, it is 
plausible that resistin might stimulate skeletal muscle lipogenesis and therefore this too 
must be quantified. Third, the role of the classical NFκB pathway in mediating any resistin-
induced increases in fatty acid uptake and lipogenesis should be explored; specifically, 
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any induction of the expression of fatty acid transporters and lipogenic enzymes should 
be considered. Demonstration of NFκB binding to the human SREBP NFκB promoter 
sequences could form part of this work. Finally, it is necessary to establish whether resistin 
activates ANT and UCP to enhance proton leak. Addressing such issues will allow a 
complete modelling of resistin’s metabolic effects on human myocytes.  
 
5.6  Conclusions 
 
1. Resistin increases ATP production, basal OCR, fatty acid oxidation, proton leak and 
lipid accumulation in primary human myotubes. 
2. Inhibiting NFκB activity reverses the above effects, with the exception of the 
changes in fatty acid oxidation. 
3. The possibility that resistin directly activates myocyte fatty acid uptake and de novo 
lipogenesis should be considered, along with the hypothesis that a futile substrate 
cycle between fatty acid oxidation and de novo lipogenesis might be insufficient to 


















Chapter  6 








6.1   Introduction 
Sarcopenia is a major contributor to frailty and disability in the elderly (9,10).  Importantly, 
recent studies in the mouse suggest that IL-15, a 14 kDa four-helix bundle cytokine may 
play a central role in the growth and maintenance of skeletal muscle (320–322,480).  
However, to date, no studies have examined the expression or functional role of IL-15 in 
human skeletal muscle tissue or primary myogenic cells. 
Stimulation of murine C2C12 myoblasts with rIL-15 increases myoblast proliferation and 
MHC expression, promoting enhanced myogenesis and the development of larger 
myotubes (49).  Furthermore, ex-vivo stimulation of rat extensor digitorum longus muscle 
with rIL-15 decreased skeletal muscle proteolytic rate (342), suggesting an anti-atrophic 
effect of IL-15 on muscle tissue.  Indeed, it is suggested that IL-15 may play an important 
key role in the maintenance of muscle mass in the presence of atrophic stimuli.  For 
example, rIL-15 ameliorated the induction of protease (cathepsin L) activity in TNFα and 
dexamethasone stimulated C2C12 myotubes (50).  Furthermore, in an experimentally-
induced sepsis mouse model, rIL-15 reduced the mRNA expression of the E3 ligases 
MAFbx and MuRF-1 which ubiquitinate and target proteins for proteasomal degradation 
(50). rIL-I5 treatment of Yoshida AH-130 ascites hepatoma rats decreased skeletal muscle 
protein degradation 8-fold and significantly limited loss of body mass as well as soleus 
and tibalis muscle mass (481).  It has been proposed that IL-15 is a compensatory factor, 
expressed in skeletal muscle to mitigate conditions promoting skeletal muscle atrophy 
(51).  
Importantly, current evidence from in vivo human studies points to a crucial role for 
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myogenesis in adult skeletal muscle maintenance, hypertrophy and remodelling in 
response to disuse atrophy as well as injurious and non-injurious exercise (482).  
Therefore, in this study, we used a model of adult human myoblast differentiation into 
myotubes to determine the effect of IL-15 on myogenesis. We further sought to establish 
whether the purported myogenic effects of IL-15 are conserved in elderly human skeletal 
muscle, since IL-15 signalling may represent an important pathway for the identification 
and development of therapeutic approaches designed to preserve the loss of skeletal 
muscle mass and quality in ageing. Given the propensity of the elderly to develop 
sarcopenia, we hypothesised that myogenic cultures derived from the skeletal muscle of 
elderly individuals would be more resistant to the pro-myogenic and hypertrophic effects 
of IL-15 than those of young individuals. Finally, we sought to examine whether IL-15 could 
protect primary human myotube development from the deleterious effects of TNFα, a pro-
inflammatory cytokine implicated in the pathogenesis of sarcopenia (483) and cachexia in 
chronic illness (22).  
 
6.2  Methods 
To examine the effect of IL-15 on human myotube development, myoblasts from young 
participants were differentiated for 8 d in the presence of rIL-15 at 1, 25 and 100 ng/mL. 
The resulting myotubes were fixed, IF stained for desmin and counterstained with DAPI. 
Plates were imaged and myogenesis quantified by determining MTT and NFI. 
The mRNA expression of known mediators of myogenesis (namely myomaker, and the 
myogenic transcription factors MyoD, myogenin and Myf5) were measured by RT-qPCR 
in undifferentiated myoblasts and in myoblasts during their differentiation into myotubes.  
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In a separate experiment, myoblasts at 90% confluence were switched to differentiation 
medium, or to differentiation media containing rIL-15 (at 1 ng/mL or 25 ng/mL). After 8 d 
of differentiation, myogenic regulatory factor gene expression was quantified by RT-qPCR.  
Next, we sought to determine whether myogenic cultures derived from elderly participants 
were sensitive to the pro-myogenic effects of rIL-15 and whether rIL-15 was capable of 
reversing the deleterious effects of recombinant TNFα (rTNFα) on myogenesis using an 
rTNFα concentration representative of those found systemically in cachexia (484,485). 
Differentiating myoblasts from young and old participants were stimulated with either 
rTNFα (1 ng/mL) alone, rIL-15 (25 ng/ml) ± rTNFα (1 ng/mL) or were left unstimulated 
(controls) over 8 d. Media were renewed every 2 d. The resulting myotubes were fixed, IF 
stained and imaged as before.   
The expression of myogenic regulatory factors (MyoD, MyoG), the E3 ubiquitin ligases 
(MAFbx, MURF-1) and the acticity of pro-myogenic signalling nodes (Akt, ERK) were 
quantified by immunoblotting in in both undifferentiated myoblasts and in differentiating 
(48 h) cultures. 
Cognisant of the suggestion that IL-15 expression increases in order to compensate for 
conditions that promote skeletal muscle loss (51), we quantified circulatory levels of IL-15 
by ELISA. We also quantified the gene expression of IL-15 and its receptors by RT-qPCR 
in young and old skeletal muscle tissue derived from skeletal muscle biopsies. We sought 
to establish whether an inflammatory stimulus could induce IL-15 secretion and 
expression in primary human myotubes. To that end, 8 d differentiated myotubes were 
stimulated with 20 ng/mL TNFα and the concentration of IL-15 in culture supernatants was 
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measured by ELISA at 24 h. Furthermore, the myotube expression of IL15, IL15RA and 
IL2RB were quantifed in such cultures by RT-qPCR. 
We then investigated whether disruption of IL15 binding to its receptor would alter 
myogenesis in the presence of TNFα. We employed an antibody against the IL-15 
receptor binding subunit, IL-15rα. Myoblasts from elderly participants were differentiated 
for 8 d in the presence of IL-15 (25 ng/mL) or TNFα (1 ng/mL) with the further addition of 
an IL-15rα neutralising antibody (1μg/mL) or an IgG isotype control (1 μg/mL). Media were 
renewed every 2 d. MTT and NFI were quantified as previously described.  
 
6.3 Results 
6.3.1 Effect of IL-15 on Human Myotube Development and Myogenic Gene 
Expression 
rIL-15 (100 ng/mL) significantly increased the MTT of differentiated myotubes by 22 ± 5 
% (p <0.01) (Fig. 6.1 A, B).  Stimulation of differentiating myotubes for 8 d with either 25 
ng/mL or 100 ng/mL rIL-15 also enhanced the NFI (35 ± 4 %, p < 0.0001; 45 ± 7 %, p < 
0.0001 at 25 and 100 ng/mL respectively), compared to unstimulated controls (Fig. 6.1, 
C). Furthermore, the average number of myonuclei in each myotube was enhanced by 
rIL-15 stimulation (114 ± 20 %, p < 0.0001; 128 ± 27 %, p < 0.0001 at 25 and 100 ng/mL 
respectively) (Fig 6.1, D).  
Stimulation of myoblasts with rIL-15 (25 ng/mL) induced a small (1.3-fold) but highly 
significant (p < 0.0001) increase in the expression of myomaker, a cell membrane protein 
that is essential for myoblast fusion (Fig. 6.1, E). Notably, this alteration in myomaker 
expression was not accompanied by changes in the expression of either MYF5, MYOG 
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or MYOD1 expression (Appendix Fig. 6.1).  
rIL-15 increased the gene expression of MYOG (1.45-fold, p = 0.09; 2.5-fold, p <0.0001 
at 1 and 25 ng/mL respectively) and MYOD (2.36 fold, p = 0.02; 3.32-fold, p < 0.05   at 1 









6.3.2 Recombinant IL-15 Stimulation of Differentiating Primary Human Myoblasts 
Partially Reverses TNFα-induced Inhibition of Myogenic Differentiation in Young 
and Old Myotubes 
rIL-15 increased the MTT of myotubes from elderly donors (22 ± 5 %, p = 0.02), indicating 
that they are sensitive to the hypertrophic effects of IL-15 that we observed in the young 
(Fig. 6.2, B). In young myotubes, rTNFα alone induced a 30 ± 5 % decrease in myotube 
thickness (p < 0.0001) compared to unstimulated control myotubes. However, co-
incubation of differentiating myoblasts with rIL-15 and rTNFα partially reversed this effect, 
limiting loss of MTT to 11 ± 6 % of the control, a significant improvement compared to the 
rTNFα alone condition (p = 0.04). In old myotubes, the decrease in MTT induced by TNFα 
was not significant, however, myotubes co-stimulated with TNFα and rIL-15 condition 
were significantly thicker (29 ± 7 %, P = 0.001) than their TNFα-stimulated counterparts 
(Fig. 6.2, B).  
rIL-15 alone did not significantly increase the NFI in old myotubes or in this cohort of young 
myotubes. However, in both age groups co-incubation of differentiating myoblasts with 
rIL-15 and rTNFα completely reversed TNFα-induced reductions in NFI, resulting in NFI 
values which did not differ significantly from the control (Fig. 6.2, C).  rIL-15 stimulation of 
proliferating myoblasts had no effect on their proliferation or survival rates (Appendix Fig. 
6.2). Furthermore, in differentiated cultures the number of nuclei per field of view did not 
differ significantly between stimulation conditions, suggesting that their effects on MTT 
and NFI were not due to differences in cell survival, proliferation or errors in cell seeding 
density (Appendix Fig. 6.2). As before (Fig. 6.1), 25 ng/mL rIL-15 induced a substantial 
and significant increase in the average number of myonuclei in each myotube. However, 
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myotubes formed in the presence of rTNFα did not differ from unstimulated controls in 
their myonuclear number, irrespective of whether they were co-stimulated with rIL-15 












Having observed pro-myogenic effects of rIL-15 both in the presence and the absence of 
a pro-inflammatory (rTNFα) stimulus, we sought further molecular corroboration for our 
observations in both undifferentiated myoblasts and in differentiating cultures. 
Subconfluent myoblasts were switched to growth medium containing the recombinant 
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cytokines (IL-15, 25 ng/mL; TNFα, 1 ng/mL) or were left unstimulated for 2 d. 
Immunoblotting demonstrated that rIL-15 induced the expression of total ERK 1/2 (p44/42 
MAPK), phosphorylated-ERK (Thr202/Tyr204) and total Akt.  A modest induction of total 
ERK and phosphorylated ERK expression was evident in cultures that were co-stimulated 
with rIL-15 and TNFα (Fig. 6.3, A). No changes in MyoD, MAFbx or MURF-1 expression 
were observed and myogenin was not detected in these undifferentiated cultures (Fig. 
6.3, A).  
Secondly, subconfluent myoblasts were switched to differentiation medium containing the 
recombinant cytokines or were left unstimulated for 2 d, at which time myotubes begin to 
form in our cultures. Similar to the undifferentiated cultures, stimulation with rIL-15 induced 
an increase in total ERK and phosphorylated ERK expression (Fig. 6.3, B).  As expected, 
myogenin protein could be detected in these differentiated cultures, and its expression 
was increased in cultures stimulated with either rIL-15 or rTNFα, compared to 
unstimulated myotubes (Fig. 6.3, B).  In addition, rIL-15 induced an increase in MHC 
protein content (Appendix Fig. 6.3), despite not significantly increasing total protein 
synthesis (Appendix Fig. 6.3), as measured using the non-radioactive surface sensing of 











6.3.3 Elderly Individuals Display Increased Skeletal Muscle IL-15 Expression and 
Increased Plasma IL-15 Concentrations 
Skeletal muscle expression of IL15 was 2-fold higher (Fig. 6.4, A) in old participants, 
compared to young participants.  Furthermore, circulatory concentrations of IL-15 were 
significantly greater in older participants, being ~ 50 % higher (p = 0.0006) in the old 
compared to the young (Fig. 6.4, D). However, we also found that the IL-15 receptor 
signalling subunit IL2RB was decreased by ~ 80 % in old skeletal muscle, compared to 














6.3.4 TNFα Induces IL-15 Expression in and its Secretion from Primary Human 
Myotubes 
Stimulation of primary human myotubes from young participants with 20 ng/mL rTNFα for 
24 h induced a 19-fold increase in myotube IL15 expression (p= 0.0004) (Fig. 6.5, A). 
Myotubes were found to express both IL15RA and IL2RB, and 24 h rTNFα stimulation 
significantly induced the expression of both IL15RA (10-fold; p = 0.0014), and IL2RB (126-
179 
 
fold; p = 0.01), relative to non-stimulated control myotubes (Fig. 6.5, B, C). We also 
observed a corresponding 4-fold (p = 0.0006) increase in culture supernatant IL-15 
concentration (Fig. 6.5, D), indicating a significant increase in IL-15 secretion from rTNFα 













6.3.5 Antibody Neutralisation of IL-15rα Eliminates the Myogenic Effects of IL-15 
and Enhances the Detrimental Effects of TNFα on Myotube Development  
The presence of the IL-15rα neutralising antibody significantly reduced the MTT of 
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otherwise untreated (24 ± 4%, p = 0.003), IL-15 stimulated (35 ± 3%, p = < 0.0001) and 
TNFα stimulated (17 ± 2%, p = 0.014) myotubes compared to their IgG isotype treated 
controls (Fig. 6.6, A). The IL-15rα neutralising antibody had a similar effect on NFI, 
although the numerically considerable reduction in NFI observed in TNFα stimulated 
myotubes (56 ± 21 %, p = 0.16) treated with a IL-15rα neutralising antibody did not reach 
significance (Fig. 6.6, B). The average number of myonuclei in each myotube was not 










We have demonstrated for the first time that IL-15 enhances human myotube 
development and can partially protect against the deleterious effects of TNFα on 
myogenesis. Secretion of IL-15 by primary human myotubes derived from patients with 
polymyositis and dermatomyositis has been previously described (489). Here we show for 
the first time that myotubes derived from the skeletal muscle of healthy participants also 
secrete IL-15. These data are a significant advancement on previous in vitro work 
describing the effects of IL-15 on skeletal muscle growth and maintenance as we have 
used primary human myogenic cultures, rather than an immortalised murine cell line. 
 
6.4.1 IL-15 Promotes in vitro Human Myotube Development, Likely by Enhancing 
the Myogenic Programme 
Our studies were primarily designed to firstly examine the functional effect of IL-15 in 
human myogenesis and revealed that IL15 had a marked effect on increasing MTT, NFI 
and the number of myonuclei per myotube (Fig. 6.1).  The magnitude of these changes (a 
22 % increase in MTT at the 100 ng/mL dose of rIL-15) is considerable when placed in an 
integrated physiological context.  A previous study in humans has shown that even a small 
reduction in quadriceps lean mass following limb immobilisation (5 % over two weeks) is 
accompanied by a significant decline in isometric strength (490). Furthermore, 12 weeks 
of progressive resistance training in older men increases MHC I fibre diameter by 20 %, 
a change which is associated with a 55 % increase in maximal isometric force production 
by individual muscle fibres (491).  We also observed that myotubes were 19 % thinner in 
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our cultures derived from elderly participants compared to young participants.   
The IL-15-mediated increase in MTT is unlikely to be due to induction of myoblast 
hyperplasia as IL-15 did not affect either the proliferation or viability of subconfluent 
myoblasts. This is in agreement with previous observations that IL-15 has no effect on 
proliferation, as measured by [3H]thymidine incorporation in C2C12 myoblasts (49). 
Instead, the hypertrophic mechanism appears to be via an enhancement of myoblast 
fusion and the myogenic program, since we observed a > 30 % increase in the NFI and a 
greater than 2-fold increase in the number of myonuclei in myotubes formed under IL-15 
stimulation conditions. This notion of enhanced myogenesis is supported by our finding of 
total Akt induction in IL-15-stimulated confluent myoblasts that were ready for myogenic 
differentiation. Induction of total Akt expression (in particular that of Akt2) is essential for 
full myotube development (492). Furthermore, we observed an increase in total ERK 1/2 
and phosphorylated-ERK expression in IL-15 stimulated myoblasts. Myogenic cultures 
appear to have a biphasic requirement for ERK1/2  activity; ERK 1/2 appears to inhibit 
differentiation in proliferating cultures, but its activity facilitates myotube formation in 
differentiating cultures (493). Given that these myoblasts had reached a confluence 
sufficient for myogenic differentiation, it is reasonable to hypothesise that ERK 1/2 
activation by IL-15 might promote their fusion. This requires further study.  
Furthermore, IL-15 induced an increase in myomaker gene expression in confluent 
myoblasts that were ready for myogenic differentiation. Myomaker is a recently discovered 
muscle-specific cell membrane protein that has been reported to be essential for myoblast 
fusion and muscle regeneration (494,495). Most recently, myomaker dependent myoblast 
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fusion to existing myofibres has been shown to be essential for overload-induced 
hypertrophy to occur in mice (496). The finding that myomaker expression increased in 
IL-15 stimulated myoblasts represents a potentially novel mechanism of myogenic action 
for IL-15 in human skeletal muscle. In chicken myoblasts, the MRFs MYOG and MYOD 
have been shown to bind to an E-box near the myomaker transcription start site, thus 
inducing myomaker expression (497). Indeed, IL-15 induced an increase in the expression 
of both MYOD and MYOG in differentiated myotubes.  
6.4.2 The Myogenic Actions of IL-15 are Retained in Myogenic Cultures Derived 
from Elderly Participants and Autocrine IL-15 Secretion from Such Myotubes 
Supports Myogenesis 
Ageing is associated with a loss of skeletal muscle mass and quality – sarcopenia (6). 
Given that our myotubes from elderly participants formed less well than those from their 
young counterparts, we hypothesised that elderly cultures might be less sensitive to the 
myogenic actions of IL-15. However, we observed no difference in the functional 
responsiveness to exogenous rIL-15 stimulation between old and young myotubes, 
demonstrating that IL-15 signalling is not functionally impaired in the elderly. Despite 
observing no difference in the functional responsiveness to exogenous rIL-15 stimulation 
between young and old myotubes we did observe that the skeletal muscle tissue 
expression of the signalling subunit of the IL-15 receptor (IL2RB) was found to be 
significantly reduced in the elderly, compared to the young participants. However, the 
expression of the IL-15 receptor binding subunit, IL15RA was maintained. Given its high 
affinity for IL-15 compared to the signalling subunit, maintenance of IL15RA expression 
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may compensate for the reduction in IL2RB expression.  
Importantly, evidence from in vivo human studies suggest an important role for 
myogenesis in adult skeletal muscle (482); this is discussed as part of a wider evaluation 
of the physiological relevance of our in vitro myogenic model in Chapter 7. Therefore, our 
finding that IL-15 also promotes myoblast fusion in developing primary human myofibres 
derived from old participants is particularly pertinent. Furthermore, one purpose of 
neutralising the high-affinity IL-15 receptor binding subunit, IL-15rα in elderly myotubes 
was to confirm that the pro-myogenic activity of IL-15 in elderly individuals is not limited to 
the pharmacological doses of the recombinant cytokine used by ourselves and others 
(50,52). Our neutralisation of the receptor was successful; it completely inhibited the 
myogenic actions of exogenous rIL-15 (Fig. 6.6). In otherwise unstimulated elderly 
myotube cultures, IL-15rα neutralisation had a deleterious effect on myogenesis, 
suggesting that autocrine IL-15 secretion in elderly myotubes is crucial to support optimal 
myotube formation. 
6.4.3 IL-15 can Ameliorate the Detrimental Effects of TNFα on Myogenic 
Differentiation 
Given the emerging importance of inflammation in the aetiology of sarcopenia (483), and 
its pathological role in cachexia (22) it is remarkable and of potential clinical importance 
that IL-15 proved capable of ameliorating the deleterious effects of TNFα on primary 
human myotube development, regardless of culture donor age (Fig. 6.2). TNFα is known 
to induce myotube atrophy (65) and its plasma levels increase with age, independent of 
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BMI (264). Given the positive myogenic actions of IL-15, we hypothesise that the observed 
TNFα-mediated induction of IL-15 secretion and expression of IL15 and its receptor 
subunits IL15RA and IL2RB (Fig. 6.4), may represent a homeostatic mechanism, whereby 
IL-15 is induced to facilitate skeletal muscle maintenance in the presence of inflammation 
e.g. in inflammaging or in chronic clinical conditions that are associated with cachexia 
(498). Indeed, we observed that MTT was decreased to an even greater degree by TNFα 
in the presence of a neutralising IL-15rα antibody (Fig. 6.6, A), supporting the notion that 
IL-15 serves as compensatory factor in highly inflammatory environments. The induction 
of IL-15 secretion from TNFα stimulated myofibres might also, in part, explain why 
concentrations of TNFα in the normal physiological range have been reported to support 
myotube formation (282). It is important to note that despite clearly demonstrating the pro-
myogenic actions of IL-15, we have not fully established the molecular mechanism by 
which IL-15 ameliorates the detrimental effects of TNFα on myogenesis.  It may be that 
that IL-15 remains pro-myogenic in the presence of TNFα.  However, our molecular 
signalling analysis showed that the IL-15-mediated induction of pERK and of total AKT 
was markedly diminished by the presence of TNFα (Fig. 6.3, A, B). Furthermore, unlike 
with IL-15 stimulation alone, co-stimulation of differentiating myotubes with IL-15 and 
TNFα did not increase the number of myonuclei per myotube (Appendix Fig. 6.2, D, E).  
6.5 Conclusion 
We have provided evidence for the first time that IL-15 enhances in vitro human 
myogenesis and can partially protect against the deleterious effects of TNFα on human 
myotube development. Targeting the IL-15 signalling pathway may therefore be an 
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effective therapeutic approach in combating skeletal muscle atrophy, particularly in 














































Extensive restatement of background information that is presented in previous chapters 
is not intended here. However, a summary of the broader scientific landscape that lead to 
the conception of this work is necessary. 
Sarcopenia is a complex, multifactorial phenomenon which dietary interventions and 
physical activity do not completely reverse. Globally, 5-10 % of those over 65 yr meet the 
criteria for its formal diagnosis and its prevalence increases with advancing age (7). 
Sarcopenia and sarcopenic obesity are associated with an increased risk of 
cardiovascular, metabolic and musculoskeletal diseases as well as poorer quality of life 
scores and an increased incidence of falls and fractures (9–12). Sarcopenia increases all-
cause mortality 4-fold (13). The ageing global population will require considerable 
increases in age-associated healthcare spending (14) and sarcopenic individuals are 
considerably more expensive in this regard than their non-sarcopenic counterparts (15). 
There are few effective therapeutic interventions available for the prevention or reversal 
of sarcopenia. 
In sarcopenia, the nature of the decline in physical performance, as well as the changes 
in myofibre size, type and number are well understood. It is the nature of the age-
associated cellular and molecular changes that underpin such aspects of sarcopenia 
pathophysiology that are incompletely understood (e.g. changes in the function of SC, 
mitochondria and the neuromuscular junction). Indeed, the interdependence of these 
cellular or molecular changes has not been fully elicited, and it is still unclear which of 
these events might be primary in the development of sarcopenia. We therefore consider 
it important that each of these aetiological factors continues to be characterised. 
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Inflammation is well established as a major contributor the cachexia of chronic illness (22). 
Ageing is often accompanied by chronic low-grade inflammation, referred to as 
‘inflammaging’ (23). Adipose tissue – which accumulates with age – is a prolific secretor 
of pro-inflammatory adipokines (34). Total adipose tissue mass and VAT mass are 
negatively correlated with skeletal muscle mass (28,29). High systemic levels of pro-
inflammatory cytokines (e.g. TNFα and IL-6) are positively associated with reduced 
skeletal muscle mass in elderly populations (25–27). The effects of many adipokines on 
skeletal muscle mass maintenance are unknown and indeed, at the outset of this work 
there existed a need to identify which adipokines are most important in this respect, 
particularly in non-lean elderly who are subject to the greatest systemic adipokine burden.  
The need to identify more avenues for the development of pharmacological therapeutic 
interventions in sarcopenia was foremost in our minds at the conception of this project. To 
that end, our attention was drawn to IL-15 as a myokine that is known to promote the 
formation of C2C12 myotubes in culture and can prevent the loss of skeletal muscle mass 
in mice exposed to systemic inflammation (49,50). We noted with interest – given the 
inflammatory burden of ageing and its proposed contribution to sarcopenia –  that it has 
been asserted that IL-15 is expressed in skeletal muscle in response to stimuli that 
promote loss of muscle mass, to mitigate such loss (51).  However, the effect of IL-15 on 
human myogenesis, as well as myofibre size maintenance and hypertrophy was 
unexplored. Furthermore, given the high concentrations of recombinant IL-15 used in 
murine studies, it was unclear to us whether autocrine skeletal muscle IL-15 secretion is 
necessary for effective myogenesis. 
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7.2 Summary of the Hypotheses and Aims of this Thesis 
The two core hypotheses that were generated at the conception of this thesis were: 
1. That there exist understudied adipokine constituents of the adipose inflammatory 
milieu that are differentially secreted by lean and non-lean adipose tissue and that the 
enhanced secretion of these adipokines is detrimental to myogenesis and in part 
responsible for sarcopenia. 
2. That the pro-myogenic and hypertrophic actions of IL-15 would be retained in 
human myogenic cultures, but that cultures derived from the skeletal muscle of elderly 
individuals would be more resistant to these effects than those of young individuals. 
 
The following aims were therefore identified: 
1. To determine the effect of the adipose inflammatory milieux secreted by lean and 
non-lean adipose tissue on primary human myogenesis and to identify 
understudied adipokine constituents that may be consequential in mediating such 
effects (Chapter 3). 
2. To identify in these adipose inflammatory milieux a candidate adipokine of apparent 
myogenic consequence and detail its myogenic actions and the mechanism of such 
action (Chapter 4). 
3. To consider whether the candidate adipokine has metabolic effects on primary 
human myocytes (Chapter 5). 
4. To detail the myogenic actions of IL-15 in primary human myogenic cultures derived 
from young and old participants and to established whether its purported pro-
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myogenic and hypertrophic actions can be sustained in a pro-inflammatory 
environment (Chapter 6).  
 
7.3 Summary of Results 
In Chapter 3, we demonstrate that OB ACM, but not NW ACM has a detrimental effect 
on in vitro myotube formation and that myogenic cultures from elderly individuals are 
more substantially affected by the anti-myogenic effects of OB ACM. This chapter also 
details our quantification of ACM constituent adipokines. This work allowed us to identify 
resistin as an adipokine that is significantly enriched within non-lean ACM. We 
hypothesised that resistin might be in part responsible for the anti-myogenic actions of 
OB ACM, and mindful of the fact that resistin is understudied in this regard, we identified 
it as an adipokine which warranted further study.  
In Chapter 4, we demonstrate that recombinant resistin – at concentrations that are found 
in OB ACM – has a detrimental effect on in vitro human myogenesis. Furthermore, 
immunoprecipitation of resistin from OB ACM, such that its concentrations were more 
reflective of those found in NW ACM, restored myogenesis. We hypothesised, based on 
findings by others in HepG2 (404), human coronary artery endothelial cells (405) and 
human macrophages (406) that resistin might be activating the classical NFκB pathway 
in our myogenic cultures. Mindful that such NFκB activity is now well established as an 
inhibitor of myogenesis (402,499), we further hypothesised that this may – at least in some 
measure – be the mechanism by which resistin exerts its anti-myogenic actions. Indeed, 
we demonstrated that this is the case and inhibition of classical NFκB pathway signalling 
with the IKKβ inhibitor TPCA-1 restored myogenesis in the presence of resistin.  
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We noted a dearth of studies on the metabolic effects of resistin in human skeletal muscle 
and questioned whether our myotubes, when formed in the presence of resistin would 
display any alterations in their oxidative metabolism. Using principally the Seahorse® 
XFe96 analyser, coupled with Oil Red O staining of myotubes, we demonstrate in Chapter 
5 that resistin is a metabolic stressor of myotubes, promoting increased ATP production, 
basal OCR, fatty acid oxidation, proton leak and lipid accumulation. This chapter, in 
particular, identifies considerable knowledge gaps and areas for future investigation which 
are discussed below.  
Chapter 6 is somewhat distinct from the other data chapters in this thesis, in that we detail 
the functional effects of a pro-myogenic myokine. However, like the other work described 
here its functional effects are considered with respect to their potential implications for 
ageing skeletal muscle. We show that IL-15 is pro-myogenic in primary human cultures, 
including those derived from older individuals, that it can mitigate the detrimental effects 
of an inflammatory environment on myogenesis and that autocrine IL-15 secretion 
supports myogenesis.   
 
7.4 Limitations 
The experimental design employed here – one in which primary human skeletal muscle 
myoblasts are fully differentiated in vitro to myotubes in the presence of a stimulus (ACM 
or recombinant cytokines) – most closely resembles physiological scenarios in which SC 
are activated to contribute to regeneration, maintenance and hypertrophy of skeletal 
muscle fibres. Skeletal muscle regeneration in response to injury is perhaps the most 
often cited example of SC proliferation and commitment to a myogenic fate (500–502). 
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However, the situations in which SC are activated are more varied and commonplace than 
simply that of serious skeletal muscle injury.  
The observation that conditional depletion of SC by > 90 % in tamoxifen-treated Pax7-
DTA mice (133) results in no difference in the degree of plantaris hypertrophy at 2 wk in 
response to synergist muscle removal has in the past prompted the conclusion the SC 
are unimportant for such hypertrophy (134). However, this hypertrophic response plateaus 
in Pax7-DTA mice beyond two weeks, with vehicle-treated mice displaying a 1.5 times 
greater increase in muscle size than the SC-depleted counterparts after 8 wk (133). 
Recent murine evidence challenges the paradigm that SC remain quiescent in their niche 
until skeletal muscle is exposed to a significant challenge (e.g. eccentric exercise or 
trauma); 20 % of hindlimb myofibres contained new tdTomato-labelled SC after a 2 wk 
lineage labelling period (135). In humans, both repetitive eccentric exercise (which may 
reasonably be considered an extraordinary activity) and typical resistance training (4 sets 
of 10 repetitions of unilateral leg press and unilateral knee extension at 75 % of one 
repetition maximum) substantially and significantly increase the number of SC in the 
G0/G1 phase of the cell cycle after 24 h, suggesting that sizeable cell division had 
occurred (503,504). It is now becoming evident that SC activation and myoblast fusion 
play an important role in skeletal muscle hypertrophy, maintenance and regeneration in 
response to a variety of stimuli over the course of an adult lifespan. Indeed, this notion is 
further supported by observations that in the elderly, atrophy-prone type IIa fibres display 
reduced nuclear numbers and the MND are significantly decreased (136). Nuclear number 
is also significantly diminished in type I fibres (136). Moreover, as with skeletal muscle 
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performance and size, age-related changes in skeletal muscle SC content are only 
partially reversible with increased physical activity (155,156,505) (see also Section 
1.6.3.1). Primary human myogenic cultures, therefore, offer a useful, in vitro model for 
examining such physiology in the context of adipose-derived inflammation. None the less, 
this model is imperfect. Myotubes cannot be maintained in culture for prolonged periods 
of time, and they are immature, displaying distinct differences when compared to skeletal 
muscle (80,81,83) (see also Section 1.5).  
Many of the experiments detailed in this thesis would be enhanced by a parallel 
examination of the effects of ACM and recombinant cytokines on the atrophy and 
hypertrophy of fully differentiated myotubes. This would have required access to 
considerably more skeletal muscle biopsies, and therefore it was not possible to carry out 
both sets of experiments. We acknowledge that it is not just the effectiveness of the 
myogenic program that might be altering MTT in our studies. Catabolic or protein synthetic 
stimuli may have altered MTT, particularly in the latter stages of myotube formation. 
Secondly, skeletal muscle mass maintenance, hypertrophy and atrophy in vivo must be 
viewed as the product of a complex interplay between factors such as muscle protein 
synthesis, muscle protein breakdown and myogenesis. Thus, the question as to what 
effects the adipose inflammatory milieu, resistin and IL-15 have on mature human 
myofibres remains to be answered and should be considered in parallel with our results 
to generate a complete picture of their effects in aged skeletal muscle.  
None the less, we feel justified in our prioritisation of the in vitro myogenic experimental 
model employed here. The immaturity of myogenic cultures and their resulting myotubes 
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(80,81,83) (see also Section 1.5) means that in our opinion, they may be more appropriate 
for the examination of myogenesis, although they undoubtedly retain usefulness as 
surrogate in vitro muscle fibres. Tissue engineering approaches to the problem of 
developing physiologically relevant ex-vivo skeletal muscle surrogates that can be 
maintained in culture continue to advance (506–509), and such surrogates are likely to be 
of both experimental and ultimately clinical utility. Had we taken the approach of examining 
the effects of ACM and recombinant cytokines on the atrophy and hypertrophy of fully 
differentiated myotubes, we would have been considerably limited by the short time-frame 
during which the myotubes are fully differentiated but not demonstrating any signs of cell 
death or atrophy – in our experience a period of about 72 h. While we still consider this 
work important to carry out, we highlight that the degree of atrophy that might be expected 
with, for example, physiological concentrations of resistin in such a time-frame might be 
difficult to accurately and precisely quantify given the limitations of the assay for 
quantifying MTT and NFI.  
For each biological replicate, MTT and NFI measurements made in this thesis comprise 
a large number of technical replications. Despite this, the 95 % confidence intervals for 
each subject’s MTT measurements represent approximately 10 % of the mean MTT. Thus, 
the labour-intensive technical replications performed by ourselves and others (47) are 
necessary to obtain accurate MTT and NFI data for individuals, prior to examining the 
variability of the response between biological replicates. Ideally, the quantification of MTT 
and NFI would be carried out by two independent investigators, but the time-consuming 
nature of the assay in its current form represents a substantial barrier to this. Adobe 
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Photoshop has been used to quantify myotube surface area; this approach is of 
considerable advantage in quantifying the area of irregularly shaped myotubes and may 
increase assay throughput (510).  The creation of an automated computer program that 
is capable of quantifying MTT and NFI in images of desmin (or MHC) and DAPI stained 
cultures would increase throughput further. Such a program would need a reliable strategy 
to deal with overlapping myotubes and myonuclei and would need to be validated using 
observations of the same images by multiple experienced investigators. The author is 
currently in the early stages of leading a collaborative project which aims to produce such 
a program to be made available to the research community.  If successful, this will be of 
considerable value to researchers interested in myotube morphology, allowing a greater 
consistency of results between images and a higher throughput, thus facilitating the 
recruitment of a greater number of participants for a given experiment.  
More specific limitations of the data presented have been considered in the relevant 
individual data chapters. However, the data in Chapter 5 warrant brief mention again here. 
These data are novel and represent a considerable advancement of our knowledge of the 
metabolic effects of resistin on skeletal myofibres. However, it is acknowledged that the 
interpretation of these data is somewhat speculative and the additional work that has been 
suggested must be carried out in the future to fully understand the metabolic 
adaptations/maladaptations that we describe.    
Finally, it should be remembered sarcopenia is a multifactorial phenomenon, whose 
aetiology is incompletely understood. As such, we believe that ours is an important 
contribution to such understanding, but are mindful that adipose-derived inflammation and 





7.5 Impact and Future directions 
In large part, the impact of the data presented and suggestions for its development has 
been considered in the relevant data chapters. Here, only those issues of most immediate 
and broad importance to the musculoskeletal ageing research community are considered 
together.  
Chapter 3 describes subcutaneous adipose inflammatory milieux that are highly variable, 
irrespective of an individual’s BMI. Our characterisation of these milieux used multiplex 
magnetic bead-based immunoassays of prominent known adipokines. Development of 
our work should involve comprehensive proteomic and lipidomic profiling of SAT ACM. It 
may be that such work will identify many more ACM constituents that may be of 
consequence in the development of sarcopenia and which may represent useful avenues 
for therapeutic targeting. The inflammatory milieux secreted by VAT and IMAT are also of 
relevance to our understanding the pathogenesis sarcopenic obesity. Given the prolific 
inflammatory profile of VAT and the proximity of IMAT to skeletal muscle, these milieux 
should be comprehensively characterised. As discussed in Section 3.3.1, such 
characterisations of IMAT are substantially impeded by the difficulties in obtaining IMAT in 
sufficient quantities for study. Given the practical and ethical difficulties associates with 
access to viable cadaveric human tissue, recent hypotheses that postulate that FAP cells 
are a possible source of adipocytes within skeletal muscle (381) may offer the possibility 
of their in vitro culture from skeletal muscle biopsies. Thus, profiling of the IMAT adipocyte 
secretome might prove possible in the immediate future.  
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Given the anti-myogenic effects of resistin that we detail in Chapter 4, any future work will 
need to consider the utility and practicality of inhibiting such actions. For example, the 
subcutaneous or intravenous administration of monoclonal antibodies or circulating decoy 
receptors is likely impractical for a population-level programme of sarcopenia prevention. 
On the other hand, we have shown that resistin exerts its anti-myogenic actions by 
activating the classical NFκB pathway. In Section 4.3.2 the role of NSAIDs as NFκB 
inhibitors was discussed. In the elderly, NSAIDs have been shown to increase muscle 
volume and strength acquisition in response to resistance training (443). Thus, future work 
should focus on exploring their effectiveness in facilitating the long-term retention of 
skeletal muscle mass and function in the elderly, while also establishing whether the risk 
of upper gastrointestinal mucosal damage can reliably and safely be prevented with 
existing proton pump inhibitors.  
In Chapter 6 we show that IL-15 is a pro-myogenic myokine, which can ameliorate the 
anti-myogenic effects of a pro-inflammatory environment. Inflammation itself (TNFα 
stimulation) induced IL-15 secretion from myotubes and indeed, the elderly have 
increased circulating concentrations of IL-15. The molecular mechanisms underpinning 
these actions of IL-15 remain to be fully elicited. However, we have identified activation of 
the ERK signalling pathway and induction of myomaker gene expression as areas for 
further exploration. The outcome of such investigations will dictate what approach, if any, 
is taken to exploiting the pro-myogenic actions of IL-15 in therapeutic interventions. IL-15 
is an important modulator of innate and adaptive immune responses and this will be an 
important consideration in its therapeutic use (511). Indeed, the first Phase I clinical trial 
to examine rIL-15 administration to human participants (with metastatic malignancies) 
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demonstrated considerable efflux of NK and memory CD8 T cells from the circulation and 
a 10-fold expansion of the NK cell population (512). However, the serum IL-15 
concentrations attained with the maximum tolerated dose (0.3μg/kg per day) were greater 
than 1000 pg/mL, similar to the pharmacological concentrations used in some of our 
experiments. Given that we have shown that autocrine IL-15 secretion from myotubes 
supports myogenesis and that the concentrations of IL-15 in the skeletal muscle 
interstitium are generally less than 20 pg/mL (513), much smaller manipulations of skeletal 
muscle IL-15 concentrations might have positive benefits in sarcopenia without 
substantially altering the immune system.  
There is a compelling argument to be made that the answer to preventing the deleterious 
consequences of adipose-derived inflammation lies in preventing the excessive 
accumulation of adipose tissue. Further, it could reasonably be argued that the answer to 
this problem is already known; sustained consumption of an energetically sufficient diet 
will prevent substantial adipose tissue accumulation. If coupled with sufficient physical 
activity – which is partially effective in preventing and reversing sarcopenia (Section 
1.6.4.1) – the phenomenon of sarcopenic obesity might be substantially mitigated. One 
argument for continuing to pursue additional understanding of the cellular and molecular 
factors underpinning sarcopenia has already been touched upon in this thesis, namely 
that physical activity interventions when adhered to diligently are only partially effective in 
reversing sarcopenia (Section 1.6.3). Furthermore, even if a population had sufficient 
knowledge of these issues to take personal responsibility for their own dietary and physical 
activity choices, there now exist considerable societal and environmental impediments to 
maintaining a healthy weight throughout one’s life (for a recent systematic review see 
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(514)). Moreover, there also exist substantial health and economic costs to society of 
having an overweight population (515–517). The author advocates addressing these 
wider societal issues and is a strong proponent of the tenets of public health promotion 
set out Ottawa Charter (518). However, the continued rise in obesity rates requires a 
pragmatic multi-faceted approach and thus the continued pursuit of a molecular 
understanding of obesity-related conditions and the development of pharmaceutical 
interventions to compliment public heath approaches.   
 
7.6 Concluding Remarks 
This thesis addresses its two core hypotheses and in doing so identifies resistin as an 
adipokine whose secretion is enhanced in non-lean human subcutaneous adipose tissue. 
Resistin is further identified as having anti-myogenic actions on primary human myogenic 
cultures and this phenomenon is shown to be mediated by its activation of the classical 
NFκB pathway. Resistin is also established as a metabolic stressor of in vitro primary 
human myotubes; it increases oxidative metabolism, fatty acid oxidation and promotes 
intramyocellular lipid accumulation.  The myokine IL-15 is shown to support myogenesis, 
and it is established that IL-15 can mitigate the detrimental effects of an inflammatory 
environment on myogenesis. Moreover, we show for the first time that these pro-myogenic 
actions are not limited to the exogenous provision of rIL-15 -  autocrine IL-15 secretion by 






































1.  Paddon-Jones D, Rasmussen BB. Dietary protein recommendations and the prevention of 
sarcopenia. Curr Opin Clin Nutr Metab Care. 2009 Jan;12(1):86–90.  
2.  Song M-Y, Ruts E, Kim J, Janumala I, Heymsfield S, Gallagher D. Sarcopenia and 
increased adipose tissue infiltration of muscle in elderly African American women. Am J 
Clin Nutr. 2004 May;79(5):874–80.  
3.  Atlantis E, Martin SA, Haren MT, Taylor AW, Wittert GA, Florey Adelaide Male Aging Study. 
Lifestyle factors associated with age-related differences in body composition: the Florey 
Adelaide Male Aging Study. Am J Clin Nutr. 2008 Jul;88(1):95–104.  
4.  Kyle UG, Genton L, Hans D, Karsegard VL, Michel JP, Slosman DO, et al. Total body mass, 
fat mass, fat-free mass, and skeletal muscle in older people: cross-sectional differences in 
60-year-old persons. J Am Geriatr Soc. 2001 Dec;49(12):1633–40.  
5.  Hunter GR, Weinsier RL, Gower BA, Wetzstein C. Age-related decrease in resting energy 
expenditure in sedentary white women: effects of regional differences in lean and fat mass. 
Am J Clin Nutr. 2001 Feb;73(2):333–7.  
6.  Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: 
European consensus on definition and diagnosis. Age Ageing. 2010 Jul;39(4):412–23.  
7.  Morley JE, Anker SD, von Haehling S. Prevalence, incidence, and clinical impact of 
sarcopenia: facts, numbers, and epidemiology—update 2014. J Cachexia Sarcopenia 
Muscle. 2014 Dec;5(4):253–9.  
8.  Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L. Sarcopenic 
obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care. 2008 
Nov;11(6):693–700.  
9.  Lim S, Kim JH, Yoon JW, Kang SM, Choi SH, Park YJ, et al. Sarcopenic obesity: 
prevalence and association with metabolic syndrome in the Korean Longitudinal Study on 
Health and Aging (KLoSHA). Diabetes Care. 2010 Jul;33(7):1652–4.  
10.  Chin SO, Rhee SY, Chon S, Hwang Y-C, Jeong I-K, Oh S, et al. Sarcopenia is 
independently associated with cardiovascular disease in older Korean adults: the Korea 
National Health and Nutrition Examination Survey (KNHANES) from 2009. PloS One. 
2013;8(3):e60119.  
11.  Rizzoli R, Reginster J-Y, Arnal J-F, Bautmans I, Beaudart C, Bischoff-Ferrari H, et al. 
Quality of life in sarcopenia and frailty. Calcif Tissue Int. 2013 Aug;93(2):101–20.  
12.  Landi F, Liperoti R, Russo A, Giovannini S, Tosato M, Capoluongo E, et al. Sarcopenia as a 
risk factor for falls in elderly individuals: results from the ilSIRENTE study. Clin Nutr Edinb 
Scotl. 2012 Oct;31(5):652–8.  
13.  Beaudart C, Zaaria M, Pasleau F, Reginster J-Y, Bruyère O. Health Outcomes of 
Sarcopenia: A Systematic Review and Meta-Analysis. PloS One. 2017;12(1):e0169548.  
205 
 
14.  Silcock D, Sinclair D. The cost of our ageing society [Internet]. The International Longevity 
Centre - UK; 2012 [cited 2015 May 31]. Available from: 
http://www.ilcuk.org.uk/index.php/publications/year/2012 
15.  Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R. The healthcare costs of sarcopenia 
in the United States. J Am Geriatr Soc. 2004 Jan;52(1):80–5.  
16.  Gouveia ÉR, Gouveia BR, Maia JA, Blimkie CJ, Freitas DL. Skeletal Muscle and Physical 
Activity in Portuguese Community-Dwelling Older Adults. J Aging Phys Act. 
2016;24(4):567–74.  
17.  Verdijk LB, Jonkers RAM, Gleeson BG, Beelen M, Meijer K, Savelberg HHCM, et al. 
Protein supplementation before and after exercise does not further augment skeletal 
muscle hypertrophy after resistance training in elderly men. Am J Clin Nutr. 2009 
Feb;89(2):608–16.  
18.  Leenders M, Verdijk LB, Van der Hoeven L, Van Kranenburg J, Nilwik R, Wodzig WKWH, et 
al. Protein supplementation during resistance-type exercise training in the elderly. Med Sci 
Sports Exerc. 2013 Mar;45(3):542–52.  
19.  Campbell WW, Trappe TA, Jozsi AC, Kruskall LJ, Wolfe RR, Evans WJ. Dietary protein 
adequacy and lower body versus whole body resistive training in older humans. J Physiol. 
2002 Jul 15;542(Pt 2):631–42.  
20.  Pearson SJ, Young A, Macaluso A, Devito G, Nimmo MA, Cobbold M, et al. Muscle function 
in elite master weightlifters. Med Sci Sports Exerc. 2002 Jul;34(7):1199–206.  
21.  Cesari M, Fielding R, Bénichou O, Bernabei R, Bhasin S, Guralnik JM, et al. 
PHARMACOLOGICAL INTERVENTIONS IN FRAILTY AND SARCOPENIA: REPORT BY 
THE INTERNATIONAL CONFERENCE ON FRAILTY AND SARCOPENIA RESEARCH 
TASK FORCE. J Frailty Aging. 2015;4(3):114–20.  
22.  Evans WJ. Skeletal muscle loss: cachexia, sarcopenia, and inactivity. Am J Clin Nutr. 2010 
Apr 1;91(4):1123S–1127S.  
23.  Franceschi C. Inflammaging as a Major Characteristic of Old People: Can It Be Prevented 
or Cured? Nutr Rev. 2007 Dec 1;65:S173–6.  
24.  Woloshin S, Schwartz LM. Distribution of C-Reactive Protein Values in the United States. N 
Engl J Med. 2005 Apr 14;352(15):1611–3.  
25.  Schaap LA, Pluijm SMF, Deeg DJH, Visser M. Inflammatory markers and loss of muscle 
mass (sarcopenia) and strength. Am J Med. 2006 Jun;119(6):526.e9-17.  
26.  Schaap LA, Pluijm SMF, Deeg DJH, Harris TB, Kritchevsky SB, Newman AB, et al. Higher 
inflammatory marker levels in older persons: associations with 5-year change in muscle 
mass and muscle strength. J Gerontol A Biol Sci Med Sci. 2009 Nov;64(11):1183–9.  
27.  Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB, et al. 
206 
 
Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle 
strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci. 
2002 May;57(5):M326-332.  
28.  Schautz B, Later W, Heller M, Müller MJ, Bosy-Westphal A. Total and regional relationship 
between lean and fat mass with increasing adiposity--impact for the diagnosis of 
sarcopenic obesity. Eur J Clin Nutr. 2012 Dec;66(12):1356–61.  
29.  Yamada M, Moriguch Y, Mitani T, Aoyama T, Arai H. Age-dependent changes in skeletal 
muscle mass and visceral fat area in Japanese adults from 40 to 79 years-of-age. Geriatr 
Gerontol Int. 2014 Feb;14 Suppl 1:8–14.  
30.  Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein 
levels in overweight and obese adults. JAMA. 1999 Dec 8;282(22):2131–5.  
31.  Weyer C, Yudkin JS, Stehouwer CDA, Schalkwijk CG, Pratley RE, Tataranni PA. Humoral 
markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo 
insulin action in Pima Indians. Atherosclerosis. 2002 Mar;161(1):233–42.  
32.  Derosa G, Fogari E, D’Angelo A, Bianchi L, Bonaventura A, Romano D, et al. Adipocytokine 
levels in obese and non-obese subjects: an observational study. Inflammation. 2013 
Aug;36(4):914–20.  
33.  Wu D-M, Chu N-F, Shen M-H, Wang S-C. Obesity, plasma high sensitivity C-reactive 
protein levels and insulin resistance status among school children in Taiwan. Clin Biochem. 
2006 Aug;39(8):810–5.  
34.  Lehr S, Hartwig S, Sell H. Adipokines: A treasure trove for the discovery of biomarkers for 
metabolic disorders. PROTEOMICS – Clin Appl. 2012;6(1–2):91–101.  
35.  Dyck DJ, Heigenhauser GJF, Bruce CR. The role of adipokines as regulators of skeletal 
muscle fatty acid metabolism and insulin sensitivity. Acta Physiol. 2006 Jan 1;186(1):5–16.  
36.  Little JP, Safdar A. Adipose-brain crosstalk: do adipokines have a role in neuroprotection? 
Neural Regen Res. 2015 Sep;10(9):1381–2.  
37.  Kwon H, Pessin JE. Adipokines Mediate Inflammation and Insulin Resistance. Front 
Endocrinol [Internet]. 2013 Jun 12 [cited 2017 Mar 2];4. Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3679475/ 
38.  Nakamura K, Fuster JJ, Walsh K. Adipokines: A link between obesity and cardiovascular 
disease. J Cardiol. 2014 Apr;63(4):250–9.  
39.  Després J-P. Body Fat Distribution and Risk of Cardiovascular Disease An Update. 
Circulation. 2012 Sep 4;126(10):1301–13.  
40.  Shuster A, Patlas M, Pinthus JH, Mourtzakis M. The clinical importance of visceral 
adiposity: a critical review of methods for visceral adipose tissue analysis. Br J Radiol. 
2012 Jan;85(1009):1–10.  
207 
 
41.  Alexopoulos N, Katritsis D, Raggi P. Visceral adipose tissue as a source of inflammation 
and promoter of atherosclerosis. Atherosclerosis. 2014 Mar;233(1):104–12.  
42.  Guglielmi V, Maresca L, D’Adamo M, Di Roma M, Lanzillo C, Federici M, et al. Age-related 
different relationships between ectopic adipose tissues and measures of central obesity in 
sedentary subjects. PloS One. 2014;9(7):e103381.  
43.  Lee Y, Shin H, Vassy JL, Kim JT, Cho SI, Kang SM, et al. Comparison of regional body 
composition and its relation with cardiometabolic risk between BMI-matched young and old 
subjects. Atherosclerosis. 2012 Sep;224(1):258–65.  
44.  Wang L, Wang W, Xu L, Cheng X, Ma Y, Liu D, et al. Relation of Visceral and 
Subcutaneous Adipose Tissue to Bone Mineral Density in Chinese Women. Int J 
Endocrinol. 2013 Jun 3;2013:e378632.  
45.  Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and 
adipokine expression and secretion. J Clin Endocrinol Metab. 2007 Mar;92(3):1023–33.  
46.  Blaber SP, Webster RA, Hill CJ, Breen EJ, Kuah D, Vesey G, et al. Analysis of in vitro 
secretion profiles from adipose-derived cell populations. J Transl Med. 2012 Aug 
22;10:172.  
47.  Pellegrinelli V, Rouault C, Rodriguez-Cuenca S, Albert V, Edom-Vovard F, Vidal-Puig A, et 
al. Human Adipocytes Induce Inflammation and Atrophy in Muscle Cells During Obesity. 
Diabetes. 2015 Sep 1;64(9):3121–34.  
48.  Schütz UH, Billich C, König K, Würslin C, Wiedelbach H, Brambs H-J, et al. Characteristics, 
changes and influence of body composition during a 4486 km transcontinental 
ultramarathon: results from the Transeurope Footrace mobile whole body MRI-project. 
BMC Med. 2013 May 8;11:122.  
49.  Quinn LS, Haugk KL, Grabstein KH. Interleukin-15: a novel anabolic cytokine for skeletal 
muscle. Endocrinology. 1995 Aug;136(8):3669–72.  
50.  Kim HC, Cho H-Y, Hah Y-S. Role of IL-15 in Sepsis-Induced Skeletal Muscle Atrophy and 
Proteolysis. Tuberc Respir Dis. 2012 Dec;73(6):312–9.  
51.  Pistilli EE, Siu PM, Alway SE. Interleukin-15 responses to aging and unloading-induced 
skeletal muscle atrophy. Am J Physiol Cell Physiol. 2007 Apr;292(4):C1298-1304.  
52.  O’Connell GC, Pistilli EE. Interleukin-15 directly stimulates pro-oxidative gene expression in 
skeletal muscle in-vitro via a mechanism that requires interleukin-15 receptor alpha. 
Biochem Biophys Res Commun. 2015 Mar 13;458(3):614–9.  
53.  Pedersen BK. Muscles and their myokines. J Exp Biol. 2011 Jan 15;214(Pt 2):337–46.  
54.  Ceafalan LC, Popescu BO, Hinescu ME. Cellular Players in Skeletal Muscle Regeneration. 
BioMed Res Int. 2014 Mar 23;2014:e957014.  
208 
 
55.  Sciorati C, Rigamonti E, Manfredi AA, Rovere-Querini P. Cell death, clearance and 
immunity in the skeletal muscle. Cell Death Differ. 2016 Jun;23(6):927–37.  
56.  Chapman MA, Mukund K, Subramaniam S, Brenner D, Lieber RL. Three Distinct Cell 
Populations Express Extracellular Matrix Proteins and Increase in Number During Skeletal 
Muscle Fibrosis. Am J Physiol Cell Physiol. 2016 Nov 23;ajpcell.00226.2016.  
57.  Mok GF, Sweetman D. Many routes to the same destination: lessons from skeletal muscle 
development. Reprod Camb Engl. 2011 Mar;141(3):301–12.  
58.  Hasty P, Bradley A, Morris JH, Edmondson DG, Venuti JM, Olson EN, et al. Muscle 
deficiency and neonatal death in mice with a targeted mutation in the myogenin gene. 
Nature. 1993 Aug 5;364(6437):501–6.  
59.  Rudnicki MA, Schnegelsberg PNJ, Stead RH, Braun T, Arnold H-H, Jaenisch R. MyoD or 
Myf-5 is required for the formation of skeletal muscle. Cell. 1993 Dec 31;75(7):1351–9.  
60.  Kassar-Duchossoy L, Gayraud-Morel B, Gomès D, Rocancourt D, Buckingham M, Shinin 
V, et al. Mrf4 determines skeletal muscle identity in Myf5:Myod double-mutant mice. 
Nature. 2004 Sep 23;431(7007):466–71.  
61.  Standring S, Gray H, editors. Gray’s anatomy: the anatomical basis of clinical practice. 40th 
ed., anniversary ed. Edinburgh: Churchill Livingstone/Elsevier; 2008. 1551 p.  
62.  Guyton AC, Hall JE. Textbook of Medical Physiology. 11th ed. Pennsylvania: Elsevier 
Saunders; 2006.  
63.  Maughan RJ, Gleeson M, Greenhaff PL. Biochemistry of exercise and training. Oxford 
University Press; 1997. 260 p.  
64.  Burattini S, Ferri P, Battistelli M, Curci R, Luchetti F, Falcieri E. C2C12 murine myoblasts as 
a model of skeletal muscle development: morpho-functional characterization. Eur J 
Histochem EJH. 2004 Sep;48(3):223–33.  
65.  Wang D-T, Yin Y, Yang Y-J, Lv P-J, Shi Y, Lu L, et al. Resveratrol prevents TNF-α-induced 
muscle atrophy via regulation of Akt/mTOR/FoxO1 signaling in C2C12 myotubes. Int 
Immunopharmacol. 2014 Apr;19(2):206–13.  
66.  Manabe Y, Miyatake S, Takagi M, Nakamura M, Okeda A, Nakano T, et al. Characterization 
of an Acute Muscle Contraction Model Using Cultured C2C12 Myotubes. PLOS ONE. 2012 
Dec 31;7(12):e52592.  
67.  Mirza KA, Pereira SL, Edens NK, Tisdale MJ. Attenuation of muscle wasting in murine C2C 
12 myotubes by epigallocatechin-3-gallate. J Cachexia Sarcopenia Muscle. 2014 
Dec;5(4):339–45.  
68.  Oita RC, Ferdinando D, Wilson S, Bunce C, Mazzatti DJ. Visfatin induces oxidative stress 
in differentiated C2C12 myotubes in an Akt- and MAPK-independent, NFkB-dependent 
manner. Pflüg Arch Eur J Physiol. 2010 Mar;459(4):619–30.  
209 
 
69.  Agley CC, Rowlerson AM, Velloso CP, Lazarus NL, Harridge SDR. Isolation and 
quantitative immunocytochemical characterization of primary myogenic cells and fibroblasts 
from human skeletal muscle. J Vis Exp JoVE. 2015 Jan 12;(95):52049.  
70.  Pawlikowski B, Lee L, Zuo J, Kramer R. Analysis of human muscle stem cells reveals a 
differentiation-resistant progenitor cell population expressing Pax7 capable of self-renewal. 
Dev Dyn Off Publ Am Assoc Anat. 2009 Jan;238(1):138–49.  
71.  Blau HM, Pavlath GK, Hardeman EC, Chiu CP, Silberstein L, Webster SG, et al. Plasticity 
of the differentiated state. Science. 1985 Nov 15;230(4727):758–66.  
72.  Yaffe D, Saxel O. Serial passaging and differentiation of myogenic cells isolated from 
dystrophic mouse muscle. Nature. 1977 Dec 22;270(5639):725–7.  
73.  Cornall L, Hryciw D, Mathai M, McAinch A. Generation and Use of Cultured Human Primary 
Myotubes. In: Sundaram C, editor. Muscle Biopsy [Internet]. InTech; 2012 [cited 2015 Jun 
6]. Available from: http://www.intechopen.com/books/muscle-biopsy/generation-and-use-of-
cultured-human-primary-myotubes 
74.  Bareja A, Holt JA, Luo G, Chang C, Lin J, Hinken AC, et al. Human and Mouse Skeletal 
Muscle Stem Cells: Convergent and Divergent Mechanisms of Myogenesis. PLOS ONE. 
2014 Feb 28;9(2):e90398.  
75.  Lorsch JR, Collins FS, Lippincott-Schwartz J. Fixing problems with cell lines. Science. 2014 
Dec 19;346(6216):1452–3.  
76.  Thompson DB, Pratley R, Ossowski V. Human primary myoblast cell cultures from non-
diabetic insulin resistant subjects retain defects in insulin action. J Clin Invest. 1996 Nov 
15;98(10):2346–50.  
77.  Mott DM, Hoyt C, Caspari R, Stone K, Pratley R, Bogardus C. Palmitate oxidation rate and 
action on glycogen synthase in myoblasts from insulin-resistant subjects. Am J Physiol 
Endocrinol Metab. 2000 Sep;279(3):E561-569.  
78.  McAinch AJ, Steinberg GR, Mollica J, O’Brien PE, Dixon JB, Macaulay SL, et al. Differential 
regulation of adiponectin receptor gene expression by adiponectin and leptin in myotubes 
derived from obese and diabetic individuals. Obes Silver Spring Md. 2006 
Nov;14(11):1898–904.  
79.  Bakke SS, Feng YZ, Nikolić N, Kase ET, Moro C, Stensrud C, et al. Myotubes from 
Severely Obese Type 2 Diabetic Subjects Accumulate Less Lipids and Show Higher 
Lipolytic Rate than Myotubes from Severely Obese Non-Diabetic Subjects. PLoS ONE 
[Internet]. 2015 Mar 19 [cited 2017 Feb 23];10(3). Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366103/ 
80.  Larkin LM, Van der Meulen JH, Dennis RG, Kennedy JB. Functional evaluation of nerve-




81.  Madden L, Juhas M, Kraus WE, Truskey GA, Bursac N. Bioengineered human myobundles 
mimic clinical responses of skeletal muscle to drugs. eLife [Internet]. [cited 2017 Feb 15];4. 
Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337710/ 
82.  Smith AST, Davis J, Lee G, Mack DL, Kim D-H. Muscular dystrophy in a dish: engineered 
human skeletal muscle mimetics for disease modeling and drug discovery. Drug Discov 
Today. 2016 Sep;21(9):1387–98.  
83.  Cheng CS, Davis BNJ, Madden L, Bursac N, Truskey GA. Physiology and Metabolism of 
Tissue Engineered Skeletal Muscle. Exp Biol Med Maywood NJ. 2014 Sep;239(9):1203–
14.  
84.  Olsson K, Cheng AJ, Alam S, Al-Ameri M, Rullman E, Westerblad H, et al. Intracellular 
Ca2+-handling differs markedly between intact human muscle fibers and myotubes. Skelet 
Muscle [Internet]. 2015 Aug 20 [cited 2017 Feb 23];5. Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545874/ 
85.  Gaster M, Beck-Nielsen H, Schrøder HD. Proliferation conditions for human satellite cells 
The fractional content of satellite cells. APMIS. 2001 Nov 1;109(11):726–34.  
86.  Agley CC, Rowlerson AM, Velloso CP, Lazarus NR, Harridge SDR. Human skeletal muscle 
fibroblasts, but not myogenic cells, readily undergo adipogenic differentiation. J Cell Sci. 
2013 Dec 15;126(24):5610–25.  
87.  JAROCHA D, STANGEL-WOJCIKIEWICZ K, BASTA A, MAJKA M. Efficient myoblast 
expansion for regenerative medicine use. Int J Mol Med. 2014 Jul;34(1):83–91.  
88.  Hill NR, Oliver NS, Choudhary P, Levy JC, Hindmarsh P, Matthews DR. Normal Reference 
Range for Mean Tissue Glucose and Glycemic Variability Derived from Continuous Glucose 
Monitoring for Subjects Without Diabetes in Different Ethnic Groups. Diabetes Technol 
Ther. 2011 Sep;13(9):921–8.  
89.  Huang C, Somwar R, Patel N, Niu W, Török D, Klip A. Sustained Exposure of L6 Myotubes 
to High Glucose and Insulin Decreases Insulin-Stimulated GLUT4 Translocation but 
Upregulates GLUT4 Activity. Diabetes. 2002 Jul 1;51(7):2090–8.  
90.  Salven P, Teerenhovi L, Joensuu H. A High Pretreatment Serum Basic Fibroblast Growth 
Factor Concentration Is an Independent Predictor of Poor Prognosis in Non-Hodgkin’s 
Lymphoma. Blood. 1999 Nov 15;94(10):3334–9.  
91.  Flisiak I, Szterling-Jaworowska M, Baran A, Rogalska-Taranta M. Effect of psoriasis activity 
on epidermal growth factor (EGF) and the concentration of soluble EGF receptor in serum 
and plaque scales. Clin Exp Dermatol. 2014 Jun;39(4):461–7.  
92.  Dos Santos L, Cyrino ES, Antunes M, Santos DA, Sardinha LB. Sarcopenia and physical 
independence in older adults: the independent and synergic role of muscle mass and 
muscle function. J Cachexia Sarcopenia Muscle. 2016 Nov 8;  
93.  Visser M, Goodpaster BH, Kritchevsky SB, Newman AB, Nevitt M, Rubin SM, et al. Muscle 
211 
 
mass, muscle strength, and muscle fat infiltration as predictors of incident mobility 
limitations in well-functioning older persons. J Gerontol A Biol Sci Med Sci. 2005 
Mar;60(3):324–33.  
94.  Hasegawa R, Islam MM, Lee SC, Koizumi D, Rogers ME, Takeshima N. Threshold of lower 
body muscular strength necessary to perform ADL independently in community-dwelling 
older adults. Clin Rehabil. 2008 Nov;22(10–11):902–10.  
95.  Cawthon PM, Blackwell TL, Cauley J, Kado DM, Barrett-Connor E, Lee CG, et al. 
Evaluation of the Usefulness of Consensus Definitions of Sarcopenia in Older Men: Results 
from the Observational Osteoporotic Fractures in Men Cohort Study. J Am Geriatr Soc. 
2015 Nov;63(11):2247–59.  
96.  Chalhoub D, Cawthon PM, Ensrud KE, Stefanick ML, Kado DM, Boudreau R, et al. Risk of 
Nonspine Fractures in Older Adults with Sarcopenia, Low Bone Mass, or Both. J Am 
Geriatr Soc. 2015 Sep;63(9):1733–40.  
97.  Jang HC. Sarcopenia, Frailty, and Diabetes in Older Adults. Diabetes Metab J. 2016 
Jun;40(3):182–9.  
98.  Lee SY, Ro HJ, Chung SG, Kang SH, Seo KM, Kim D-K. Low Skeletal Muscle Mass in the 
Lower Limbs Is Independently Associated to Knee Osteoarthritis. PLOS ONE. 2016 Nov 
10;11(11):e0166385.  
99.  Maeda K, Akagi J. Cognitive impairment is independently associated with definitive and 
possible sarcopenia in hospitalized older adults: The prevalence and impact of 
comorbidities. Geriatr Gerontol Int. 2016 Jun 7;  
100.  Tan BHL, Birdsell LA, Martin L, Baracos VE, Fearon KCH. Sarcopenia in an overweight or 
obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res Off J 
Am Assoc Cancer Res. 2009 Nov 15;15(22):6973–9.  
101.  Collins J, Noble S, Chester J, Coles B, Byrne A. The assessment and impact of sarcopenia 
in lung cancer: a systematic literature review. BMJ Open. 2014 Jan 1;4(1):e003697.  
102.  Sheetz KH, Waits SA, Terjimanian MN, Sullivan J, Campbell DA, Wang SC, et al. Cost of 
major surgery in the sarcopenic patient. J Am Coll Surg. 2013 Nov;217(5):813–8.  
103.  Englesbe MJ, Patel SP, He K, Lynch RJ, Schaubel DE, Harbaugh C, et al. Sarcopenia and 
mortality after liver transplantation. J Am Coll Surg. 2010 Aug;211(2):271–8.  
104.  Lexell J. Human aging, muscle mass, and fiber type composition. J Gerontol A Biol Sci Med 
Sci. 1995 Nov;50 Spec No:11–6.  
105.  Lexell J, Taylor CC. Variability in muscle fibre areas in whole human quadriceps muscle: 
effects of increasing age. J Anat. 1991 Feb;174:239–49.  
106.  Jakobsson F, Borg K, Edström L. Fibre-type composition, structure and cytoskeletal protein 
location of fibres in anterior tibial muscle. Acta Neuropathol (Berl). 80(5):459–68.  
212 
 
107.  Monemi M, Eriksson PO, Eriksson A, Thornell LE. Adverse changes in fibre type 
composition of the human masseter versus biceps brachii muscle during aging. J Neurol 
Sci. 1998 Jan 21;154(1):35–48.  
108.  Grimby G, Saltin B. The ageing muscle. Clin Physiol. 1983 Jun 1;3(3):209–18.  
109.  Sato T, Tauchi H. Age changes in human vocal muscle. Mech Ageing Dev. 1982 
Jan;18(1):67–74.  
110.  Sato T, Akatsuka H, Kito K, Tokoro Y, Tauchi H, Kato K. Age changes in size and number of 
muscle fibers in human minor pectoral muscle. Mech Ageing Dev. 1984 Nov;28(1):99–109.  
111.  Lexell J, Taylor CC, Sjöström M. What is the cause of the ageing atrophy? Total number, 
size and proportion of different fiber types studied in whole vastus lateralis muscle from 15- 
to 83-year-old men. J Neurol Sci. 1988 Apr;84(2–3):275–94.  
112.  Lexell J, Downham D. What determines the muscle cross-sectional area? J Neurol Sci. 
1992 Aug;111(1):113–4.  
113.  Tomlinson BE, Irving D. The numbers of limb motor neurons in the human lumbosacral cord 
throughout life. J Neurol Sci. 1977 Nov;34(2):213–9.  
114.  Larsson L, Li X, Frontera WR. Effects of aging on shortening velocity and myosin isoform 
composition in single human skeletal muscle cells. Am J Physiol. 1997 Feb;272(2 Pt 
1):C638-649.  
115.  D’Antona G, Pellegrino MA, Adami R, Rossi R, Carlizzi CN, Canepari M, et al. The effect of 
ageing and immobilization on structure and function of human skeletal muscle fibres. J 
Physiol. 2003 Oct 15;552(Pt 2):499–511.  
116.  Frontera WR, Suh D, Krivickas LS, Hughes VA, Goldstein R, Roubenoff R. Skeletal muscle 
fiber quality in older men and women. Am J Physiol Cell Physiol. 2000 Sep;279(3):C611-
618.  
117.  Trappe S, Gallagher P, Harber M, Carrithers J, Fluckey J, Trappe T. Single muscle fibre 
contractile properties in young and old men and women. J Physiol. 2003 Oct 1;552(Pt 
1):47–58.  
118.  Parente V, D’Antona G, Adami R, Miotti D, Capodaglio P, De Vito G, et al. Long-term 
resistance training improves force and unloaded shortening velocity of single muscle fibres 
of elderly women. Eur J Appl Physiol. 2008 Nov;104(5):885–93.  
119.  Höök P, Sriramoju V, Larsson L. Effects of aging on actin sliding speed on myosin from 
single skeletal muscle cells of mice, rats, and humans. Am J Physiol Cell Physiol. 2001 
Apr;280(4):C782-788.  
120.  Addison O, Drummond MJ, LaStayo PC, Dibble LE, Wende AR, McClain DA, et al. 
Intramuscular fat and inflammation differ in older adults: the impact of frailty and inactivity. J 
Nutr Health Aging. 2014 May;18(5):532–8.  
213 
 
121.  Visser M, Kritchevsky SB, Goodpaster BH, Newman AB, Nevitt M, Stamm E, et al. Leg 
muscle mass and composition in relation to lower extremity performance in men and 
women aged 70 to 79: the health, aging and body composition study. J Am Geriatr Soc. 
2002 May;50(5):897–904.  
122.  Marcus RL, Addison O, Dibble LE, Foreman KB, Morrell G, Lastayo P. Intramuscular 
adipose tissue, sarcopenia, and mobility function in older individuals. J Aging Res. 
2012;2012:629637.  
123.  Rahemi H, Nigam N, Wakeling JM. The effect of intramuscular fat on skeletal muscle 
mechanics: implications for the elderly and obese. J R Soc Interface R Soc. 2015 Aug 
6;12(109):20150365.  
124.  McLester J, Pierre PS. Applied Biomechanics: Concepts and Connections. Cengage 
Learning; 2007. 433 p.  
125.  Suetta C, Hvid LG, Justesen L, Christensen U, Neergaard K, Simonsen L, et al. Effects of 
aging on human skeletal muscle after immobilization and retraining. J Appl Physiol 
Bethesda Md 1985. 2009 Oct;107(4):1172–80.  
126.  Narici MV, Flueck M, Koesters A, Gimpl M, Reifberger A, Seynnes OR, et al. Skeletal 
muscle remodeling in response to alpine skiing training in older individuals. Scand J Med 
Sci Sports. 2011 Aug;21 Suppl 1:23–8.  
127.  Rastelli F, Capodaglio P, Orgiu S, Santovito C, Caramenti M, Cadioli M, et al. Effects of 
muscle composition and architecture on specific strength in obese older women. Exp 
Physiol. 2015 Oct;100(10):1159–67.  
128.  Mauro A. Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol. 1961 Feb;9:493–
5.  
129.  Yablonka-Reuveni Z. The Skeletal Muscle Satellite Cell. J Histochem Cytochem. 2011 
Dec;59(12):1041–59.  
130.  Seale P, Sabourin LA, Girgis-Gabardo A, Mansouri A, Gruss P, Rudnicki MA. Pax7 is 
required for the specification of myogenic satellite cells. Cell. 2000 Sep 15;102(6):777–86.  
131.  Seale P, Ishibashi J, Scimè A, Rudnicki MA. Pax7 is necessary and sufficient for the 
myogenic specification of CD45+:Sca1+ stem cells from injured muscle. PLoS Biol. 2004 
May;2(5):E130.  
132.  Relaix F, Montarras D, Zaffran S, Gayraud-Morel B, Rocancourt D, Tajbakhsh S, et al. Pax3 
and Pax7 have distinct and overlapping functions in adult muscle progenitor cells. J Cell 
Biol. 2006 Jan 2;172(1):91–102.  
133.  Fry CS, Lee JD, Jackson JR, Kirby TJ, Stasko SA, Liu H, et al. Regulation of the muscle 
fiber microenvironment by activated satellite cells during hypertrophy. FASEB J Off Publ 
Fed Am Soc Exp Biol. 2014 Apr;28(4):1654–65.  
214 
 
134.  McCarthy JJ, Mula J, Miyazaki M, Erfani R, Garrison K, Farooqui AB, et al. Effective fiber 
hypertrophy in satellite cell-depleted skeletal muscle. Dev Camb Engl. 2011 
Sep;138(17):3657–66.  
135.  Pawlikowski B, Pulliam C, Betta ND, Kardon G, Olwin BB. Pervasive satellite cell 
contribution to uninjured adult muscle fibers. Skelet Muscle. 2015;5:42.  
136.  Cristea A, Qaisar R, Edlund PK, Lindblad J, Bengtsson E, Larsson L. Effects of aging and 
gender on the spatial organization of nuclei in single human skeletal muscle cells. Aging 
Cell. 2010 Oct;9(5):685–97.  
137.  Murphy MM, Lawson JA, Mathew SJ, Hutcheson DA, Kardon G. Satellite cells, connective 
tissue fibroblasts and their interactions are crucial for muscle regeneration. Dev Camb 
Engl. 2011 Sep;138(17):3625–37.  
138.  Sambasivan R, Yao R, Kissenpfennig A, Van Wittenberghe L, Paldi A, Gayraud-Morel B, et 
al. Pax7-expressing satellite cells are indispensable for adult skeletal muscle regeneration. 
Dev Camb Engl. 2011 Sep;138(17):3647–56.  
139.  Oustanina S, Hause G, Braun T. Pax7 directs postnatal renewal and propagation of 
myogenic satellite cells but not their specification. EMBO J. 2004 Aug 18;23(16):3430–9.  
140.  Verdijk LB, Koopman R, Schaart G, Meijer K, Savelberg HHCM, van Loon LJC. Satellite 
cell content is specifically reduced in type II skeletal muscle fibers in the elderly. Am J 
Physiol Endocrinol Metab. 2007 Jan;292(1):E151-157.  
141.  Verdijk LB, Dirks ML, Snijders T, Prompers JJ, Beelen M, Jonkers RAM, et al. Reduced 
satellite cell numbers with spinal cord injury and aging in humans. Med Sci Sports Exerc. 
2012 Dec;44(12):2322–30.  
142.  Verdijk LB, Snijders T, Drost M, Delhaas T, Kadi F, van Loon LJC. Satellite cells in human 
skeletal muscle; from birth to old age. Age Dordr Neth. 2014 Apr;36(2):545–7.  
143.  Zwetsloot KA, Childs TE, Gilpin LT, Booth FW. Non-passaged muscle precursor cells from 
32-month old rat skeletal muscle have delayed proliferation and differentiation. Cell Prolif. 
2013 Feb;46(1):45–57.  
144.  Velleman SG, Zhang X, Coy CS, Song Y, McFarland DC. Changes in satellite cell 
proliferation and differentiation during turkey muscle development. Poult Sci. 2010 
Apr;89(4):709–15.  
145.  Harthan LB, McFarland DC, Velleman SG. Changes in proliferation, differentiation, 
fibroblast growth factor 2 responsiveness and expression of syndecan-4 and glypican-1 
with turkey satellite cell age. Dev Growth Differ. 2013 Jun;55(5):622–34.  
146.  Alsharidah M, Lazarus NR, George TE, Agley CC, Velloso CP, Harridge SDR. Primary 
human muscle precursor cells obtained from young and old donors produce similar 




147.  George T, Velloso CP, Alsharidah M, Lazarus NR, Harridge SDR. Sera from young and 
older humans equally sustain proliferation and differentiation of human myoblasts. Exp 
Gerontol. 2010 Nov;45(11):875–81.  
148.  Barberi L, Scicchitano BM, De Rossi M, Bigot A, Duguez S, Wielgosik A, et al. Age-
dependent alteration in muscle regeneration: the critical role of tissue niche. 
Biogerontology. 2013 Jun;14(3):273–92.  
149.  Jackson JR, Mula J, Kirby TJ, Fry CS, Lee JD, Ubele MF, et al. Satellite cell depletion does 
not inhibit adult skeletal muscle regrowth following unloading-induced atrophy. Am J Physiol 
Cell Physiol. 2012 Oct 15;303(8):C854-861.  
150.  Bentzinger CF, Wang YX, Rudnicki MA. Building Muscle: Molecular Regulation of 
Myogenesis. Cold Spring Harb Perspect Biol. 2012 Feb 1;4(2):a008342.  
151.  Minet AD, Gaster M. Cultured senescent myoblasts derived from human vastus lateralis 
exhibit normal mitochondrial ATP synthesis capacities with correlating concomitant ROS 
production while whole cell ATP production is decreased. Biogerontology. 2012 
Jun;13(3):277–85.  
152.  Alway SE, Myers MJ, Mohamed JS. Regulation of satellite cell function in sarcopenia. Front 
Aging Neurosci. 2014;6:246.  
153.  Fulle S, Di Donna S, Puglielli C, Pietrangelo T, Beccafico S, Bellomo R, et al. Age-
dependent imbalance of the antioxidative system in human satellite cells. Exp Gerontol. 
2005 Mar;40(3):189–97.  
154.  Snijders T, Wall BT, Dirks ML, Senden JMG, Hartgens F, Dolmans J, et al. Muscle disuse 
atrophy is not accompanied by changes in skeletal muscle satellite cell content. Clin Sci 
Lond Engl 1979. 2014 Apr;126(8):557–66.  
155.  Snijders T, Verdijk LB, Smeets JSJ, McKay BR, Senden JMG, Hartgens F, et al. The 
skeletal muscle satellite cell response to a single bout of resistance-type exercise is 
delayed with aging in men. Age Dordr Neth. 2014;36(4):9699.  
156.  Nederveen JP, Joanisse S, Séguin CML, Bell KE, Baker SK, Phillips SM, et al. The effect of 
exercise mode on the acute response of satellite cells in old men. Acta Physiol Oxf Engl. 
2015 Dec;215(4):177–90.  
157.  McKenzie AI, D’Lugos AC, Saunders MJ, Gworek KD, Luden ND. Fiber Type-Specific 
Satellite Cell Content in Cyclists Following Heavy Training with Carbohydrate and 
Carbohydrate-Protein Supplementation. Front Physiol. 2016;7:550.  
158.  Hoedt A, Christensen B, Nellemann B, Mikkelsen UR, Hansen M, Schjerling P, et al. 
Satellite cell response to erythropoietin treatment and endurance training in healthy young 
men. J Physiol. 2016 Feb 1;594(3):727–43.  
159.  Mackey AL, Karlsen A, Couppé C, Mikkelsen UR, Nielsen RH, Magnusson SP, et al. 
Differential satellite cell density of type I and II fibres with lifelong endurance running in old 
216 
 
men. Acta Physiol Oxf Engl. 2014 Mar;210(3):612–27.  
160.  Hepple RT. Impact of aging on mitochondrial function in cardiac and skeletal muscle. Free 
Radic Biol Med. 2016 Sep;98:177–86.  
161.  Rygiel KA, Picard M, Turnbull DM. The ageing neuromuscular system and sarcopenia: a 
mitochondrial perspective. J Physiol. 2016 Aug 15;594(16):4499–512.  
162.  St-Jean-Pelletier F, Pion CH, Leduc-Gaudet J-P, Sgarioto N, Zovilé I, Barbat-Artigas S, et 
al. The impact of ageing, physical activity, and pre-frailty on skeletal muscle phenotype, 
mitochondrial content, and intramyocellular lipids in men. J Cachexia Sarcopenia Muscle. 
2016 Sep 2;  
163.  Cobley JN, Bartlett JD, Kayani A, Murray SW, Louhelainen J, Donovan T, et al. PGC-1α 
transcriptional response and mitochondrial adaptation to acute exercise is maintained in 
skeletal muscle of sedentary elderly males. Biogerontology. 2012 Dec;13(6):621–31.  
164.  Trappe S, Hayes E, Galpin A, Kaminsky L, Jemiolo B, Fink W, et al. New records in aerobic 
power among octogenarian lifelong endurance athletes. J Appl Physiol Bethesda Md 1985. 
2013 Jan 1;114(1):3–10.  
165.  Brierley EJ, Johnson MA, James OF, Turnbull DM. Effects of physical activity and age on 
mitochondrial function. QJM Mon J Assoc Physicians. 1996 Apr;89(4):251–8.  
166.  Bua E, Johnson J, Herbst A, Delong B, McKenzie D, Salamat S, et al. Mitochondrial DNA–
Deletion Mutations Accumulate Intracellularly to Detrimental Levels in Aged Human 
Skeletal Muscle Fibers. Am J Hum Genet. 2006 Sep;79(3):469–80.  
167.  Diaz F, Thomas CK, Garcia S, Hernandez D, Moraes CT. Mice lacking COX10 in skeletal 
muscle recapitulate the phenotype of progressive mitochondrial myopathies associated 
with cytochrome c oxidase deficiency. Hum Mol Genet. 2005 Sep 15;14(18):2737–48.  
168.  Chabi B, Ljubicic V, Menzies KJ, Huang JH, Saleem A, Hood DA. Mitochondrial function 
and apoptotic susceptibility in aging skeletal muscle. Aging Cell. 2008 Jan;7(1):2–12.  
169.  Capel F, Buffière C, Patureau Mirand P, Mosoni L. Differential variation of mitochondrial 
H2O2 release during aging in oxidative and glycolytic muscles in rats. Mech Ageing Dev. 
2004 May;125(5):367–73.  
170.  Mansouri A, Muller FL, Liu Y, Ng R, Faulkner J, Hamilton M, et al. Alterations in 
mitochondrial function, hydrogen peroxide release and oxidative damage in mouse hind-
limb skeletal muscle during aging. Mech Ageing Dev. 2006 Mar;127(3):298–306.  
171.  Picard M, Ritchie D, Wright KJ, Romestaing C, Thomas MM, Rowan SL, et al. 
Mitochondrial functional impairment with aging is exaggerated in isolated mitochondria 
compared to permeabilized myofibers. Aging Cell. 2010 Dec;9(6):1032–46.  
172.  Picard M, Ritchie D, Thomas MM, Wright KJ, Hepple RT. Alterations in intrinsic 
mitochondrial function with aging are fiber type-specific and do not explain differential 
217 
 
atrophy between muscles. Aging Cell. 2011 Dec;10(6):1047–55.  
173.  Spendiff S, Vuda M, Gouspillou G, Aare S, Perez A, Morais JA, et al. Denervation drives 
mitochondrial dysfunction in skeletal muscle of octogenarians. J Physiol. 2016 Dec 
15;594(24):7361–79.  
174.  Gouspillou G, Sgarioto N, Kapchinsky S, Purves-Smith F, Norris B, Pion CH, et al. 
Increased sensitivity to mitochondrial permeability transition and myonuclear translocation 
of endonuclease G in atrophied muscle of physically active older humans. FASEB J Off 
Publ Fed Am Soc Exp Biol. 2014 Apr;28(4):1621–33.  
175.  Marzetti E, Privitera G, Simili V, Wohlgemuth SE, Aulisa L, Pahor M, et al. Multiple 
pathways to the same end: mechanisms of myonuclear apoptosis in sarcopenia of aging. 
ScientificWorldJournal. 2010 Feb 19;10:340–9.  
176.  Sun N, Youle RJ, Finkel T. The Mitochondrial Basis of Aging. Mol Cell. 2016 Mar 
3;61(5):654–66.  
177.  Luff AR. Age-associated changes in the innervation of muscle fibers and changes in the 
mechanical properties of motor units. Ann N Y Acad Sci. 1998 Nov 20;854:92–101.  
178.  Piasecki M, Ireland A, Jones DA, McPhee JS. Age-dependent motor unit remodelling in 
human limb muscles. Biogerontology. 2016 Jun;17(3):485–96.  
179.  Piasecki M, Ireland A, Coulson J, Stashuk DW, Hamilton-Wright A, Swiecicka A, et al. Motor 
unit number estimates and neuromuscular transmission in the tibialis anterior of master 
athletes: evidence that athletic older people are not spared from age-related motor unit 
remodeling. Physiol Rep. 2016 Oct;4(19).  
180.  Rygiel KA, Grady JP, Turnbull DM. Respiratory chain deficiency in aged spinal motor 
neurons. Neurobiol Aging. 2014 Oct;35(10):2230–8.  
181.  García ML, Fernández A, Solas MT. Mitochondria, motor neurons and aging. J Neurol Sci. 
2013 Jul 15;330(1):18–26.  
182.  Vos M, Lauwers E, Verstreken P. Synaptic mitochondria in synaptic transmission and 
organization of vesicle pools in health and disease. Front Synaptic Neurosci. 2010;2:139.  
183.  Rudolf R, Khan MM, Labeit S, Deschenes MR. Degeneration of neuromuscular junction in 
age and dystrophy. Front Aging Neurosci. 2014;6:99.  
184.  Deschenes MR, Roby MA, Eason MK, Harris MB. Remodeling of the neuromuscular 
junction precedes sarcopenia related alterations in myofibers. Exp Gerontol. 2010 
May;45(5):389–93.  
185.  Gonzalez-Freire M, de Cabo R, Studenski SA, Ferrucci L. The Neuromuscular Junction: 
Aging at the Crossroad between Nerves and Muscle. Front Aging Neurosci [Internet]. 2014 




186.  Hamer M, Kivimaki M, Steptoe A. Longitudinal patterns in physical activity and sedentary 
behaviour from mid-life to early old age: a substudy of the Whitehall II cohort. J Epidemiol 
Community Health. 2012 Dec;66(12):1110–5.  
187.  Hagströmer M, Kwak L, Oja P, Sjöström M. A 6 year longitudinal study of accelerometer-
measured physical activity and sedentary time in Swedish adults. J Sci Med Sport Sports 
Med Aust. 2014 Aug 5;  
188.  Kim S-H, Kim T-H, Hwang H-J. The relationship of physical activity (PA) and walking with 
sarcopenia in Korean males aged 60 years and older using the Fourth Korean National 
Health and Nutrition Examination Survey (KNHANES IV-2, 3), 2008–2009. Arch Gerontol 
Geriatr. 2013 May;56(3):472–7.  
189.  Crane JD, MacNeil LG, Tarnopolsky MA. Long-term Aerobic Exercise Is Associated With 
Greater Muscle Strength Throughout the Life Span. J Gerontol A Biol Sci Med Sci. 2013 
Jun 1;68(6):631–8.  
190.  Harridge S, Magnusson G, Saltin B. Life-long endurance-trained elderly men have high 
aerobic power, but have similar muscle strength to non-active elderly men. Aging Milan 
Italy. 1997 Apr;9(1–2):80–7.  
191.  Klitgaard H, Mantoni M, Schiaffino S, Ausoni S, Gorza L, Laurent-Winter C, et al. Function, 
morphology and protein expression of ageing skeletal muscle: a cross-sectional study of 
elderly men with different training backgrounds. Acta Physiol Scand. 1990 Sep;140(1):41–
54.  
192.  Alway SE, Coggan AR, Sproul MS, Abduljalil AM, Robitaille PM. Muscle torque in young 
and older untrained and endurance-trained men. J Gerontol A Biol Sci Med Sci. 1996 
May;51(3):B195-201.  
193.  Trappe S, Harber M, Creer A, Gallagher P, Slivka D, Minchev K, et al. Single muscle fiber 
adaptations with marathon training. J Appl Physiol Bethesda Md 1985. 2006 
Sep;101(3):721–7.  
194.  Iglay HB, Thyfault JP, Apolzan JW, Campbell WW. Resistance training and dietary protein: 
effects on glucose tolerance and contents of skeletal muscle insulin signaling proteins in 
older persons. Am J Clin Nutr. 2007 Apr;85(4):1005–13.  
195.  Pennings B, Groen B, de Lange A, Gijsen AP, Zorenc AH, Senden JMG, et al. Amino acid 
absorption and subsequent muscle protein accretion following graded intakes of whey 
protein in elderly men. Am J Physiol Endocrinol Metab. 2012 Apr 15;302(8):E992-999.  
196.  Katsanos CS, Kobayashi H, Sheffield-Moore M, Aarsland A, Wolfe RR. Aging is associated 
with diminished accretion of muscle proteins after the ingestion of a small bolus of essential 
amino acids. Am J Clin Nutr. 2005 Nov;82(5):1065–73.  
197.  Yang Y, Breen L, Burd NA, Hector AJ, Churchward-Venne TA, Josse AR, et al. Resistance 
exercise enhances myofibrillar protein synthesis with graded intakes of whey protein in 
older men. Br J Nutr. 2012 Nov 28;108(10):1780–8.  
219 
 
198.  Chernoff R. Micronutrient requirements in older women. Am J Clin Nutr. 2005 May 
1;81(5):1240S–1245S.  
199.  Brotto M, Abreu EL. Sarcopenia: Pharmacology of Today and Tomorrow. J Pharmacol Exp 
Ther. 2012 Dec;343(3):540–6.  
200.  Kyle UG, Gremion G, Genton L, Slosman DO, Golay A, Pichard C. Physical activity and fat-
free and fat mass by bioelectrical impedance in 3853 adults. Med Sci Sports Exerc. 2001 
Apr;33(4):576–84.  
201.  Carnac G, Vernus B, Bonnieu A. Myostatin in the Pathophysiology of Skeletal Muscle. Curr 
Genomics. 2007 Nov;8(7):415–22.  
202.  Kilsby AJ, Sayer AA, Witham MD. Selecting Potential Pharmacological Interventions in 
Sarcopenia. Drugs Aging. 2017 Feb 28;  
203.  Becker C, Lord SR, Studenski SA, Warden SJ, Fielding RA, Recknor CP, et al. Myostatin 
antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial. 
Lancet Diabetes Endocrinol. 2015 Dec;3(12):948–57.  
204.  Allen NE, Appleby PN, Kaaks R, Rinaldi S, Davey GK, Key TJ. Lifestyle determinants of 
serum insulin-like growth-factor-I (IGF-I), C-peptide and hormone binding protein levels in 
British women. Cancer Causes Control CCC. 2003 Feb;14(1):65–74.  
205.  Papadakis MA, Grady D, Black D, Tierney MJ, Gooding GA, Schambelan M, et al. Growth 
hormone replacement in healthy older men improves body composition but not functional 
ability. Ann Intern Med. 1996 Apr 15;124(8):708–16.  
206.  Franco C, Brandberg J, Lönn L, Andersson B, Bengtsson B-A, Johannsson G. Growth 
hormone treatment reduces abdominal visceral fat in postmenopausal women with 
abdominal obesity: a 12-month placebo-controlled trial. J Clin Endocrinol Metab. 2005 
Mar;90(3):1466–74.  
207.  Gilden D. Human growth hormone available for AIDS wasting. GMHC Treat Issues Gay 
Mens Health Crisis Newsl Exp AIDS Ther. 1995 Jan;9(1):9–11.  
208.  Samaras N, Papadopoulou M-A, Samaras D, Ongaro F. Off-label use of hormones as an 
antiaging strategy: a review. Clin Interv Aging. 2014;9:1175–86.  
209.  Mitchell R, Hollis S, Rothwell C, Robertson WR. Age related changes in the pituitary-
testicular axis in normal men; lower serum testosterone results from decreased bioactive 
LH drive. Clin Endocrinol (Oxf). 1995 May;42(5):501–7.  
210.  Morley JE, Kaiser FE, Perry HM, Patrick P, Morley PM, Stauber PM, et al. Longitudinal 
changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy 
older men. Metabolism. 1997 Apr;46(4):410–3.  
211.  Morley JE, Perry HM, Kaiser FE, Kraenzle D, Jensen J, Houston K, et al. Effects of 
testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am 
220 
 
Geriatr Soc. 1993 Feb;41(2):149–52.  
212.  Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE. Oral testosterone 
supplementation increases muscle and decreases fat mass in healthy elderly males with 
low-normal gonadal status. J Gerontol A Biol Sci Med Sci. 2003 Jul;58(7):618–25.  
213.  Page ST, Amory JK, Bowman FD, Anawalt BD, Matsumoto AM, Bremner WJ, et al. 
Exogenous testosterone (T) alone or with finasteride increases physical performance, grip 
strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005 
Mar;90(3):1502–10.  
214.  Morgentaler A, Miner MM, Caliber M, Guay AT, Khera M, Traish AM. Testosterone therapy 
and cardiovascular risk: advances and controversies. Mayo Clin Proc. 2015 
Feb;90(2):224–51.  
215.  Pierorazio PM, Ferrucci L, Kettermann A, Longo DL, Metter EJ, Carter HB. Serum 
testosterone is associated with aggressive prostate cancer in older men: results from the 
Baltimore Longitudinal Study of Aging. BJU Int. 2010 Mar;105(6):824–9.  
216.  Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam AW, Allen NE, 
Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative 
analysis of 18 prospective studies. J Natl Cancer Inst. 2008 Feb 6;100(3):170–83.  
217.  Travis RC, Key TJ, Allen NE, Appleby PN, Roddam AW, Rinaldi S, et al. Serum androgens 
and prostate cancer among 643 cases and 643 controls in the European Prospective 
Investigation into Cancer and Nutrition. Int J Cancer. 2007 Sep 15;121(6):1331–8.  
218.  Drinka PJ, Jochen AL, Cuisinier M, Bloom R, Rudman I, Rudman D. Polycythemia as a 
Complication of Testosterone Replacement Therapy in Nursing Home Men with Low 
Testosterone Levels. J Am Geriatr Soc. 1995 Aug 1;43(8):899–901.  
219.  Basaria S, Collins L, Dillon EL, Orwoll K, Storer TW, Miciek R, et al. The safety, 
pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen 
receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2013 
Jan;68(1):87–95.  
220.  Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, et al. Effects of 
enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, 
randomised controlled phase 2 trial. Lancet Oncol. 2013 Apr;14(4):335–45.  
221.  Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST, et al. The 
selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass 
and physical function in healthy elderly men and postmenopausal women: results of a 
double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011 
Sep;2(3):153–61.  
222.  Roubenoff R. Sarcopenic Obesity: Does Muscle Loss Cause Fat Gain?: Lessons from 
Rheumatoid Arthritis and Osteoarthritisa. Ann N Y Acad Sci. 2000 May 1;904(1):553–7.  
221 
 
223.  Alfonzo-González G, Doucet E, Bouchard C, Tremblay A. Greater than predicted decrease 
in resting energy expenditure with age: cross-sectional and longitudinal evidence. Eur J 
Clin Nutr. 2006 Jan;60(1):18–24.  
224.  Bosy-Westphal A, Eichhorn C, Kutzner D, Illner K, Heller M, Müller MJ. The age-related 
decline in resting energy expenditure in humans is due to the loss of fat-free mass and to 
alterations in its metabolically active components. J Nutr. 2003 Jul;133(7):2356–62.  
225.  Ravussin E, Lillioja S, Knowler WC, Christin L, Freymond D, Abbott WGH, et al. Reduced 
Rate of Energy Expenditure as a Risk Factor for Body-Weight Gain. N Engl J Med. 1988 
Feb 25;318(8):467–72.  
226.  Tataranni PA, Harper IT, Snitker S, Parigi AD, Vozarova B, Bunt J, et al. Body weight gain in 
free-living Pima Indians: effect of energy intake vs expenditure. Int J Obes. 2003 Sep 
16;27(12):1578–83.  
227.  Weyer C, Snitker S, Bogardus C, Ravussin E. Energy metabolism in African Americans: 
potential risk factors for obesity. Am J Clin Nutr. 1999 Jul 1;70(1):13–20.  
228.  Westerterp KR. Daily physical activity and ageing. Curr Opin Clin Nutr Metab Care. 2000 
Nov;3(6):485–8.  
229.  Sethi JK, Vidal-Puig AJ. Thematic review series: Adipocyte Biology. Adipose tissue function 
and plasticity orchestrate nutritional adaptation. J Lipid Res. 2007 Jun 1;48(6):1253–62.  
230.  Pellegrinelli V, Carobbio S, Vidal-Puig A. Adipose tissue plasticity: how fat depots respond 
differently to pathophysiological cues. Diabetologia. 2016 Jun;59(6):1075–88.  
231.  Sacks H, Symonds ME. Anatomical Locations of Human Brown Adipose Tissue. Diabetes. 
2013 Jun 1;62(6):1783–90.  
232.  Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is 
associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003 
Dec;112(12):1796–808.  
233.  Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays 
a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003 
Dec;112(12):1821–30.  
234.  Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, et al. Reduction of 
macrophage infiltration and chemoattractant gene expression changes in white adipose 
tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes. 2005 
Aug;54(8):2277–86.  
235.  Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue 
macrophage polarization. J Clin Invest. 2007 Jan 2;117(1):175–84.  
236.  Fujisaka S, Usui I, Bukhari A, Ikutani M, Oya T, Kanatani Y, et al. Regulatory mechanisms 




237.  Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is 
associated with systemic inflammation in obese humans. Diabetes. 2007 Apr;56(4):1010–3.  
238.  Drolet R, Richard C, Sniderman AD, Mailloux J, Fortier M, Huot C, et al. Hypertrophy and 
hyperplasia of abdominal adipose tissues in women. Int J Obes. 2007 Aug 28;32(2):283–
91.  
239.  Joe AWB, Yi L, Even Y, Vogl AW, Rossi FMV. Depot-specific differences in adipogenic 
progenitor abundance and proliferative response to high-fat diet. Stem Cells Dayt Ohio. 
2009 Oct;27(10):2563–70.  
240.  Harman-Boehm I, Blüher M, Redel H, Sion-Vardy N, Ovadia S, Avinoach E, et al. 
Macrophage infiltration into omental versus subcutaneous fat across different populations: 
effect of regional adiposity and the comorbidities of obesity. J Clin Endocrinol Metab. 2007 
Jun;92(6):2240–7.  
241.  Chee C, Shannon CE, Burns A, Selby AL, Wilkinson D, Smith K, et al. Relative Contribution 
of Intramyocellular Lipid to Whole-Body Fat Oxidation Is Reduced With Age but 
Subsarcolemmal Lipid Accumulation and Insulin Resistance Are Only Associated With 
Overweight Individuals. Diabetes. 2016 Apr;65(4):840–50.  
242.  Anderson SR, Gilge DA, Steiber AL, Previs SF. Diet-induced obesity alters protein 
synthesis: tissue-specific effects in fasted versus fed mice. Metab - Clin Exp. 2008 Mar 
1;57(3):347–54.  
243.  Masgrau A, Mishellany-Dutour A, Murakami H, Beaufrère A-M, Walrand S, Giraudet C, et 
al. Time-course changes of muscle protein synthesis associated with obesity-induced 
lipotoxicity. J Physiol. 2012 Oct 1;590(20):5199–210.  
244.  Tardif N, Salles J, Guillet C, Tordjman J, Reggio S, Landrier J-F, et al. Muscle ectopic fat 
deposition contributes to anabolic resistance in obese sarcopenic old rats through eIF2α 
activation. Aging Cell. 2014 Dec 1;13(6):1001–11.  
245.  Stephens FB, Chee C, Wall BT, Murton AJ, Shannon CE, Loon LJC van, et al. Lipid-
Induced Insulin Resistance Is Associated With an Impaired Skeletal Muscle Protein 
Synthetic Response to Amino Acid Ingestion in Healthy Young Men. Diabetes. 2015 May 
1;64(5):1615–20.  
246.  Tremblay F, Marette A. Amino Acid and Insulin Signaling via the mTOR/p70 S6 Kinase 
Pathway A NEGATIVE FEEDBACK MECHANISM LEADING TO INSULIN RESISTANCE IN 
SKELETAL MUSCLE CELLS. J Biol Chem. 2001 Oct 12;276(41):38052–60.  
247.  Fujita S, Rasmussen BB, Cadenas JG, Grady JJ, Volpi E. Effect of insulin on human 
skeletal muscle protein synthesis is modulated by insulin-induced changes in muscle blood 




248.  Gallagher P, Richmond S, Dudley K, Prewitt M, Gandy N, Kudrna B, et al. Interaction of 
Resistance Exercise and BCAA Supplementation on Akt and p70 s6 kinase 
Phosphorylation in Human Skeletal Muscle. FASEB J. 2007 Apr 1;21(6):A1206–A1206.  
249.  Timmerman KL, Lee JL, Dreyer HC, Dhanani S, Glynn EL, Fry CS, et al. Insulin stimulates 
human skeletal muscle protein synthesis via an indirect mechanism involving endothelial-
dependent vasodilation and mammalian target of rapamycin complex 1 signaling. J Clin 
Endocrinol Metab. 2010 Aug;95(8):3848–57.  
250.  Volpi E, Mittendorfer B, Rasmussen BB, Wolfe RR. The response of muscle protein 
anabolism to combined hyperaminoacidemia and glucose-induced hyperinsulinemia is 
impaired in the elderly. J Clin Endocrinol Metab. 2000 Dec;85(12):4481–90.  
251.  Volpi E, Mittendorfer B, Wolf SE, Wolfe RR. Oral amino acids stimulate muscle protein 
anabolism in the elderly despite higher first-pass splanchnic extraction. Am J Physiol. 1999 
Sep;277(3 Pt 1):E513-520.  
252.  Paddon-Jones D, Sheffield-Moore M, Zhang X-J, Volpi E, Wolf SE, Aarsland A, et al. Amino 
acid ingestion improves muscle protein synthesis in the young and elderly. Am J Physiol 
Endocrinol Metab. 2004 Mar;286(3):E321-328.  
253.  Welle S, Thornton C, Statt M, McHenry B. Postprandial myofibrillar and whole body protein 
synthesis in young and old human subjects. Am J Physiol. 1994 Oct;267(4 Pt 1):E599-604.  
254.  Rasmussen BB, Fujita S, Wolfe RR, Mittendorfer B, Roy M, Rowe VL, et al. Insulin 
resistance of muscle protein metabolism in aging. FASEB J Off Publ Fed Am Soc Exp Biol. 
2006 Apr;20(6):768–9.  
255.  Guillet C, Zangarelli A, Gachon P, Morio B, Giraudet C, Rousset P, et al. Whole body 
protein breakdown is less inhibited by insulin, but still responsive to amino acid, in 
nondiabetic elderly subjects. J Clin Endocrinol Metab. 2004 Dec;89(12):6017–24.  
256.  Wilkes EA, Selby AL, Atherton PJ, Patel R, Rankin D, Smith K, et al. Blunting of insulin 
inhibition of proteolysis in legs of older subjects may contribute to age-related sarcopenia. 
Am J Clin Nutr. 2009 Nov;90(5):1343–50.  
257.  Tomlinson DJ, Erskine RM, Morse CI, Winwood K, Onambélé-Pearson G. The impact of 
obesity on skeletal muscle strength and structure through adolescence to old age. 
Biogerontology. 2016 Jun;17(3):467–83.  
258.  Yagi S, Kadota M, Aihara K, Nishikawa K, Hara T, Ise T, et al. Association of lower limb 
muscle mass and energy expenditure with visceral fat mass in healthy men. Diabetol 
Metab Syndr. 2014 Feb 26;6:27.  
259.  Kim TN, Park MS, Kim YJ, Lee EJ, Kim M-K, Kim JM, et al. Association of Low Muscle 
Mass and Combined Low Muscle Mass and Visceral Obesity with Low Cardiorespiratory 
Fitness. PLoS ONE. 2014 Jun 17;9(6):e100118.  
260.  Carpenter CL, Yan E, Chen S, Hong K, Arechiga A, Kim WS, et al. Body Fat and Body-
224 
 
Mass Index among a Multiethnic Sample of College-Age Men and Women. J Obes. 2013 
Apr 8;2013:e790654.  
261.  Morley JE, Thomas DR, Wilson M-MG. Cachexia: pathophysiology and clinical relevance. 
Am J Clin Nutr. 2006 Apr 1;83(4):735–43.  
262.  Carson JA, Baltgalvis KA. Interleukin-6 as a Key Regulator of Muscle Mass during 
Cachexia. Exerc Sport Sci Rev. 2010 Oct;38(4):168–76.  
263.  TAZAKI E, SHIMIZU N, TANAKA R, YOSHIZUMI M, KAMMA H, IMOTO S, et al. Serum 
cytokine profiles in patients with prostate carcinoma. Exp Ther Med. 2011;2(5):887–91.  
264.  Himmerich H, Fulda S, Linseisen J, Seiler H, Wolfram G, Himmerich S, et al. TNF-alpha, 
soluble TNF receptor and interleukin-6 plasma levels in the general population. Eur 
Cytokine Netw. 2006 Sep;17(3):196–201.  
265.  Cartier A, Côté M, Lemieux I, Pérusse L, Tremblay A, Bouchard C, et al. Age-related 
differences in inflammatory markers in men: contribution of visceral adiposity. Metabolism. 
2009 Oct;58(10):1452–8.  
266.  Serrano AL, Baeza-Raja B, Perdiguero E, Jardí M, Muñoz-Cánoves P. Interleukin-6 is an 
essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab. 2008 
Jan;7(1):33–44.  
267.  White JP, Reecy JM, Washington TA, Sato S, Le ME, Davis JM, et al. Overload-induced 
skeletal muscle extracellular matrix remodelling and myofibre growth in mice lacking IL-6. 
Acta Physiol Oxf Engl. 2009 Dec;197(4):321–32.  
268.  Washington TA, White JP, Davis JM, Wilson LB, Lowe LL, Sato S, et al. Skeletal muscle 
mass recovery from atrophy in IL-6 knockout mice. Acta Physiol Oxf Engl. 2011 
Aug;202(4):657–69.  
269.  Zhang C, Li Y, Wu Y, Wang L, Wang X, Du J. Interleukin-6/signal transducer and activator 
of transcription 3 (STAT3) pathway is essential for macrophage infiltration and myoblast 
proliferation during muscle regeneration. J Biol Chem. 2013 Jan 18;288(3):1489–99.  
270.  Tsujinaka T, Ebisui C, Fujita J, Kishibuchi M, Morimoto T, Ogawa A, et al. Muscle 
undergoes atrophy in association with increase of lysosomal cathepsin activity in 
interleukin-6 transgenic mouse. Biochem Biophys Res Commun. 1995 Feb 6;207(1):168–
74.  
271.  Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, Suzuki K, et al. Interleukin 6 receptor 
antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 
transgenic mice. J Clin Invest. 1996 Jan 1;97(1):244–9.  
272.  Pelosi M, De Rossi M, Barberi L, Musarò A. IL-6 impairs myogenic differentiation by 
downmodulation of p90RSK/eEF2 and mTOR/p70S6K axes, without affecting AKT activity. 
BioMed Res Int. 2014;2014:206026.  
225 
 
273.  Haddad F, Zaldivar F, Cooper DM, Adams GR. IL-6-induced skeletal muscle atrophy. J Appl 
Physiol Bethesda Md 1985. 2005 Mar;98(3):911–7.  
274.  Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-
alpha: direct role in obesity-linked insulin resistance. Science. 1993 Jan 1;259(5091):87–
91.  
275.  Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue 
expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin 
Invest. 1995 May;95(5):2409–15.  
276.  Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is 
associated with systemic inflammation in obese humans. Diabetes. 2007 Apr;56(4):1010–3.  
277.  Jorge ASB, Andrade JMO, Paraíso AF, Jorge GCB, Silveira CM, de Souza LR, et al. Body 
mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are 
associated with the morphological severity of non-alcoholic fatty liver disease in individuals 
with class III obesity. Obes Res Clin Pract. 2016 Apr 12;  
278.  Li Y-P, Chen Y, John J, Moylan J, Jin B, Mann DL, et al. TNF-alpha acts via p38 MAPK to 
stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J Off 
Publ Fed Am Soc Exp Biol. 2005 Mar;19(3):362–70.  
279.  García-Martínez C, Llovera M, Agell N, López-Soriano FJ, Argilés JM. Ubiquitin gene 
expression in skeletal muscle is increased by tumour necrosis factor-alpha. Biochem 
Biophys Res Commun. 1994 Jun 15;201(2):682–6.  
280.  García-Martínez C, Agell N, Llovera M, López-Soriano FJ, Argilés JM. Tumour necrosis 
factor-alpha increases the ubiquitinization of rat skeletal muscle proteins. FEBS Lett. 1993 
Jun 1;323(3):211–4.  
281.  Adams V, Mangner N, Gasch A, Krohne C, Gielen S, Hirner S, et al. Induction of MuRF1 is 
essential for TNF-alpha-induced loss of muscle function in mice. J Mol Biol. 2008 Dec 
5;384(1):48–59.  
282.  Chen S-E, Jin B, Li Y-P. TNF-α regulates myogenesis and muscle regeneration by 
activating p38 MAPK. Am J Physiol Cell Physiol. 2007 May;292(5):C1660–71.  
283.  Li Y-P. TNF-α is a mitogen in skeletal muscle. Am J Physiol - Cell Physiol. 2003 Aug 
1;285(2):C370–6.  
284.  Shah JP, Phillips TM, Danoff JV, Gerber LH. An in vivo microanalytical technique for 
measuring the local biochemical milieu of human skeletal muscle. J Appl Physiol Bethesda 
Md 1985. 2005 Nov;99(5):1977–84.  
285.  Christidis N, Ghafouri B, Larsson A, Palstam A, Mannerkorpi K, Bileviciute-Ljungar I, et al. 
Comparison of the Levels of Pro-Inflammatory Cytokines Released in the Vastus Lateralis 
Muscle of Patients with Fibromyalgia and Healthy Controls during Contractions of the 
Quadriceps Muscle--A Microdialysis Study. PloS One. 2015;10(12):e0143856.  
226 
 
286.  Pratt B. Using microdialysis to investigate the local skeletal muscle Inflammatory response 
to resistance exercise. [Internet] [MSc]. Appalachian State University; 2011. Available from: 
https://libres.uncg.edu/ir/asu/f/Pratt,%20Brian_2011_Thesis.pdf 
287.  Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, et al. Resistin / 
Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-
gamma action in humans. Diabetes. 2001 Oct;50(10):2199–202.  
288.  Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with 
potent proinflammatory properties. J Immunol Baltim Md 1950. 2005 May 1;174(9):5789–
95.  
289.  Vilarrasa N, Vendrell J, Maravall J, Broch M, Estepa A, Megia A, et al. Distribution and 
determinants of adiponectin, resistin and ghrelin in a randomly selected healthy population. 
Clin Endocrinol (Oxf). 2005 Sep 1;63(3):329–35.  
290.  Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A, et al. Correlation 
between serum resistin level and adiposity in obese individuals. Obes Res. 2003 
Aug;11(8):997–1001.  
291.  Bucci L, Yani SL, Fabbri C, Bijlsma AY, Maier AB, Meskers CG, et al. Circulating levels of 
adipokines and IGF-1 are associated with skeletal muscle strength of young and old 
healthy subjects. Biogerontology. 2013 Jun;14(3):261–72.  
292.  Sheng CH, Du ZW, Song Y, Wu XD, Zhang YC, Wu M, et al. Human resistin inhibits 
myogenic differentiation and induces insulin resistance in myocytes. BioMed Res Int. 
2013;2013:804632.  
293.  Ghosh S, Singh AK, Aruna B, Mukhopadhyay S, Ehtesham NZ. The genomic organization 
of mouse resistin reveals major differences from the human resistin: functional implications. 
Gene. 2003 Feb 13;305(1):27–34.  
294.  Upadhyay J, Farr OM, Mantzoros CS. The role of leptin in regulating bone metabolism. 
Metabolism. 2015 Jan;64(1):105–13.  
295.  Hamrick MW, Herberg S, Arounleut P, He H-Z, Shiver A, Qi R-Q, et al. The adipokine leptin 
increases skeletal muscle mass and significantly alters skeletal muscle miRNA expression 
profile in aged mice. Biochem Biophys Res Commun. 2010 Sep 24;400(3):379–83.  
296.  Hamrick MW, Pennington C, Newton D, Xie D, Isales C. Leptin deficiency produces 
contrasting phenotypes in bones of the limb and spine. Bone. 2004 Mar;34(3):376–83.  
297.  Fernández-Real JM, Vayreda M, Casamitjana R, Gonzalez-Huix F, Ricart W. The fat-free 
mass compartment influences serum leptin in men. Eur J Endocrinol Eur Fed Endocr Soc. 
2000 Jan;142(1):25–9.  
298.  Kohara K, Ochi M, Tabara Y, Nagai T, Igase M, Miki T. Leptin in Sarcopenic Visceral 
Obesity: Possible Link between Adipocytes and Myocytes. PLoS ONE [Internet]. 2011 Sep 




299.  Waters DL, Qualls CR, Dorin RI, Veldhuis JD, Baumgartner RN. Altered growth hormone, 
cortisol, and leptin secretion in healthy elderly persons with sarcopenia and mixed body 
composition phenotypes. J Gerontol A Biol Sci Med Sci. 2008 May;63(5):536–41.  
300.  Hubbard RE, O’Mahony MS, Calver BL, Woodhouse KW. Nutrition, inflammation, and leptin 
levels in aging and frailty. J Am Geriatr Soc. 2008 Feb;56(2):279–84.  
301.  Tilg H, Moschen AR. Role of adiponectin and PBEF/visfatin as regulators of inflammation: 
involvement in obesity-associated diseases. Clin Sci Lond Engl 1979. 2008 
Feb;114(4):275–88.  
302.  Jurdana M, Petelin A, Černelič Bizjak M, Bizjak M, Biolo G, Jenko-Pražnikar Z. Increased 
serum visfatin levels in obesity and its association with anthropometric/biochemical 
parameters, physical inactivity and nutrition. E-SPEN J. 2013 Apr;8(2):e59–67.  
303.  Sandeep S, Velmurugan K, Deepa R, Mohan V. Serum visfatin in relation to visceral fat, 
obesity, and type 2 diabetes mellitus in Asian Indians. Metabolism. 2007 Apr;56(4):565–70.  
304.  Martos-Moreno GÁ, Kratzsch J, Körner A, Barrios V, Hawkins F, Kiess W, et al. Serum 
visfatin and vaspin levels in prepubertal children: effect of obesity and weight loss after 
behavior modifications on their secretion and relationship with glucose metabolism. Int J 
Obes 2005. 2011 Oct;35(10):1355–62.  
305.  Koltai E, Szabo Z, Atalay M, Boldogh I, Naito H, Goto S, et al. Exercise alters SIRT1, 
SIRT6, NAD and NAMPT levels in skeletal muscle of aged rats. Mech Ageing Dev. 2010 
Jan;131(1):21–8.  
306.  Costford SR, Bajpeyi S, Pasarica M, Albarado DC, Thomas SC, Xie H, et al. Skeletal 
muscle NAMPT is induced by exercise in humans. Am J Physiol Endocrinol Metab. 2010 
Jan;298(1):E117-126.  
307.  Krzysik-Walker SM, Hadley JA, Pesall JE, McFarland DC, Vasilatos-Younken R, 
Ramachandran R. Nampt/visfatin/PBEF affects expression of myogenic regulatory factors 
and is regulated by interleukin-6 in chicken skeletal muscle cells. Comp Biochem Physiol A 
Mol Integr Physiol. 2011 Aug;159(4):413–21.  
308.  Fan H-Q, Gu N, Liu F, Fei L, Pan X-Q, Guo M, et al. Prolonged exposure to resistin inhibits 
glucose uptake in rat skeletal muscles. Acta Pharmacol Sin. 2007 Mar;28(3):410–6.  
309.  Palanivel R, Maida A, Liu Y, Sweeney G. Regulation of insulin signalling, glucose uptake 
and metabolism in rat skeletal muscle cells upon prolonged exposure to resistin. 
Diabetologia. 2006 Jan;49(1):183–90.  
310.  Palanivel R, Sweeney G. Regulation of fatty acid uptake and metabolism in L6 skeletal 
muscle cells by resistin. FEBS Lett. 2005 Sep 12;579(22):5049–54.  
311.  Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK. 
228 
 
Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human 
subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes. 2005 
Oct;54(10):2939–45.  
312.  Roher N, Samokhvalov V, Díaz M, MacKenzie S, Klip A, Planas JV. The proinflammatory 
cytokine tumor necrosis factor-alpha increases the amount of glucose transporter-4 at the 
surface of muscle cells independently of changes in interleukin-6. Endocrinology. 2008 
Apr;149(4):1880–9.  
313.  Alvaro C de, Teruel T, Hernandez R, Lorenzo M. Tumor Necrosis Factor α Produces Insulin 
Resistance in Skeletal Muscle by Activation of Inhibitor κB Kinase in a p38 MAPK-
dependent Manner. J Biol Chem. 2004 Apr 23;279(17):17070–8.  
314.  Patiag D, Gray S, Idris I, Donnelly R. Effects of tumour necrosis factor-alpha and inhibition 
of protein kinase C on glucose uptake in L6 myoblasts. Clin Sci Lond Engl 1979. 2000 
Oct;99(4):303–7.  
315.  Ranganathan S, Davidson MB. Effect of tumor necrosis factor-alpha on basal and insulin-
stimulated glucose transport in cultured muscle and fat cells. Metabolism. 1996 
Sep;45(9):1089–94.  
316.  Petersen EW, Carey AL, Sacchetti M, Steinberg GR, Macaulay SL, Febbraio MA, et al. 
Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue 
culture in vitro. Am J Physiol Endocrinol Metab. 2005 Jan;288(1):E155-162.  
317.  van Hall G, Steensberg A, Sacchetti M, Fischer C, Keller C, Schjerling P, et al. Interleukin-6 
stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab. 2003 
Jul;88(7):3005–10.  
318.  Wolsk E, Mygind H, Grøndahl TS, Pedersen BK, van Hall G. IL-6 selectively stimulates fat 
metabolism in human skeletal muscle. Am J Physiol Endocrinol Metab. 2010 
Nov;299(5):E832-840.  
319.  Lam YY, Janovská A, McAinch AJ, Belobrajdic DP, Hatzinikolas G, Game P, et al. The use 
of adipose tissue-conditioned media to demonstrate the differential effects of fat depots on 
insulin-stimulated glucose uptake in a skeletal muscle cell line. Obes Res Clin Pract. 2011 
Mar;5(1):e1–78.  
320.  Grabstein KH, Eisenman J, Shanebeck K, Rauch C, Srinivasan S, Fung V, et al. Cloning of 
a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. 
Science. 1994 May 13;264(5161):965–8.  
321.  Burton JD, Bamford RN, Peters C, Grant AJ, Kurys G, Goldman CK, et al. A lymphokine, 
provisionally designated interleukin T and produced by a human adult T-cell leukemia line, 
stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc 
Natl Acad Sci U S A. 1994 May 24;91(11):4935–9.  
322.  Giri JG, Anderson DM, Kumaki S, Park LS, Grabstein KH, Cosman D. IL-15, a novel T cell 




323.  Anderson DM, Johnson L, Glaccum MB, Copeland NG, Gilbert DJ, Jenkins NA, et al. 
Chromosomal assignment and genomic structure of Il15. Genomics. 1995 Feb 
10;25(3):701–6.  
324.  Krause H, Jandrig B, Wernicke C, Bulfone-Paus S, Pohl T, Diamantstein T. Genomic 
structure and chromosomal localization of the human interleukin 15 gene (IL-15). Cytokine. 
1996 Sep;8(9):667–74.  
325.  Tagaya Y, Kurys G, Thies TA, Losi JM, Azimi N, Hanover JA, et al. Generation of secretable 
and nonsecretable interleukin 15 isoforms through alternate usage of signal peptides. Proc 
Natl Acad Sci U S A. 1997 Dec 23;94(26):14444–9.  
326.  Meazza R, Verdiani S, Biassoni R, Coppolecchia M, Gaggero A, Orengo AM, et al. 
Identification of a novel interleukin-15 (IL-15) transcript isoform generated by alternative 
splicing in human small cell lung cancer cell lines. Oncogene. 1996 May 16;12(10):2187–
92.  
327.  Onu A, Pohl T, Krause H, Bulfone-Paus S. Regulation of IL-15 secretion via the leader 
peptide of two IL-15 isoforms. J Immunol Baltim Md 1950. 1997 Jan 1;158(1):255–62.  
328.  Nishimura H, Yajima T, Naiki Y, Tsunobuchi H, Umemura M, Itano K, et al. Differential roles 
of interleukin 15 mRNA isoforms generated by alternative splicing in immune responses in 
vivo. J Exp Med. 2000 Jan 3;191(1):157–70.  
329.  Prinz M, Hanisch U-K, Kettenmann H, Kirchhoff F. Alternative splicing of mouse IL-15 is 
due to the use of an internal splice site in exon 5. Mol Brain Res. 1998 Dec 10;63(1):155–
62.  
330.  Kozak M. Structural features in eukaryotic mRNAs that modulate the initiation of 
translation. J Biol Chem. 1991 Oct 25;266(30):19867–70.  
331.  Bates B, Hardin J, Zhan X, Drickamer K, Goldfarb M. Biosynthesis of human fibroblast 
growth factor-5. Mol Cell Biol. 1991 Apr;11(4):1840–5.  
332.  Bamford RN, Battiata AP, Burton JD, Sharma H, Waldmann TA. Interleukin (IL) 15/IL-T 
production by the adult T-cell leukemia cell line HuT-102 is associated with a human T-cell 
lymphotrophic virus type I region /IL-15 fusion message that lacks many upstream AUGs 
that normally attenuates IL-15 mRNA translation. Proc Natl Acad Sci U S A. 1996 Apr 
2;93(7):2897–902.  
333.  Nishimura H, Washizu J, Nakamura N, Enomoto A, Yoshikai Y. Translational efficiency is 
up-regulated by alternative exon in murine IL-15 mRNA. J Immunol Baltim Md 1950. 1998 
Jan 15;160(2):936–42.  
334.  Bamford RN, DeFilippis AP, Azimi N, Kurys G, Waldmann TA. The 5’ untranslated region, 
signal peptide, and the coding sequence of the carboxyl terminus of IL-15 participate in its 
multifaceted translational control. J Immunol Baltim Md 1950. 1998 May 1;160(9):4418–26.  
230 
 
335.  Bergamaschi C, Jalah R, Kulkarni V, Rosati M, Zhang G-M, Alicea C, et al. Secretion and 
biological activity of short signal peptide IL-15 is chaperoned by IL-15 receptor alpha in 
vivo. J Immunol Baltim Md 1950. 2009 Sep 1;183(5):3064–72.  
336.  Quinn LS. Interleukin-15: a muscle-derived cytokine regulating fat-to-lean body 
composition. J Anim Sci. 2008 Apr;86(14 Suppl):E75-83.  
337.  Sugamura K, Asao H, Kondo M, Tanaka N, Ishii N, Ohbo K, et al. THE INTERLEUKIN-2 
RECEPTOR γ CHAIN: Its Role in the Multiple Cytokine Receptor Complexes and T Cell 
Development in XSCID. Annu Rev Immunol. 1996;14(1):179–205.  
338.  Lorenzen I, Dingley AJ, Jacques Y, Grötzinger J. The structure of the interleukin-15 alpha 
receptor and its implications for ligand binding. J Biol Chem. 2006 Mar 10;281(10):6642–7.  
339.  Dubois S, Magrangeas F, Lehours P, Raher S, Bernard J, Boisteau O, et al. Natural splicing 
of exon 2 of human interleukin-15 receptor alpha-chain mRNA results in a shortened form 
with a distinct pattern of expression. J Biol Chem. 1999 Sep 17;274(38):26978–84.  
340.  Bouchaud G, Garrigue-Antar L, Solé V, Quéméner A, Boublik Y, Mortier E, et al. The exon-
3-encoded domain of IL-15ralpha contributes to IL-15 high-affinity binding and is crucial for 
the IL-15 antagonistic effect of soluble IL-15Ralpha. J Mol Biol. 2008 Sep 26;382(1):1–12.  
341.  Mishra A, Sullivan L, Caligiuri MA. Molecular pathways: interleukin-15 signaling in health 
and in cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2014 Apr 15;20(8):2044–50.  
342.  Busquets S, Figueras MT, Meijsing S, Carbó N, Quinn LS, Almendro V, et al. Interleukin-15 
decreases proteolysis in skeletal muscle: a direct effect. Int J Mol Med. 2005 
Sep;16(3):471–6.  
343.  Quinn LS, Anderson BG, Strait-Bodey L, Stroud AM, Argilés JM. Oversecretion of 
interleukin-15 from skeletal muscle reduces adiposity. Am J Physiol Endocrinol Metab. 
2009 Jan;296(1):E191-202.  
344.  Kim H-J, Park JY, Oh SL, Kim Y-A, So B, Seong JK, et al. Effect of treadmill exercise on 
interleukin-15 expression and glucose tolerance in zucker diabetic Fatty rats. Diabetes 
Metab J. 2013 Oct;37(5):358–64.  
345.  Yang H-T, Luo L-J, Chen W-J, Zhao L, Tang C-S, Qi Y-F, et al. IL-15 expression increased 
in response to treadmill running and inhibited endoplasmic reticulum stress in skeletal 
muscle in rats. Endocrine. 2015 Feb;48(1):152–63.  
346.  Li F, Li Y, Tang Y, Lin B, Kong X, Oladele OA, et al. Protective effect of myokine IL-15 
against H2O2-mediated oxidative stress in skeletal muscle cells. Mol Biol Rep. 2014 
Nov;41(11):7715–22.  
347.  Quinn LS, Anderson BG, Conner JD, Wolden-Hanson T. IL-15 overexpression promotes 
endurance, oxidative energy metabolism, and muscle PPARδ, SIRT1, PGC-1α, and PGC-
1β expression in male mice. Endocrinology. 2013 Jan;154(1):232–45.  
231 
 
348.  Rinnov A, Yfanti C, Nielsen S, Akerström TCA, Peijs L, Zankari A, et al. Endurance training 
enhances skeletal muscle interleukin-15 in human male subjects. Endocrine. 2014 
Mar;45(2):271–8.  
349.  Nielsen AR, Mounier R, Plomgaard P, Mortensen OH, Penkowa M, Speerschneider T, et al. 
Expression of interleukin-15 in human skeletal muscle effect of exercise and muscle fibre 
type composition. J Physiol. 2007 Oct 1;584(Pt 1):305–12.  
350.  Pérez-López A, McKendry J, Martin-Rincon M, Morales-Alamo D, Pérez-Köhler B, Valadés 
D, et al. Skeletal muscle IL-15/IL-15Rα and myofibrillar protein synthesis after resistance 
exercise. Scand J Med Sci Sports. 2017 Apr 27;  
351.  Riechman SE, Balasekaran G, Roth SM, Ferrell RE. Association of interleukin-15 protein 
and interleukin-15 receptor genetic variation with resistance exercise training responses. J 
Appl Physiol Bethesda Md 1985. 2004 Dec;97(6):2214–9.  
352.  Shanely RA, Zwetsloot KA, Triplett NT, Meaney MP, Farris GE, Nieman DC. Human 
skeletal muscle biopsy procedures using the modified Bergström technique. J Vis Exp 
JoVE. 2014;(91):51812.  
353.  Rasband W. Image J. Bethesda, MD, USA: U. S. National Institutes of Health;  
354.  Huang KT, Chen YH, Walker AM. Inaccuracies in MTS assays: major distorting effects of 
medium, serum albumin, and fatty acids. BioTechniques. 2004 Sep;37(3):406, 408, 410–2.  
355.  Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, et al. Mediation of IGF-
1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 
pathways. Nat Cell Biol. 2001 Nov;3(11):1009–13.  
356.  Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ. Myostatin 
reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. 
Am J Physiol - Cell Physiol. 2009 Jun 1;296(6):C1258–70.  
357.  Jacquemin V, Furling D, Bigot A, Butler-Browne GS, Mouly V. IGF-1 induces human 
myotube hypertrophy by increasing cell recruitment. Exp Cell Res. 2004 Sep 
10;299(1):148–58.  
358.  Koopman R, Schaart G, Hesselink MK. Optimisation of oil red O staining permits 
combination with immunofluorescence and automated quantification of lipids. Histochem 
Cell Biol. 2001 Jul;116(1):63–8.  
359.  García-Martínez C, Agell N, Llovera M, López-Soriano FJ, Argilés JM. Tumour necrosis 
factor-alpha increases the ubiquitinization of rat skeletal muscle proteins. FEBS Lett. 1993 
Jun 1;323(3):211–4.  
360.  Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and 
potential as drug targets. Nat Rev Drug Discov. 2008 Jun;7(6):489–503.  
361.  Queipo-Ortuño MI, Escoté X, Ceperuelo-Mallafré V, Garrido-Sanchez L, Miranda M, 
232 
 
Clemente-Postigo M, et al. FABP4 dynamics in obesity: discrepancies in adipose tissue 
and liver expression regarding circulating plasma levels. PloS One. 2012;7(11):e48605.  
362.  Wotherspoon AC, Young IS, McCance DR, Patterson CC, Maresh MJA, Pearson DWM, et 
al. Serum Fatty Acid Binding Protein 4 (FABP4) Predicts Pre-eclampsia in Women With 
Type 1 Diabetes. Diabetes Care. 2016 Oct;39(10):1827–9.  
363.  Ning H, Tao H, Weng Z, Zhao X. Plasma fatty acid-binding protein 4 (FABP4) as a novel 
biomarker to predict gestational diabetes mellitus. Acta Diabetol. 2016 Dec;53(6):891–8.  
364.  Furuhashi M, Ishimura S, Ota H, Hayashi M, Nishitani T, Tanaka M, et al. Serum Fatty Acid-
Binding Protein 4 Is a Predictor of Cardiovascular Events in End-Stage Renal Disease. 
PLOS ONE. 2011 Nov 10;6(11):e27356.  
365.  Fuseya T, Furuhashi M, Yuda S, Muranaka A, Kawamukai M, Mita T, et al. Elevation of 
circulating fatty acid-binding protein 4 is independently associated with left ventricular 
diastolic dysfunction in a general population. Cardiovasc Diabetol. 2014 Aug 21;13:126.  
366.  Gramling MW, Church FC. Plasminogen activator inhibitor-1 is an aggregate response 
factor with pleiotropic effects on cell signaling in vascular disease and the tumor 
microenvironment. Thromb Res. 2010 May;125(5):377–81.  
367.  Ghosh AK, Vaughan DE. PAI-1 in tissue fibrosis. J Cell Physiol. 2012 Feb;227(2):493–507.  
368.  Serrano AL, Muñoz-Cánoves P. Regulation and dysregulation of fibrosis in skeletal muscle. 
Exp Cell Res. 2010 Nov 1;316(18):3050–8.  
369.  Chen Y, Budd RC, Kelm RJ, Sobel BE, Schneider DJ. Augmentation of proliferation of 
vascular smooth muscle cells by plasminogen activator inhibitor type 1. Arterioscler Thromb 
Vasc Biol. 2006 Aug;26(8):1777–83.  
370.  Degryse B, Neels JG, Czekay R-P, Aertgeerts K, Kamikubo Y-I, Loskutoff DJ. The low 
density lipoprotein receptor-related protein is a motogenic receptor for plasminogen 
activator inhibitor-1. J Biol Chem. 2004 May 21;279(21):22595–604.  
371.  Lluís F, Roma J, Suelves M, Parra M, Aniorte G, Gallardo E, et al. Urokinase-dependent 
plasminogen activation is required for efficient skeletal muscle regeneration in vivo. Blood. 
2001 Mar 15;97(6):1703–11.  
372.  Suelves M, López-Alemany R, Lluís F, Aniorte G, Serrano E, Parra M, et al. Plasmin activity 
is required for myogenesis in vitro and skeletal muscle regeneration in vivo. Blood. 2002 
Apr 15;99(8):2835–44.  
373.  Krause MP, Al-Sajee D, D’Souza DM, Rebalka IA, Moradi J, Riddell MC, et al. Impaired 
macrophage and satellite cell infiltration occurs in a muscle-specific fashion following injury 
in diabetic skeletal muscle. PloS One. 2013;8(8):e70971.  
374.  Fibbi G, Barletta E, Dini G, Del Rosso A, Pucci M, Cerletti M, et al. Cell invasion is affected 
by differential expression of the urokinase plasminogen activator/urokinase plasminogen 
233 
 
activator receptor system in muscle satellite cells from normal and dystrophic patients. Lab 
Investig J Tech Methods Pathol. 2001 Jan;81(1):27–39.  
375.  Chen Y, Copeland WK, Vedanthan R, Grant E, Lee JE, Gu D, et al. Association between 
body mass index and cardiovascular disease mortality in east Asians and south Asians: 
pooled analysis of prospective data from the Asia Cohort Consortium. BMJ. 2013 Oct 
1;347:f5446.  
376.  Gregg EW, Cheng YJ, Cadwell BL, Imperatore G, Williams DE, Flegal KM, et al. Secular 
Trends in Cardiovascular Disease Risk Factors According to Body Mass Index in US 
Adults. JAMA. 2005 Apr 20;293(15):1868–74.  
377.  Zemski AJ, Slater GJ, Broad EM. Body composition characteristics of elite Australian rugby 
union athletes according to playing position and ethnicity. J Sports Sci. 2015;33(9):970–8.  
378.  Scafoglieri A, Provyn S, Bautmans I, Van Roy P, Clarys JP. Direct relationship of body mass 
index and waist circumference with body tissue distribution in elderly persons. J Nutr 
Health Aging. 2011 Dec;15(10):924–31.  
379.  Gallagher D, Heymsfield SB, Heo M, Jebb SA, Murgatroyd PR, Sakamoto Y. Healthy 
percentage body fat ranges: an approach for developing guidelines based on body mass 
index. Am J Clin Nutr. 2000 Sep;72(3):694–701.  
380.  White JP, Reecy JM, Washington TA, Sato S, Le ME, Davis JM, et al. Overload-induced 
skeletal muscle extracellular matrix remodelling and myofibre growth in mice lacking IL-6. 
Acta Physiol Oxf Engl. 2009 Dec;197(4):321–32.  
381.  Uezumi A, Ikemoto-Uezumi M, Tsuchida K. Roles of nonmyogenic mesenchymal 
progenitors in pathogenesis and regeneration of skeletal muscle. Front Physiol. 2014;5:68.  
382.  Joe AWB, Yi L, Natarajan A, Le Grand F, So L, Wang J, et al. Muscle injury activates 
resident fibro/adipogenic progenitors that facilitate myogenesis. Nat Cell Biol. 2010 
Feb;12(2):153–63.  
383.  Uezumi A, Fukada S, Yamamoto N, Takeda S ’ichi, Tsuchida K. Mesenchymal progenitors 
distinct from satellite cells contribute to ectopic fat cell formation in skeletal muscle. Nat 
Cell Biol. 2010 Feb;12(2):143–52.  
384.  Arrighi N, Moratal C, Clément N, Giorgetti-Peraldi S, Peraldi P, Loubat A, et al. 
Characterization of adipocytes derived from fibro/adipogenic progenitors resident in human 
skeletal muscle. Cell Death Dis. 2015;6:e1733.  
385.  Lim J-M, Wollaston-Hayden EE, Teo CF, Hausman D, Wells L. Quantitative secretome and 
glycome of primary human adipocytes during insulin resistance. Clin Proteomics. 
2014;11(1):20.  
386.  Xie X, Yi Z, Sinha S, Madan M, Bowen BP, Langlais P, et al. Proteomics analyses of 
subcutaneous adipocytes reveal novel abnormalities in human insulin resistance. Obes 
Silver Spring Md. 2016 Jul;24(7):1506–14.  
234 
 
387.  Fang L, Kojima K, Zhou L, Crossman DK, Mobley JA, Grams J. Analysis of the Human 
Proteome in Subcutaneous and Visceral Fat Depots in Diabetic and Non-diabetic Patients 
with Morbid Obesity. J Proteomics Bioinform. 2015 Jun;8(6):133–41.  
388.  Philp AM, Davis ET, Jones SW. Developing anti-inflammatory therapeutics for patients with 
osteoarthritis. Rheumatol Oxf Engl. 2016 Aug 7;  
389.  van Loon LJC, Manders RJF, Koopman R, Kaastra B, Stegen JHCH, Gijsen AP, et al. 
Inhibition of adipose tissue lipolysis increases intramuscular lipid use in type 2 diabetic 
patients. Diabetologia. 2005 Oct;48(10):2097–107.  
390.  van Loon LJC, Koopman R, Manders R, van der Weegen W, van Kranenburg GP, Keizer 
HA. Intramyocellular lipid content in type 2 diabetes patients compared with overweight 
sedentary men and highly trained endurance athletes. Am J Physiol Endocrinol Metab. 
2004 Sep;287(3):E558-565.  
391.  Santomauro AT, Boden G, Silva ME, Rocha DM, Santos RF, Ursich MJ, et al. Overnight 
lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance 
in obese diabetic and nondiabetic subjects. Diabetes. 1999 Sep;48(9):1836–41.  
392.  Utsuyama M, Hirokawa K. Differential expression of various cytokine receptors in the brain 
after stimulation with LPS in young and old mice. Exp Gerontol. 2002 Mar;37(2–3):411–20.  
393.  Hazeldine J, Lord JM. The impact of ageing on natural killer cell function and potential 
consequences for health in older adults. Ageing Res Rev. 2013 Sep;12(4):1069–78.  
394.  Warburg O. On the Origin of Cancer Cells. Science. 1956 Feb 24;123(3191):309–14.  
395.  Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg Effect: The 
Metabolic Requirements of Cell Proliferation. Science. 2009 May 22;324(5930):1029–33.  
396.  Petersen AM, Plomgaard P, Fischer CP, Ibfelt T, Pedersen BK, van Hall G. Acute moderate 
elevation of TNF-alpha does not affect systemic and skeletal muscle protein turnover in 
healthy humans. J Clin Endocrinol Metab. 2009 Jan;94(1):294–9.  
397.  van Hall G, Steensberg A, Fischer C, Keller C, Møller K, Moseley P, et al. Interleukin-6 
markedly decreases skeletal muscle protein turnover and increases nonmuscle amino acid 
utilization in healthy individuals. J Clin Endocrinol Metab. 2008 Jul;93(7):2851–8.  
398.  Kamolrat T, Gray SR. The effect of eicosapentaenoic and docosahexaenoic acid on protein 
synthesis and breakdown in murine C2C12 myotubes. Biochem Biophys Res Commun. 
2013 Mar 22;432(4):593–8.  
399.  Zentella A, Manogue K, Cerami A. Cachectin/TNF-mediated lactate production in cultured 
myocytes is linked to activation of a futile substrate cycle. Cytokine. 1993 Sep 1;5(5):436–
47.  
400.  Bédard S, Marcotte B, Marette A. Cytokines modulate glucose transport in skeletal muscle 
by inducing the expression of inducible nitric oxide synthase. Biochem J. 1997 Jul 15;325 ( 
235 
 
Pt 2):487–93.  
401.  Bakkar N, Guttridge DC. NF-kappaB signaling: a tale of two pathways in skeletal 
myogenesis. Physiol Rev. 2010 Apr;90(2):495–511.  
402.  Bakkar N, Wang J, Ladner KJ, Wang H, Dahlman JM, Carathers M, et al. IKK/NF-kappaB 
regulates skeletal myogenesis via a signaling switch to inhibit differentiation and promote 
mitochondrial biogenesis. J Cell Biol. 2008 Feb 25;180(4):787–802.  
403.  Lu A, Proto JD, Guo L, Tang Y, Lavasani M, Tilstra JS, et al. NF-κB negatively impacts the 
myogenic potential of muscle-derived stem cells. Mol Ther J Am Soc Gene Ther. 2012 
Mar;20(3):661–8.  
404.  Zhou L, Yu X, Meng Q, Li H, Niu C, Jiang Y, et al. Resistin reduces mitochondria and 
induces hepatic steatosis in mice by the protein kinase C/protein kinase G/p65/PPAR 
gamma coactivator 1 alpha pathway. Hepatol Baltim Md. 2013 Apr;57(4):1384–93.  
405.  Calabrò P, Cirillo P, Limongelli G, Maddaloni V, Riegler L, Palmieri R, et al. Tissue factor is 
induced by resistin in human coronary artery endothelial cells by the NF-ĸB-dependent 
pathway. J Vasc Res. 2011;48(1):59–66.  
406.  Zuniga MC, Raghuraman G, Hitchner E, Weyand C, Robinson W, Zhou W. PKC-epsilon 
and TLR4 synergistically regulate resistin-mediated inflammation in human macrophages. 
Atherosclerosis. 2017 Apr;259:51–9.  
407.  Cai D, Frantz JD, Tawa NE, Melendez PA, Oh B-C, Lidov HGW, et al. IKKbeta/NF-kappaB 
activation causes severe muscle wasting in mice. Cell. 2004 Oct 15;119(2):285–98.  
408.  Wu C-L, Kandarian SC, Jackman RW. Identification of genes that elicit disuse muscle 
atrophy via the transcription factors p50 and Bcl-3. PloS One. 2011 Jan 13;6(1):e16171.  
409.  Sánchez-Solana B, Laborda J, Baladrón V. Mouse resistin modulates adipogenesis and 
glucose uptake in 3T3-L1 preadipocytes through the ROR1 receptor. Mol Endocrinol Baltim 
Md. 2012 Jan;26(1):110–27.  
410.  Daquinag AC, Zhang Y, Amaya-Manzanares F, Simmons PJ, Kolonin MG. An isoform of 
decorin is a resistin receptor on the surface of adipose progenitor cells. Cell Stem Cell. 
2011 Jul 8;9(1):74–86.  
411.  Tarkowski A, Bjersing J, Shestakov A, Bokarewa MI. Resistin competes with 
lipopolysaccharide for binding to toll-like receptor 4. J Cell Mol Med. 2010 
Jun;14(6b):1419–31.  
412.  Reyna SM, Ghosh S, Tantiwong P, Meka CSR, Eagan P, Jenkinson CP, et al. Elevated Toll-
Like Receptor 4 Expression and Signaling in Muscle From Insulin-Resistant Subjects. 
Diabetes. 2008 Oct;57(10):2595–602.  
413.  Lee S, Lee H-C, Kwon Y-W, Lee SE, Cho Y, Kim J, et al. Adenylyl Cyclase-Associated 
Protein 1(CAP1) is a Receptor for Human Resistin and Mediates Inflammatory Actions of 
236 
 
Human Monocytes. Cell Metab. 2014 Mar 4;19(3):484–97.  
414.  Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. 
Proteomics. Tissue-based map of the human proteome. Science. 2015 Jan 
23;347(6220):1260419.  
415.  von Maltzahn J, Chang NC, Bentzinger CF, Rudnicki MA. Wnt Signaling in Myogenesis. 
Trends Cell Biol. 2012 Nov;22(11):602–9.  
416.  Pansters N a. M, van der Velden JLJ, Kelders MCJM, Laeremans H, Schols AMWJ, 
Langen RCJ. Segregation of myoblast fusion and muscle-specific gene expression by 
distinct ligand-dependent inactivation of GSK-3β. Cell Mol Life Sci CMLS. 2011 
Feb;68(3):523–35.  
417.  Rochat A, Fernandez A, Vandromme M, Molès J-P, Bouschet T, Carnac G, et al. Insulin and 
Wnt1 Pathways Cooperate to Induce Reserve Cell Activation in Differentiation and Myotube 
Hypertrophy. Mol Biol Cell. 2004 Oct;15(10):4544–55.  
418.  Brack AS, Conboy IM, Conboy MJ, Shen J, Rando TA. A temporal switch from notch to Wnt 
signaling in muscle stem cells is necessary for normal adult myogenesis. Cell Stem Cell. 
2008 Jan 10;2(1):50–9.  
419.  Philp AM, Collier RL, Grover LM, Davis ET, Jones SW. Resistin promotes the abnormal 
Type I collagen phenotype of subchondral bone in obese patients with end stage hip 
osteoarthritis. Sci Rep. 2017 Jun 22;7(1):4042.  
420.  Klinke DJ, Ustyugova IV, Brundage KM, Barnett JB. Modulating Temporal Control of NF-κB 
Activation: Implications for Therapeutic and Assay Selection. Biophys J. 2008 Jun 
1;94(11):4249–59.  
421.  Hellman LM, Fried MG. Electrophoretic Mobility Shift Assay (EMSA) for Detecting Protein-
Nucleic Acid Interactions. Nat Protoc. 2007;2(8):1849–61.  
422.  Bakkar N, Wackerhage H, Guttridge DC. Myostatin and NF-κB Regulate Skeletal 
Myogenesis Through Distinct Signaling Pathways. Signal Transduct. 2005 Aug 1;5(4):202–
10.  
423.  Oh J, Sinha I, Tan KY, Rosner B, Dreyfuss JM, Gjata O, et al. Age-associated NF-κB 
signaling in myofibers alters the satellite cell niche and re-strains muscle stem cell function. 
Aging. 2016 Nov 14;8(11):2871–84.  
424.  Jackman RW, Wu C-L, Kandarian SC. The ChIP-seq-Defined Networks of Bcl-3 Gene 
Binding Support Its Required Role in Skeletal Muscle Atrophy. PLoS ONE [Internet]. 2012 
Dec 10;7(12). Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519692/ 
425.  Tintignac LA, Lagirand J, Batonnet S, Sirri V, Leibovitch MP, Leibovitch SA. Degradation of 




426.  Nicolas N, Marazzi G, Kelley K, Sassoon D. Embryonic deregulation of muscle stress 
signaling pathways leads to altered postnatal stem cell behavior and a failure in postnatal 
muscle growth. Dev Biol. 2005 May 15;281(2):171–83.  
427.  Skapek SX, Rhee J, Spicer DB, Lassar AB. Inhibition of myogenic differentiation in 
proliferating myoblasts by cyclin D1-dependent kinase. Science. 1995 Feb 
17;267(5200):1022–4.  
428.  Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS. NF-kappaB controls cell 
growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999 
Aug;19(8):5785–99.  
429.  Dahlman JM, Wang J, Bakkar N, Guttridge DC. The RelA/p65 subunit of NF-kappaB 
specifically regulates cyclin D1 protein stability: implications for cell cycle withdrawal and 
skeletal myogenesis. J Cell Biochem. 2009 Jan 1;106(1):42–51.  
430.  Wang H, Hertlein E, Bakkar N, Sun H, Acharyya S, Wang J, et al. NF-kappaB regulation of 
YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Mol 
Cell Biol. 2007 Jun;27(12):4374–87.  
431.  Wei W, He H-B, Zhang W-Y, Zhang H-X, Bai J-B, Liu H-Z, et al. miR-29 targets Akt3 to 
reduce proliferation and facilitate differentiation of myoblasts in skeletal muscle 
development. Cell Death Dis. 2013 Jun 13;4:e668.  
432.  Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J, et al. NF-kappaB-YY1-miR-29 
regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell. 2008 Nov 
4;14(5):369–81.  
433.  Proto JD, Tang Y, Lu A, Chen WCW, Stahl E, Poddar M, et al. NF-κB inhibition reveals a 
novel role for HGF during skeletal muscle repair. Cell Death Dis. 2015;6:e1730.  
434.  Miller SC, Huang R, Sakamuru S, Shukla SJ, Attene-Ramos MS, Shinn P, et al. 
Identification of known drugs that act as inhibitors of NF-kappaB signaling and their 
mechanism of action. Biochem Pharmacol. 2010 May 1;79(9):1272–80.  
435.  Aguiar PM, de Mendonça Lima T, Colleoni GWB, Storpirtis S. Efficacy and safety of 
bortezomib, thalidomide, and lenalidomide in multiple myeloma: An overview of systematic 
reviews with meta-analyses. Crit Rev Oncol Hematol. 2017 May;113:195–212.  
436.  Li F, Zhang J, Arfuso F, Chinnathambi A, Zayed ME, Alharbi SA, et al. NF-κB in cancer 
therapy. Arch Toxicol. 2015 May;89(5):711–31.  
437.  Stolfi C, De Simone V, Pallone F, Monteleone G. Mechanisms of Action of Non-Steroidal 
Anti-Inflammatory Drugs (NSAIDs) and Mesalazine in the Chemoprevention of Colorectal 
Cancer. Int J Mol Sci. 2013 Sep 3;14(9):17972–85.  
438.  Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal anti-inflammatory agents differ 
in their ability to suppress NF-κB activation, inhibition of expression of cyclooxygenase-2 




439.  Mikkelsen UR, Langberg H, Helmark IC, Skovgaard D, Andersen LL, Kjaer M, et al. Local 
NSAID infusion inhibits satellite cell proliferation in human skeletal muscle after eccentric 
exercise. J Appl Physiol Bethesda Md 1985. 2009 Nov;107(5):1600–11.  
440.  Mackey AL, Kjaer M, Dandanell S, Mikkelsen KH, Holm L, Døssing S, et al. The influence 
of anti-inflammatory medication on exercise-induced myogenic precursor cell responses in 
humans. J Appl Physiol Bethesda Md 1985. 2007 Aug;103(2):425–31.  
441.  Krentz JR, Quest B, Farthing JP, Quest DW, Chilibeck PD. The effects of ibuprofen on 
muscle hypertrophy, strength, and soreness during resistance training. Appl Physiol Nutr 
Metab Physiol Appl Nutr Metab. 2008 Jun;33(3):470–5.  
442.  Mackey AL, Rasmussen LK, Kadi F, Schjerling P, Helmark IC, Ponsot E, et al. Activation of 
satellite cells and the regeneration of human skeletal muscle are expedited by ingestion of 
nonsteroidal anti-inflammatory medication. FASEB J. 2016 Jun;30(6):2266–81.  
443.  Trappe TA, Carroll CC, Dickinson JM, LeMoine JK, Haus JM, Sullivan BE, et al. Influence 
of acetaminophen and ibuprofen on skeletal muscle adaptations to resistance exercise in 
older adults. Am J Physiol Regul Integr Comp Physiol. 2011 Mar;300(3):R655-662.  
444.  Buttgereit F, Burmester GR, Simon LS. Gastrointestinal toxic side effects of nonsteroidal 
anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors. Am J Med. 2001 Feb 
19;110 Suppl 3A:13S–9S.  
445.  Gamble C, McIntosh K, Scott R, Ho KH, Plevin R, Paul A. Inhibitory kappa B kinases as 
targets for pharmacological regulation. Br J Pharmacol. 2012 Feb 1;165(4):802–19.  
446.  Xu W, Yu L, Zhou W, Luo M. Resistin increases lipid accumulation and CD36 expression in 
human macrophages. Biochem Biophys Res Commun. 2006 Dec 15;351(2):376–82.  
447.  Aas V, Kase ET, Solberg R, Jensen J, Rustan AC. Chronic hyperglycaemia promotes 
lipogenesis and triacylglycerol accumulation in human skeletal muscle cells. Diabetologia. 
2004 Aug;47(8):1452–61.  
448.  Dulloo AG, Gubler M, Montani JP, Seydoux J, Solinas G. Substrate cycling between de 
novo lipogenesis and lipid oxidation: a thermogenic mechanism against skeletal muscle 
lipotoxicity and glucolipotoxicity. Int J Obes. 2004;28(S4):S29–37.  
449.  Summermatter S, Baum O, Santos G, Hoppeler H, Handschin C. Peroxisome Proliferator-
activated Receptor γ Coactivator 1α (PGC-1α) Promotes Skeletal Muscle Lipid Refueling in 
Vivo by Activating de Novo Lipogenesis and the Pentose Phosphate Pathway. J Biol Chem. 
2010 Oct 22;285(43):32793–800.  
450.  N K, E H, M K, O M, Ya T, E W, et al. ArrayExpress update--simplifying data submissions. 
Nucleic Acids Res. 2015 Jan;43(Database issue):D1113-6.  
451.  Ge JF, Walewski JL, Anglade D, Berk PD. Regulation of Hepatocellular Fatty Acid Uptake in 
239 
 
Mouse Models of Fatty Liver Disease with and without Functional Leptin Signaling: Roles of 
NfKB and SREBP-1C and the Effects of Spexin. Semin Liver Dis. 2016 Sep;36(4):360–72.  
452.  Sini S, Deepa D, Harikrishnan S, Jayakumari N. High-density lipoprotein from subjects with 
coronary artery disease promotes macrophage foam cell formation: role of scavenger 
receptor CD36 and ERK/MAPK signaling. Mol Cell Biochem. 2017 Mar;427(1–2):23–34.  
453.  Barma P, Bhattacharya S, Bhattacharya A, Kundu R, Dasgupta S, Biswas A, et al. Lipid 
induced overexpression of NF-kappaB in skeletal muscle cells is linked to insulin 
resistance. Biochim Biophys Acta. 2009 Mar;1792(3):190–200.  
454.  Singhal NS, Patel RT, Qi Y, Lee Y-S, Ahima RS. Loss of resistin ameliorates hyperlipidemia 
and hepatic steatosis in leptin-deficient mice. Am J Physiol Endocrinol Metab. 2008 
Aug;295(2):E331-338.  
455.  Costandi J, Melone M, Zhao A, Rashid S. Human resistin stimulates hepatic overproduction 
of atherogenic ApoB-containing lipoprotein particles by enhancing ApoB stability and 
impairing intracellular insulin signaling. Circ Res. 2011 Mar 18;108(6):727–42.  
456.  Shimano H. Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators 
of lipid synthetic genes. Prog Lipid Res. 2001 Nov;40(6):439–52.  
457.  Ma TY, Iwamoto GK, Hoa NT, Akotia V, Pedram A, Boivin MA, et al. TNF-alpha-induced 
increase in intestinal epithelial tight junction permeability requires NF-kappa B activation. 
Am J Physiol Gastrointest Liver Physiol. 2004 Mar;286(3):G367-376.  
458.  Zhang C, Shin D-J, Osborne TF. A simple promoter containing two Sp1 sites controls the 
expression of sterol-regulatory-element-binding protein 1a (SREBP-1a). Biochem J. 2005 
Feb 15;386(Pt 1):161–8.  
459.  Im S-S, Yousef L, Blaschitz C, Liu JZ, Edwards RA, Young SG, et al. Linking Lipid 
Metabolism to the Innate Immune Response in Macrophages through Sterol Regulatory 
Element Binding Protein -1a. Cell Metab. 2011 May 4;13(5):540–9.  
460.  Yates A, Akanni W, Amode MR, Barrell D, Billis K, Carvalho-Silva D, et al. Ensembl 2016. 
Nucleic Acids Res. 2016 Jan 4;44(D1):D710–6.  
461.  Suzuki Y, Yamashita R, Nakai K, Sugano S. DBTSS: DataBase of human Transcriptional 
Start Sites and full-length cDNAs. Nucleic Acids Res. 2002 Jan 1;30(1):328–31.  
462.  Suzuki A, Wakaguri H, Yamashita R, Kawano S, Tsuchihara K, Sugano S, et al. DBTSS as 
an integrative platform for transcriptome, epigenome and genome sequence variation data. 
Nucleic Acids Res. 2015 Jan 28;43(Database issue):D87–91.  
463.  Solinas G, Summermatter S, Mainieri D, Gubler M, Pirola L, Wymann MP, et al. The direct 
effect of leptin on skeletal muscle thermogenesis is mediated by substrate cycling between 
de novo lipogenesis and lipid oxidation. FEBS Lett. 2004 Nov 19;577(3):539–44.  
464.  Minokoshi Y, Kim Y-B, Peroni OD, Fryer LGD, Müller C, Carling D, et al. Leptin stimulates 
240 
 
fatty-acid oxidation by activating AMP-activated protein kinase. Nature. 2002 Jan 
17;415(6869):339–43.  
465.  Zammit VA. Carnitine palmitoyltransferase 1: central to cell function. IUBMB Life. 2008 
May;60(5):347–54.  
466.  Louet JF, Chatelain F, Decaux JF, Park EA, Kohl C, Pineau T, et al. Long-chain fatty acids 
regulate liver carnitine palmitoyltransferase I gene (L-CPT I) expression through a 
peroxisome-proliferator-activated receptor alpha (PPARalpha)-independent pathway. 
Biochem J. 2001 Feb 15;354(Pt 1):189–97.  
467.  Louet JF, Le May C, Pégorier JP, Decaux JF, Girard J. Regulation of liver carnitine 
palmitoyltransferase I gene expression by hormones and fatty acids. Biochem Soc Trans. 
2001 May;29(Pt 2):310–6.  
468.  Toral M, Romero M, Jiménez R, Mahmoud AM, Barroso E, Gómez-Guzmán M, et al. 
Carnitine palmitoyltransferase-1 up-regulation by PPAR-β/δ prevents lipid-induced 
endothelial dysfunction. Clin Sci Lond Engl 1979. 2015 Nov;129(9):823–37.  
469.  Skulachev VP. Fatty acid circuit as a physiological mechanism of uncoupling of oxidative 
phosphorylation. FEBS Lett. 1991 Dec 9;294(3):158–62.  
470.  Andreyev AYu  null, Bondareva TO, Dedukhova VI, Mokhova EN, Skulachev VP, Tsofina 
LM, et al. The ATP/ADP-antiporter is involved in the uncoupling effect of fatty acids on 
mitochondria. Eur J Biochem. 1989 Jul 1;182(3):585–92.  
471.  Sparks LM, Gemmink A, Phielix E, Bosma M, Schaart G, Moonen-Kornips E, et al. ANT1-
mediated fatty acid-induced uncoupling as a target for improving myocellular insulin 
sensitivity. Diabetologia. 2016 May;59(5):1030–9.  
472.  Bouillaud F, Alves-Guerra M-C, Ricquier D. UCPs, at the interface between bioenergetics 
and metabolism. Biochim Biophys Acta. 2016 Oct;1863(10):2443–56.  
473.  Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in 
insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet Lond Engl. 
1963 Apr 13;1(7285):785–9.  
474.  Echtay KS, Roussel D, St-Pierre J, Jekabsons MB, Cadenas S, Stuart JA, et al. 
Superoxide activates mitochondrial uncoupling proteins. Nature. 2002 Jan 3;415(6867):96–
9.  
475.  Echtay KS, Murphy MP, Smith RAJ, Talbot DA, Brand MD. Superoxide activates 
mitochondrial uncoupling protein 2 from the matrix side. Studies using targeted 
antioxidants. J Biol Chem. 2002 Dec 6;277(49):47129–35.  
476.  Aguirre E, Cadenas S. GDP and carboxyatractylate inhibit 4-hydroxynonenal-activated 
proton conductance to differing degrees in mitochondria from skeletal muscle and heart. 
Biochim Biophys Acta. 2010 Oct;1797(10):1716–26.  
241 
 
477.  Vidal-Puig AJ, Grujic D, Zhang CY, Hagen T, Boss O, Ido Y, et al. Energy metabolism in 
uncoupling protein 3 gene knockout mice. J Biol Chem. 2000 May 26;275(21):16258–66.  
478.  Seifert EL, Bézaire V, Estey C, Harper M-E. Essential Role for Uncoupling Protein-3 in 
Mitochondrial Adaptation to Fasting but Not in Fatty Acid Oxidation or Fatty Acid Anion 
Export. J Biol Chem. 2008 Sep 12;283(37):25124–31.  
479.  Nabben M, Hoeks J, Moonen-Kornips E, van Beurden D, Briedé JJ, Hesselink MKC, et al. 
Significance of uncoupling protein 3 in mitochondrial function upon mid- and long-term 
dietary high-fat exposure. FEBS Lett. 2011 Dec 15;585(24):4010–7.  
480.  Ali AK, Nandagopal N, Lee S-H. IL-15–PI3K–AKT–mTOR: A Critical Pathway in the Life 
Journey of Natural Killer Cells. Front Immunol [Internet]. 2015 Jul 20 [cited 2016 Mar 13];6. 
Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4507451/ 
481.  Carbó N, López-Soriano J, Costelli P, Busquets S, Alvarez B, Baccino FM, et al. Interleukin-
15 antagonizes muscle protein waste in tumour-bearing rats. Br J Cancer. 2000 
Aug;83(4):526–31.  
482.  Snijders T, Nederveen JP, McKay BR, Joanisse S, Verdijk LB, van Loon LJC, et al. Satellite 
cells in human skeletal muscle plasticity. Front Physiol. 2015;6:283.  
483.  Bowen TS, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: 
molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle. 
2015 Sep;6(3):197–207.  
484.  Nakashima J, Tachibana M, Ueno M, Miyajima A, Baba S, Murai M. Association between 
tumor necrosis factor in serum and cachexia in patients with prostate cancer. Clin Cancer 
Res. 1998 Jul 1;4(7):1743–8.  
485.  Zhao SP, Zeng LH. Elevated plasma levels of tumor necrosis factor in chronic heart failure 
with cachexia. Int J Cardiol. 1997 Feb;58(3):257–61.  
486.  Schmidt EK, Clavarino G, Ceppi M, Pierre P. SUnSET, a nonradioactive method to monitor 
protein synthesis. Nat Methods. 2009 Apr;6(4):275–7.  
487.  Goodman CA, Hornberger TA. Measuring protein synthesis with SUnSET: a valid 
alternative to traditional techniques? Exerc Sport Sci Rev. 2013 Apr;41(2):107–15.  
488.  Pistilli EE, Bogdanovich S, Garton F, Yang N, Gulbin JP, Conner JD, et al. Loss of IL-15 
receptor α alters the endurance, fatigability, and metabolic characteristics of mouse fast 
skeletal muscles. J Clin Invest. 2011 Aug;121(8):3120–32.  
489.  Sugiura T, Harigai M, Kawaguchi Y, Takagi K, Fukasawa C, Ohsako-Higami S, et al. 
Increased IL-15 production of muscle cells in polymyositis and dermatomyositis. Int 
Immunol. 2002 Aug;14(8):917–24.  
490.  Jones SW, Hill RJ, Krasney PA, O’Conner B, Peirce N, Greenhaff PL. Disuse atrophy and 
exercise rehabilitation in humans profoundly affects the expression of genes associated 
242 
 
with the regulation of skeletal muscle mass. FASEB J [Internet]. 2004 Apr 14 [cited 2016 
Mar 18]; Available from: http://www.fasebj.org/content/early/2004/06/02/fj.03-1228fje 
491.  Trappe S, Williamson D, Godard M, Porter D, Rowden G, Costill D. Effect of resistance 
training on single muscle fiber contractile function in older men. J Appl Physiol. 2000 Jul 
1;89(1):143–52.  
492.  Rotwein P, Wilson EM. Distinct actions of Akt1 and Akt2 in skeletal muscle differentiation. J 
Cell Physiol. 2009 May;219(2):503–11.  
493.  Knight JD, Kothary R. The myogenic kinome: protein kinases critical to mammalian skeletal 
myogenesis. Skelet Muscle. 2011 Sep 8;1:29.  
494.  Millay DP, Sutherland LB, Bassel-Duby R, Olson EN. Myomaker is essential for muscle 
regeneration. Genes Dev. 2014 Aug 1;28(15):1641–6.  
495.  Millay DP, O’Rourke JR, Sutherland LB, Bezprozvannaya S, Shelton JM, Bassel-Duby R, et 
al. Myomaker is a membrane activator of myoblast fusion and muscle formation. Nature. 
2013 Jul 18;499(7458):301–5.  
496.  Goh Q, Millay DP. Requirement of myomaker-mediated stem cell fusion for skeletal muscle 
hypertrophy. eLife. 2017 Feb 10;6.  
497.  Luo W, Li E, Nie Q, Zhang X. Myomaker, Regulated by MYOD, MYOG and miR-140-3p, 
Promotes Chicken Myoblast Fusion. Int J Mol Sci. 2015;16(11):26186–201.  
498.  Lutz CT, Quinn LS. Sarcopenia, obesity, and natural killer cell immune senescence in 
aging: altered cytokine levels as a common mechanism. Aging. 2012 Aug;4(8):535–46.  
499.  Lu A, Proto JD, Guo L, Tang Y, Lavasani M, Tilstra JS, et al. NF-κB negatively impacts the 
myogenic potential of muscle-derived stem cells. Mol Ther J Am Soc Gene Ther. 2012 
Mar;20(3):661–8.  
500.  Carosio S, Berardinelli MG, Aucello M, Musarò A. Impact of ageing on muscle cell 
regeneration. Ageing Res Rev. 2011 Jan;10(1):35–42.  
501.  Lepper C, Partridge TA, Fan C-M. An absolute requirement for Pax7-positive satellite cells 
in acute injury-induced skeletal muscle regeneration. Development. 2011 Sep 
1;138(17):3639–46.  
502.  Bm C, Ja F. The regeneration of skeletal muscle fibers following injury: a review. Med Sci 
Sports Exerc. 1983;15(3):187–98.  
503.  McKay BR, Toth KG, Tarnopolsky MA, Parise G. Satellite cell number and cell cycle kinetics 
in response to acute myotrauma in humans: immunohistochemistry versus flow cytometry. 
J Physiol. 2010 Sep 1;588(Pt 17):3307–20.  
504.  McKay BR, Ogborn DI, Bellamy LM, Tarnopolsky MA, Parise G. Myostatin is associated 
with age-related human muscle stem cell dysfunction. FASEB J Off Publ Fed Am Soc Exp 
243 
 
Biol. 2012 Jun;26(6):2509–21.  
505.  Verdijk LB, Jonkers RAM, Gleeson BG, Beelen M, Meijer K, Savelberg HHCM, et al. 
Protein supplementation before and after exercise does not further augment skeletal 
muscle hypertrophy after resistance training in elderly men. Am J Clin Nutr. 2009 
Feb;89(2):608–16.  
506.  Heher P, Maleiner B, Prüller J, Teuschl AH, Kollmitzer J, Monforte X, et al. A novel 
bioreactor for the generation of highly aligned 3D skeletal muscle-like constructs through 
orientation of fibrin via application of static strain. Acta Biomater. 2015 Sep;24:251–65.  
507.  VanDusen KW, Syverud BC, Williams ML, Lee JD, Larkin LM. Engineered skeletal muscle 
units for repair of volumetric muscle loss in the tibialis anterior muscle of a rat. Tissue Eng 
Part A. 2014 Nov;20(21–22):2920–30.  
508.  Ostrovidov S, Ahadian S, Ramon-Azcon J, Hosseini V, Fujie T, Parthiban SP, et al. Three-
dimensional co-culture of C2C12/PC12 cells improves skeletal muscle tissue formation and 
function. J Tissue Eng Regen Med. 2017 Feb;11(2):582–95.  
509.  Ostrovidov S, Shi X, Zhang L, Liang X, Kim SB, Fujie T, et al. Myotube formation on gelatin 
nanofibers - multi-walled carbon nanotubes hybrid scaffolds. Biomaterials. 2014 
Aug;35(24):6268–77.  
510.  Agley CC, Velloso CP, Lazarus NR, Harridge SDR. An Image Analysis Method for the 
Precise Selection and Quantitation of Fluorescently Labeled Cellular Constituents. J 
Histochem Cytochem. 2012 Jun;60(6):428–38.  
511.  Perera P-Y, Lichy JH, Waldmann TA, Perera LP. The role of Interleukin-15 in inflammation 
and immune responses to infection: implications for its therapeutic use. Microbes Infect Inst 
Pasteur. 2012 Mar;14(3):247–61.  
512.  Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, et al. Redistribution, 
hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production 
during first-in-human clinical trial of recombinant human interleukin-15 in patients with 
cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2015 Jan 1;33(1):74–82.  
513.  Pierce JR, Maples JM, Hickner RC. IL-15 concentrations in skeletal muscle and 
subcutaneous adipose tissue in lean and obese humans: local effects of IL-15 on adipose 
tissue lipolysis. Am J Physiol Endocrinol Metab. 2015 Jun 15;308(12):E1131-1139.  
514.  Kelly S, Martin S, Kuhn I, Cowan A, Brayne C, Lafortune L. Barriers and Facilitators to the 
Uptake and Maintenance of Healthy Behaviours by People at Mid-Life: A Rapid Systematic 
Review. PLoS ONE [Internet]. 2016 Jan 27;11(1). Available from: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731386/ 
515.  Keaver L, Webber L, Dee A, Shiely F, Marsh T, Balanda K, et al. Application of the UK 
foresight obesity model in Ireland: the health and economic consequences of projected 
obesity trends in Ireland. PloS One. 2013;8(11):e79827.  
244 
 
516.  Anis AH, Zhang W, Bansback N, Guh DP, Amarsi Z, Birmingham CL. Obesity and 
overweight in Canada: an updated cost-of-illness study. Obes Rev Off J Int Assoc Study 
Obes. 2010 Jan;11(1):31–40.  
517.  Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown M. Health and economic burden 
of the projected obesity trends in the USA and the UK. The Lancet. 2011 Aug 
27;378(9793):815–25.  
518.  Koelen MA, Lindström B. Making healthy choices easy choices: the role of empowerment. 



























































































Appendix Table 1. Skeletal Muscle Biopsy Participant Characteristics for Each 
Experiment in this Thesis 
Figure Sex (n, M/F) Age BMI Participants 
3.5 Young 3/0 23.8 ± 1.8 24.0 ± 1.0 IS07, IS17, IS18 
3.5 Old 2/1 71.3 ± 3.8 22.8 ± 1.2 IS14, IS15, IS16 
4.2 Young 2/1 20.8 ± 0.8 23.8 ± 2.5 IS08, IS09, IS10 
4.2 Old 2/1 71.3 ± 3.8 22.8 ± 1.2 IS14, IS15, IS16 
4.3 2/1 71.3 ± 3.8 22.8 ± 1.2 IS14, IS15, IS16 
4.4 Young 2/1 20.8 ± 0.8 23.8 ± 2.5 IS08, IS09, IS10 
4.4 Old 2/1 71.3 ± 3.8 22.8 ± 1.2 IS14, IS15, IS16 
6.1 1/2 21.7 ± 1.4 20.8 ± 0.9 IS03, IS04, IS05 
6.2 Young 1/2 23 ± 0.5 20.4 ± 1.6 IS05, IS06, IS07 
6.2 Old 2/1 67.7 ± 0.3 23.7 ± 4.1 IS12, IS13, IS14 
6.5 2/1 21.1 ± 1.1 19.5 ± 0.9 IS02, IS03, IS04  
6.6 2/1 67.7 ± 0.3 23.7 ± 4.1 IS12, IS13, IS14 
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Appendix Table 2. Mean Ct Values of Control Conditions for Primers Used in this 
Thesis. 







FBX032 (MAFbx) 23.9 











TMEM8C (Myomaker) 20.7 
The efficiency of all primers was established in our lab to be > 95 % under the conditions 
recommended by Primerdesign (detailed in this thesis). Given this high degree of 
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efficiency concordance between primers, efficiency was assumed to be 100% for 

























9.2 Appendix to Chapter 3 
To calculate the AVS: 
• The mean concentration of each adipokine in NW individuals (n = 13) was 
calculated. 
• For each subject ACM, the concentration of an individual adipokine was expressed 
as a fold change relative to the NW mean value for that adipokine.  
• These fold change values were log10 transformed to achieve a linear scale.  
• All negative fold change values were converted to positive numbers. 
• For each subject ACM, the average of the values for all adipokines was calculated 
to attain a subject AVS score. 
 The AVS score for one OB individual is graphically represented in Appendix Fig. 3.1, A. It 
may be thought of as the average distance of the log10 fold change adipokine 
concentrations (purple dots) for that subject from zero. The resulting AVS scores are 
represented in Appendix Fig. 3.1, B. Both the OW and OB cohorts displayed significantly 
(p = 0.0006, p = 0.0002 respectively) more variability in their adipokine secretory milieu 
compared to the NW cohort, despite the concentrations of few individual adipokines being 
significantly different from their NW mean values (Chapter 3 Fig. 3.1, Table 3.2). It should 
not be assumed that the ACM concentration of a given adipokine is predictive of an 
adipose secretory pattern for all the adipokines that were measured. Four OB subjects 
with similar resistin ACM concentrations are highlighted (Appendix Fig. 3.1, C). It is evident 
that similar resistin concentrations in these ACM are not predictive of an adipokine 




































































9.5 Appendix to Chapter 6 
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